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Thesis Summary 
 
 Angiotensin converting enzyme (ACE) inhibitors lisinopril and ramipril were 
selected from EMA/480197/2010 and the potassium-sparing diuretic spironolactone was 
selected from the NHS specials list for November 2011 drug tariff with the view to 
produce oral liquid formulations providing dosage forms targeting paediatrics. Lisinopril, 
ramipril and spironolactone were chosen for their interaction with transporter proteins in 
the small intestine. 
 Formulation limitations such as poor solubility or pH sensitivity needed 
consideration. Lisinopril was formulated without extensive development as drug and 
excipients were water soluble. Ramipril and spironolactone are both insoluble in water 
and strategies combating this were employed. Ramipril was successfully solubilised 
using low concentrations of acetic acid in a co-solvent system and also via complexation 
with hydroxypropyl-β-cyclodextrin. A ramipril suspension was produced to take 
formulation development in a third direction. Spironolactone dosages were too high for 
solubilisation techniques to be effective so suspensions were developed. A buffer 
controlled pH for the sensitive drug whilst a precisely balanced surfactant and 
suspending agent mix provided excellent physical stability. Characterisation, stability 
profiling and permeability assessment were performed following formulation 
development. The formulation process highlighted current shortcomings in techniques 
for taste assessment of pharmaceutical preparations resulting in early stage research 
into a novel in vitro cell based assay.   
 The formulations developed in the initial phase of the research were used as 
model formulations investigating microarray application in an in vitro-in vivo correlation 
for carrier mediated drug absorption. Caco-2 cells were assessed following transport 
studies for changes in genetic expression of the ATP-binding cassette and solute carrier 
transporter superfamilies. Findings of which were compared to in vitro and in vivo 
permeability findings. It was not possible to ascertain a correlation between in vivo drug 
absorption and the expression of individual genes or even gene families, however there 
was a correlation (R2 = 0.9934) between the total number of genes with significantly 
changed expression levels and the predicted human absorption.  
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1.1 THE GLOBAL PROBLEM 
 The United States identified the problem of the poor availability of paediatric 
medication in the 1990’s and since 1998 there has been a regulation in place (Federal 
Register 66632, 1998) requiring all medicines produced to be assessed for safety and 
efficacy in paediatrics. As such since the 4th January 2002 under the ‘best 
pharmaceuticals for children’ act (FDA/Pub L No. 107-109, 2002) the FDA require, in 
instances where drugs are intended for paediatric use, evidence that the medication is 
both safe and effective. In 2007 the European Medical Agency (EMEA) followed suit in 
the recognition of the problem and has since devised a priority list of off patent paediatric 
medications with the goal of directing the research and development in the direction of 
the medications deemed the most important and the most in need of reformulation and 
investigation. 
1.2 DELIVERY ROUTES AND THEIR ASSOCIATED DOSAGE FORMS 
 The complex physiology of the human body provides a diverse range of routes 
which can be utilised as a potential pathway for the administration of a dosage form to a 
patient. The choice of which route is to be taken is dependent upon a number of things 
such as the desired site of absorption of the drug, the site of action of the drug and 
stability considerations. For example there would be little point in administering a drug 
which was rapidly degraded in acidic conditions via the oral route with the aim of 
achieving absorption in the intestine as the drug would be degraded in the stomach. By 
altering either the dosage form or if possible the site of absorption this limitation can be 
overcome, the drug could be orally administered with the intention of absorption through 
the buccal mucosa or alternatively an alternative route of administration such as injection 
or suppository could be implemented. From this example it is clear that the correct 
selection of both delivery route and dosage form is critical in the production of a 
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successful medication. The most common delivery routes and their associated dosage 
forms are detailed in this section (Mohammed and Russell 2012).    
1.2.1 Oral Administration 
 The delivery of active pharmaceutical ingredients (API)’s via the oral route can 
be achieved in a variety of ways depending upon the limitations of the drug in question. 
Oral dosage forms may be liquid or solid. Solutions, suspensions, and emulsions 
account for the liquid dosage forms, while tablets, capsules, and powders make up the 
solid dosage forms that are used in oral administration. A variety of liquid medicines are 
designed to be swallowed and delivered enterally:  
 Oral solutions are normally an aqueous vehicle into which all of the formulation 
ingredients are dissolved.  
 Elixirs involve the incorporation of an alcohol as a co-solvent which is present to 
optimise the solubilisation of all of the formulation ingredients. As all of the 
ingredients are solubilized then elixirs qualify as solutions however there are 
potential limitations for the use of elixirs in paediatric treatment and also for adult 
groups which avoid alcohol.  
 Oral syrups are solutions which contain concentrations of sugars or sugar 
substitutes at concentrations of up to 85% dissolved in an aqueous vehicle. As 
syrups are classed as solutions it is important that the API remains soluble in the 
syrup vehicle and no precipitation is observed.  
 Linctuses are normally produced for the treatment of throat irritations and also 
most cough medicines fall into this category, their high viscosity resulting from 
their syrup like formulation aids their soothing effect by increasing contact time 
with the irritated area.  
 Gargles and mouthwashes are orally administered aqueous solutions which are 
designed to treat ailments in the buccal cavity although these are not designed 
to swallowed, being classified as oropharyngeal formulations. 
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 Suspensions are only employed as a dosage form for oral administration if the 
API has a low aqueous solubility. They are often alternatively described as colloidal or 
coarse dispersions depending upon the size of the particles in the suspension. Unlike 
solutions, suspensions are inherently unstable and sedimentation of the suspended 
particles often occurs upon storage. As such it is important that homogeneity can be 
easily achieved before administration in order to ensure accurate dosage. This is of 
particular relevance when viscosity increasing excipients are used to slow sedimentation. 
A balance must be reached where sedimentation is slowed without inhibiting re-
suspension. Ideally a suspension should display pseudoplastic flow properties which 
yields a vehicle with greater viscosity during storage which decreases upon dispensation 
of the formulation. The aesthetics of a suspension are also important from a consumer 
point of view (Jones 2008, Mohammed and Russell 2012).         
 Emulsions, although more often used in external applications they are at times 
also used in oral liquids but only when the emulsion is in the oil in water form. This refers 
to the API being contained in a disperse oil phase stabilised within a water external 
phase. Emulsions are of benefit over suspensions where insoluble drugs are more stable 
in oil than they are in aqueous environments. They can also at times provide formulations 
which are more readily absorbed than suspensions. A major drawback of emulsions is 
that they are often difficult to manufacture (Griffin et al 2007, Mohammed and Russell 
2012).  
 Tablets and capsules account for the solid dosage forms which are orally 
administered. These are widely used as they provide many characteristics which makes 
them attractive as a dosage form. For example they allow for easy administration and 
can be modified to provide controlled release both in the rate and location of release. 
They are also useful in the taste masking of unpleasant tasting drugs at the same time 
as being easy to manufacture and providing an ‘elegant’ dosage form. There are many 
sub-classes of tablets including; conventional compressed, multiple compressed, sugar-
 
 
41 
 
coated, film-coated, enteric-coated, chewable, buccal, sublingual and effervescent 
(Mohammed and Russell 2012). Tablets are normally produced in one of four ways; dry-
granulation, wet-granulation, direct compression and roller compression. Other methods 
such as freeze-drying are also used however carry higher running costs (Bolhuis and 
Zuurman 1995).   
 Conventional compressed tablets provide rapid drug release as they are 
designed to have rapid disintegration rates upon digestion in the stomach, they 
are produced via the direct compression of granules or powders containing the 
drug.  
 Multiple compressed tablets involve the use of layering different granules or 
powders compressing the tablet after each addition to produce a controlled 
release tablet which is capable of releasing its API at different locations in the 
gastro-intestinal (GI) tract or at different rates. Layering also allows for increased 
potential for taste masking and layering also allows for the incorporation of more 
than one API where in other conditions one API may be incompatible with the 
other(s). Increasing the number of layers incorporated results in greatly 
increased complexity of the manufacturing process. 
 Sugar coated tablets involve the coating of a conventional compressed tablet 
with a sugar or sugar substitute to improve the palatability or the aesthetic appeal 
of a tablet. Although once a popular technique the advent of film-coated tablets 
has seen a reduction in the incidence of sugar-coated tablets formulated. 
 Film-coated tablets are similar to sugar-coated tablets only the sugar solution 
previously used has been replaced with a polymer or a blend of polymers. They 
can be designed to target the release of the API where sugar coated tablets 
cannot. In some cases the drug release can be brought about as a result of 
diffusion of the API through the insoluble coating, this allows a specific site of the 
GI tract to be targeted. 
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 Enteric-coated tablets are designed for targeted release and this is achieved by 
coating the tabled in a polymer which remains intact through much of the GI tract 
thanks to its pH dependent solubility and as such reaches the intestine before 
any breakdown of the tablet will occur. This has advantages in circumstances 
where the API is sensitive to acid degradation in that the drug is protected until it 
arrives in the alkaline environment of the small intestine. There are also the 
benefits of being able to minimise any irritation caused by the API. 
 Chewable, buccal and sublingual tablets are designed for break down in the 
mouth and this can be for a number of reasons. Buccal absorption is one of the 
most rapid means of delivering an API and also carries the benefit of avoiding 
first pass metabolism, the main limitation of tablets breaking down in the mouth 
is bitter tasting drugs. Chewable, buccal and sublingual tablets also have the 
advantages that they can be produced to larger sizes than tablets which need 
swallowing and also increase the ease of administration for patients who struggle 
to swallow solid dosage forms. Buccal and sublingual tables differ in the location 
in which they should be placed to dissolve, buccal tablets are placed against the 
inside of either cheek whereas sublingual tablets are placed under the tongue. 
 Effervescent tablets are added to water where they rapidly dissolve to produce 
an aqueous solution or suspension before being drank. The advantage of this is 
that there are no problems with swallowing solid dosage forms and the 
absorption of the API will be sped up coming from a pre-dissolved tablet in 
comparison to a swallowed solid form.     
 Capsules are less complicated than tablets and normally fall into one of two 
categories; hard gelatin capsules or soft gelatin capsules. The type of capsule shell used 
is dependent upon the intended contents of the capsule. Soft gelatin capsules consist of 
a one piece shell and normally contain non-aqueous liquid in which the API is present. 
Hard gelatin capsules are formed from two sections which fit together to form the 
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complete shell and usually contain either a non-aqueous liquid, semisolid or dry 
preparations such as tablets or powder.  
 In the case of both tablets and capsules, the instructions for use will indicate 
when these solid forms should be taken. Some medicines, for example, may need to be 
taken on an empty stomach or immediately after eating (Mohammed and Russell 2012). 
1.2.2 Ocular Administration 
 Ocular administration involves the treatment of conditions affecting the eyes 
using either:  
  • Solutions 
  • Suspensions  
  • Ointments  
 Liquid dosage forms used for ocular administration most commonly include eye-
drops. For the most part the conditions treated are external and treated via the 
application of the solution, suspension or ointment via eye drops. There are also some 
intraocular ailments which can be treated in the same manor although for most 
intraocular conditions and more serious conditions intraocular injections are applied. 
There are many disadvantages of ocular treatment including blurring of vision and local 
irritation. The main advantages of ocular drops are that they are applied directly to the 
problem site and with practice they can be administered effectively by the patient (Losa 
et al 1993, Mohammed and Russell 2012). 
1.2.3 Nasal Administration 
 Nasal administration involves delivery of an API via a spray and it is most 
commonly used in the relief of congestion. The spray is always an aqueous based 
system as maintaining the action of the cilia in the nasal cavity is considered of upmost 
importance and non-aqueous systems impair the action of the cilia. The nasal route of 
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administration provides rapid absorption of an API thanks to the thin membrane good 
blood supply. Problems can arise in the treatment of congestion if there is any irritation 
as a result of the presence of preservatives which leads to increased congestion (Ilium 
et al 1998, Mohammed and Russell 2012).               
1.2.4 Otic Administration 
 Otic administration is necessary for the treatment of infection, inflammation and 
ear ache or more severe pain. Similarly to ocular administration suspensions, solutions 
and ointments are all used in the treatment of ear conditions. Otic treatment is almost 
always via the use of solutions and regularly contain more than one API, usually an 
anaesthetic and an agent to soften the ear wax. The viscosity of otic preparations is 
important to ensure ease of administration and also the retention of the preparation at 
the site of action (Koulich et al 2010, Mohammed and Russell 2012).   
1.2.5 Vaginal Administration 
 There are many types of dosage form which are suitable for vaginal 
administration including; semisolid preparations, tablets, capsules, peccaries and 
implants. The semisolid preparations contain the creams, ointments and gels which are 
applied via the use of a specially designed applicator. In a similar manner the tablets 
and capsules which are designed for vaginal application also require the use of an 
applicator and the patient requires teaching how to correctly use it. Peccaries are similar 
to rectal suppositories and have a range of usages. Vaginal implants are excellent in the 
controlled release of the API and the fixed nature of the dosage form ensures the 
accurate delivery of the API (Ceschel et al 2001, Mohammed and Russell 2012).     
1.2.6 Rectal Administration 
 Suppositories are the main mode of rectal administration although ointments, 
pastes, lotions, liniments, collodions and gels are also used in rectal administration. 
Suppositories are solid dosage forms which undergo melting, softening or dissolution 
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and have the advantages that they can be suitably administered to patients who are 
unconscious or vomiting. Drugs which are liable to degradation in the upper areas of the 
GI tract can also be administered rectally to avoid this problem. The main disadvantages 
of rectal administration are the slow absorption, the patient to patient variation in the rate 
of rectal absorption and also the patient acceptability of the dosage form 
(Jongjaroenprasert et al 2002, Mohammed and Russell 2012).       
1.2.7 Pulmonary Administration 
 The administration of API’s via the respiratory system is predominantly for the 
treatment of respiratory disorders. Due to the physiology of the lungs and their 
optimisation for exchange of substances drug absorption is understandably efficient and 
as such has been exploited as a route of drug delivery using dry powder inhalers (DPI), 
metered dose inhalers (MDI), nebulisers and aerosols, with this route of administration 
comes the added benefit that the administration in this way avoids direct passage 
through the liver. DPI and MDI differ in that DPI’s administer dry powders containing the 
API whereas the MDI’s administer a suspension or a solution much in the same way 
(Muller et al 2011). Nebulisers involve the administration of solutions to the respiratory 
tract. The pH of the solution is important as acidic conditions can result in the tightening 
of the chest and make breathing difficult. 
1.2.8 Topical Administration 
 Topical administration is where gels, pastes, collodions, lotions, ointments or 
liniments are applied externally to the area in need of treatment. Gels are produced using 
either dispersed solids or hydrophilic polymers and fall into two categories; Type 1 gels 
or hydrogels display covalent bonding between the polymer chains and are capable of 
taking up huge volumes of liquid vehicle whilst still maintaining flexibility and tough 
mechanical characteristics. Type 2 gels display weaker bonding between the polymer 
chains than are seen in type 1 gels and as a result display improved flow with 
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pseudoplastic properties. Pastes and ointments are in essence the same thing with the 
only real difference the concentration of API present. Pastes usually contain greater than 
50% w/w of API where in comparison the concentration present in ointments is much 
lower. Collodions, lotions and liniments all fall into the categories of either solutions or 
suspensions and are often applied for the treatment of parasitic, bacterial, fungal and 
viral infection (Simpson 2010, Mohammed and Russell 2012).   
1.2.9 Parenteral Administration 
 Parenteral administration is used extensively and there are numerous routes of 
administration; intravenous route (IV), intramuscular route (IM), subcutaneous route 
(SC), Intradermal (ID), Intra-arterial (IA), Intrathecal (IT), Intradural/extradural and 
Intracardiac (IC).  
 Intravenous (IV) administration is used widely and has many advantages 
including the administration of large amounts of parenteral preparation up to 
500ml. The IV route also allows for the administration of API’s directly into a vein 
which would otherwise result in irritation if administered via another method. The 
bioavailability of IV administrated drugs cannot be beaten with 100% of the 
administered dose being available for action. The main drawback of IV 
administration is the need for training to ensure correct targeting of the injection 
and that the drug is administered to the vein at the correct rate (Jones 2008). 
  Intramuscular (IM) administration is usually delivered to the muscles in the 
buttocks, the thigh or the upper arm. The maximum volume for administration via 
IM is lower than IV and the time from delivery to response is slower than the IV 
method of administration. Response is also slower for suspensions than it is for 
solutions. Bruising and soreness at the site of injection can often result if the 
injection technique is poor (Fan et al 2010). 
 Subcutaneous (SC) administration involves the administration of the preparation 
to the fat layer directly below the skin. One of the most common uses for SC 
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administration is in the self-delivery of insulin in the treatment of diabetes. This 
method of administration is also used when there are problems accessing a vein 
for IV delivery. The time for the availability of the drug is slower when 
administered subcutaneously when compared with IV and IM administration. 
Normally the volume of parenteral preparation administered is low, 1ml or so 
however in some instances volumes of up to 1000ml can be delivered 
subcutaneously (Woolums et al 2011, Mohammed and Russell 2012).       
 IV, IM and SC are the three most common routes of administration with the 
remaining routes of intradermal (ID), intra-arterial (IA), intrathecal (IT), 
Intradural/extradural and intracardiac (IC) used less frequently but often for more 
specialist treatments (Jones 2008, Mohammed and Russell 2012).   
 Solid parenteral implants are also used as a means of drug delivery and these 
involve the subcutaneous insertion of a sterile solid preparation of a suitable shape and 
size. This may be placed inside the upper arm to minimize the risk of the implant breaking 
and includes devices that rely on an osmotic pump to deliver the API. In general, implants 
have the advantage of being able to deliver an API over a long period of time, which is 
not possible with other parenteral methods (British Pharmacopeia, 2011). 
1.3 DRUG AND DOSAGE FORM SELECTION 
 Following examination of the drugs listed in the EMA priority list of off patent 
paediatric medications (EMA/480197/2010) and the NHS specials list for November 
2011 tariff (Chaplin 2012), the angiotensin converting enzyme (ACE) inhibitors ramipril 
and lisinopril in addition to the potassium sparing diuretic spironolactone were selected 
(Table 1). They were all listed with the specific requirement of the production of an age 
appropriate dosage form and the drugs all interact with transporters in the intestinal 
transport network. As an age appropriate dosage form was to be produced and only 
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tablets and capsules with no liquid alternative existed for the drugs in question it was 
settled upon that the formulations would be produced as oral liquids.  
Table 1 - Lisinopril, ramipril and spironolactone are the drugs selected for formulation. 
Shown in the table is the information governing the key considerations in their selection. 
The drugs were required to interact with intestinal transporters and not already exist as 
oral liquid formulations. Solubility although not an important criteria in drug selection it is 
one of the most important pre-formulation considerations. 
Drugs Selected For Reformulation 
Drug Transporters Oral Liquid Formulation? Solubility 
Lisinopril ABCB1 (Inhibitor), 
SLC15A1 
(Substrate). 
NO Soluble 
Ramipril SLC15A1 
(Substrate), 
SLC15A2 
(Substrate) 
NO 0.0035mg/ml 
 
Spironolactone ABCC2 (Inducer), 
ABCB1 (inhibitor), 
SLCO1A2 (Inhibitor). 
NO 0.022mg/ml 
 
1.3.1  ACE Inhibitors  
 ACE inhibitors act in the renin-angiotensin-aldosterone system (RAAS), a 
homeostatic mechanism charged with controlling hemodynamic conditions via 
competitive inhibition of the peptidyl dipeptidase ACE. The ACE inhibitors are an 
analogue of angiotensin I and occupy the active site on ACE preventing the conversion 
of angiotensin I to angiotensin II (Dzau et al 1981). 
 There are two ACE isoforms, the first is the somatic isoform, and this is a 
glycoprotein formed from a single polypeptide chain. The second isoform is known as 
the testicular isoform, which has a role in reproduction. Somatic ACE has two functionally 
active domains, N and C, which have distinct physiological roles. The C-domain is 
predominantly involved in blood pressure regulation while the N-domain plays a role in 
hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit 
the activity of both domains, but have much greater affinity for and inhibitory activity 
against the C-domain. 
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 In normal conditions, a response to a reduction in blood pressure triggers the 
release of the enzyme renin into the blood stream from the kidneys, here renin acts to 
convert angiotensinogen to angiotensin I. This is then in turn converted from angiotensin 
I to angiotensin II by ACE. Angiotensin II is responsible for increasing blood pressure by 
bringing about multiple responses including increased sodium and water re-absorption 
in the kidneys and arterial vasoconstriction. The re-absorption of sodium and water in 
the kidneys is increased indirectly by angiotensin II which acts to bring about the 
secretion of aldosterone and vasopressin. Aldosterone increases the number of Na+ 
channels and Na+/K+ATPase pumps present in the distal convoluted tubule and 
collecting duct of the kidneys. Vasopressin which is more commonly known as the anti-
diuretic hormone (ADH) increases the number of aquaporin-2 channels present in the 
distal convoluted tubule and collecting duct of the kidneys which allows for increased 
water re-absorption. The increased volume of salts and water re-absorbed into the blood 
has the effect of increasing the blood volume and therefore the pressure of the system. 
The increased re-absorption is complemented by vasoconstriction which by decreasing 
the volume available in the blood vessels increases the blood pressure. It is brought 
about by the binding of angiotensin II to receptors found in smooth muscle. In addition 
to stimulating vasoconstriction, vasodilatation is prevented by ACE via the inactivation 
of bradykinin. Through the use of ACE inhibitors, reductions in blood pressure are 
achieved as the action of ACE is prevented halting the production of angiotensin II and 
resulting in both vasoconstriction and salt and water re-absorption being reduced (Dzau 
et al 1981) (Figure 1). 
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Figure 1 - Renin-Angiotensin-Aldosterone System (RAAS). Under normal conditions the 
RAAS progresses through the stages in the flow chart displayed in blue and green. When 
ACE inhibitors are present however the RAAS cannot progress below the dashed line. 
In this way increases in blood pressure are prevented and coupled with the effect of ACE 
inhibitors preventing the degradation of bradykinin by ACE, vasodilatation is brought 
about thereby lowering blood pressure (Dzau et al 1981). 
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1.3.2 Potassium Sparing Diuretics 
 Diuretics are a group of medicines which cause the kidneys to remove a higher 
than normal volume of water from the blood stream. They can be used for the treatment 
of a variety of symptoms, including hypertension, oedema and ascites in cirrhosis of the 
liver, malignant ascites, nephrotic syndrome, oedema in congestive heart failure, 
moderate to severe heart failure (adjunct), resistant hypertension (adjunct) and primary 
hyperaldosteronism (Paediatric Formulary Committee 2012).  
 Potassium sparing diuretics are a variety of diuretic which as the name indicates, 
aid potassium retention whilst still increasing the volume of water removed from the 
blood. There are two main groups of potassium sparing diuretics, in one group amiloride 
and triamterene are found and in the other eplerenone and spironolactone exist. The 
drugs in each group bring about their pharmaceutical action in differing ways. 
 Amiloride and triamterene interfere with the passage of water and salts across 
cells in the kidneys by blocking the epithelial sodium channel (ENaC) on the luminal side 
of the collecting duct. This results in less water being reabsorbed and the blood volume 
decreasing. This relieves hypertension and allows water to re-enter the blood in sites of 
oedema for example.  
 Eplerenone and spironolactone are competitive aldosterone antagonists and 
achieve a diuretic effect by inhibiting the action of aldosterone. In turn this causes an 
increase in the net volume of water removed from the bloodstream while maintaining the 
amount of potassium retained.  
 Potassium sparing diuretics are relatively weak in their effect so it is not 
uncommon for them to be used in conjunction with loop diuretics. These have a greater 
effect on the water volume reduction however do not carry the benefit of potassium 
retention and so need to be carefully balanced when used to achieve the desired rate of 
water extraction while maintaining a suitably acceptable potassium level.   
 
 
52 
 
1.4 PREFORMULATION CONSIDERATIONS 
 Prior to any formulation development the physiochemical properties, structure 
and assay methods for the drug in question need consideration. Information on these 
are generated during the drug discovery process and referring back to them during 
reformulation of existing medicines is essential. The various studies that are carried out 
during drug discovery include:  
• The determination of the fundamental physical and chemical properties.  
• The analysis of powder characteristics (micrometrics).  
• Excipient compatibility studies.  
• The development of assays for identification and quantification of the drug. 
 Preformulation studies consist of two sets of studies and can be broadly classified 
into drug profiling and analytical characterization. Data generated from analytical studies 
is also used to help understand the pharmaceutical development of the new chemical 
entity (NCE). For instance, the development of an assay such as high-pressure liquid 
chromatography (HPLC) to identify and quantitatively determine the NCE can be used 
to study the oxidative or photolytic stability, as well as excipient compatibility 
(Mohammed and Russell 2012).  
 Assay via ultraviolet (UV) spectroscopy is one of the first stages during 
preformulation studies. It includes the determination of specific wavelength at which drug 
exhibits maximum absorption.  The development of UV assay is vital as it provides a 
rapid method to assess quantitative measurements of drug substance. This is achieved 
by running a broad wave scan in the UV region (approx 200-400nm) and choosing the 
right absorption wavelength (λmax) for the drug in question.  Once a wavelength has been 
decided upon, the next phase involves the development of a calibration curve to assess 
unknown drug concentrations for any future experiments. However utmost care should 
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be taken when developing the calibration curve due to the limitations stated by Beer-
Lambert law (Mohammed and Russell 2012).  
1.4.1 Solubility 
 The solubility of drug candidate is one of the critical parameters that have an 
influence on the amount of drug absorbed into systemic circulation (bioavailability). Drug 
candidates with solubility values below 1% over the pH range of 1-7 at 37˚C can pose 
potential problems with drug absorption.  Also intrinsic dissolution rate less than 0.1 
mg/cm2min can result in dissolution rate limited absorption.  Therefore determination of 
drug solubility and pKa for ionisable drugs helps in choosing the right pH to ensure 
sufficient drug solubility and decide on the type of counter ion for salt formation.   An 
increase in drug solubility in the acidic media is indicative of basic nature of the moiety 
and vice versa. However an increase in solubility in both acidic as well as basic media 
suggests either amphoteric or zwitterionic molecule comprising of two ionisable groups. 
During preformulation studies, intrinsic solubility (Co) of the NCE is determined where 
the drug exists in its unionised form.  This is done by measuring solubility in acid medium 
for acidic drug and in alkaline medium for basic drug and is carried out at two different 
temperatures of 4 and 37˚C. Solubility measurements at 4˚C are correct as water 
exhibits anomalous expansion at this temperature and due to its high density results in 
low solubility.  Studies for solubility at 37˚C would be indicative of drug solubility profile 
in humans (Tong and Wen 2000). 
 Another important parameter that is studied for ionisable drugs is the 
measurement of pKa. As a rule of thumb, for acidic drug, two pH units below pKa will 
result in the formation of unionised form of the drug and two units above will result in 
complete ionisation.  Henderson-Hasselbach equation can be used to calculate the 
extent of drug ionisation upon changes in pH and in turn predict solubility profiles for 
ionisable drugs. A solubility value of less than 0.1% presents the need for salt formation 
if the intended dosage form is a tablet or a capsule. Alternatively novel drug delivery 
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systems such as liposomes, polymer based nanoparticles and use of co solvents can be 
implemented (Mohammed and Russell 2012). 
1.4.2 Solvents 
 The solubility of a drug is assessed in various solvents including water and 
cosolvent mixtures such as ethanol and water. The choice of appropriate solvent or 
mixtures of solvents is important to facilitate drug extraction and separation in 
chromatography, improve solubility and formulation development (e.g.-injection for initial 
pre-clinical evaluation of the drug). When a suitable solvent or mixture of solvents cannot 
be found due to drug instability or insufficient solubility, oils such as castor oil or liquid 
paraffin are used.   
 The choice of the solvent is influenced by drug properties. When the log P of the 
drug candidate is greater than 2, it results in poor aqueous solubility which necessitates 
the use of water miscible solvents to improve solubility and stability. The choice of the 
exact composition of the solvent mixtures can be determined using a phase diagram 
which measures the effect of increasing/changing the ratio of solvent mixtures on drug 
solubility.  The most suitable solvent/mixtures of solvents is the one where polarity of the 
solvent matches that of the solute (Millard et al 2002). Data from these experiments can 
be used for both formulation development in the future as well as choosing right 
combination of solvents for chromatography (HPLC) during assay development 
(Mohammed and Russell 2012)). 
1.4.3 Partition Coefficient 
 The extent of distribution of drug between water and organic phase (usually 
octanol) is termed as partition coefficient(𝐾). The solubility parameter of octanol which 
is around 10 lies mid-way in the range for majority of the drugs. This enables convenient 
partition of the drug between the polar and the non-polar phases (Leo et al 1971).  The 
most commonly used technique is the shake flask method where a known amount of the 
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drug is dissolved in one of the phases and is shaken for about 30 minutes, allowed to 
stand for 5 minutes followed by separation of the aqueous phase (lower layer).  The 
separated phase is then centrifuged and the drug content assayed using either UV 
spectroscopy or HPLC to determine drug concentration (Mohammed and Russell 2012). 
Partition coefficient is calculated as follows: 
𝐾 = (
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟
𝑢𝑛−𝑖𝑜𝑛𝑖𝑠𝑒𝑑
) 
  Determination of partition coefficient has a wide range of applications such as; 
a) Identification of the drug’s solubility which in turn sheds light on hydrophilic/lipophilic 
nature of the drug.  
b) Prediction of the drug permeability in vivo.  
c) Allows for the choice of mobile phase and stationary phase for chromatography 
techniques such as HPLC and thin layer chromatography (TLC). 
1.4.4 Melting Point 
 Determination of melting point of a drug provides information on drug purity and 
polymorphism. A pure compound is characterised by a sharp well defined melting 
temperature and the existence of polymorphism is detected by multiple melting 
temperatures (Lipinski et al 1997). Understanding of the melting point of an API allows 
for decisions to be made with regards to the developmental procedure, for example an 
API with a low melting point may be unsuitable to undergo processes such as high speed 
rotary pressing which produces significant heat due to friction and as such implementing 
encapsulation of the API would be a more suitable option for the dosage form production 
(Mohammed and Russell 2012). 
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1.4.5 Micromeritics 
 Micrometrics is the science and technology of small particles and is used during 
investigations into:  
• Particle size and size distribution.  
• Identification of particle shape and surface area.  
• Pore size. 
 In pharmaceutical formulations, the size, shape, and surface area of the drug 
particles play a large role in the physical stability of that formulation and also the rate of 
release of an API from the formulation. Generally, reducing the particle size increases 
the rate of dissolution and this enhances absorption. The flow properties of granules and 
powders are also linked with particle size. This is of particular relevance during the 
production of tablets where the uniformity of the tablets produced can be compromised 
if there are large variations in particle sizes and flow properties (Mohammed and Russell 
2012).  
1.5 SOLUBILISATION OF INSOLUBLE DRUGS 
 As the best option for paediatric administration is the production of an oral liquid 
formulation the aqueous solubility of a drug can be a determinate in the dosage form 
selection, soluble drugs lend themselves easily to the production of solutions. For 
insoluble drugs however the options are to produce a suspension where the drug 
remains undissolved or alternatively to utilise techniques to solubilise the insoluble drug, 
e.g. complexation, co-solvency or micelles. 
 Cyclodextrins are used to aid the solubilisation of a compound in water via the 
complexation of hydrophobic molecules to the cavity formed in the cyclodextrin. This in 
encapsulates the molecule of interest rendering the molecule water soluble. When the 
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solution becomes more dilute, e.g. in the body, then the much larger volume of aqueous 
solvent reverses the encapsulation releasing the molecule of interest.  
 There are three main sub classes of cyclodextrins; α, β and γ. These consist of 
6, 7, and 8 glucopyranose units respectively and form cyclic oligosaccharides (Figure 2) 
(Brewster and Loftsson 2007).  
Figure 2 - General Cyclodextrin Structure – The above example is that of β-CD 
exhibiting 7 glucopyranose units where n=1. Alteration of ‘n’ to 0 or 2 would then depict 
the structure of α-CD and γ-CD respectively. 
 
 Cavity size is the major determinate as to which sub-group of cyclodextrin is used 
for complexation. β – cyclodextrins are the most widely used and are well suited to 
molecules the size of hormones and vitamins. α – cyclodextrins are the smallest of the 
sub classes and γ – cyclodextrins are the largest (Challa et al. 2005).    
 Co-solvency incorporates the use of two miscible solvents in which the 
compound of interest is known to be soluble. The reason for using a co-solvent system 
is that the compound’s stability can be increased and as a result, more compound can 
be dissolved than if either solvent was used on their own. Although co-solvents can 
consist of more than two solvents, they most commonly consist of only two.  
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 Micelles can be either oil in water or water in oil formations and work by 
encapsulating the molecule of interest. For oral administration the type of micelle would 
have to be an oil in water formation. Micelles are formed from surfactants present at a 
concentration above the critical micelle concentration (CMC) in a system at a 
temperature above the critical micelle temperature (Krafft Temperature) (Francis et al. 
2004). Although micelles can be used for the solubilisation of insoluble drugs the 
formation of micelles can reduce the effectiveness of preservatives and so could be 
unfavourable for use in a pharmaceutical formulation intended for long term storage and 
use.    
1.6 EXCIPIENTS FOR INCLUSION IN ORAL LIQUID FORMULATIONS 
 The formulation of solutions and even more so for suspensions requires the use 
of several excipients. It is important that all ingredients in the formulations are chemically 
compatible to ensure the stability of a formulation. In addition to the previously mentioned 
solubilising agents, flavours and sweeteners there is the inclusion of preservatives to 
protect against microbial contamination and in the majority of cases antioxidants are 
included to protect the API from oxidising agents. 
1.6.1 Preservatives 
 The preservatives for inclusion in oral liquid formulations should be effective over 
a broad spectrum in order to prevent contamination as a result of bacterial (Gram 
negative and Gram positive) and fungal infection. They must also however be harmless 
to the patients taking the medication and also remain active and stable for the life of the 
product. There are a multitude of preservatives available for use with some of the most 
commonly used including benzoic acid, sorbic acid and the Parabens group of 
preservatives (Bean 1972).  
 There are many factors in liquid formulations which can have an effect on the 
efficacy of the preservatives included in the formulation. The first determinant is the 
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concentration of preservative included in the formulation. Below the minimum inhibitory 
concentration (MIC) the preservative will not be sufficiently effective to fully protect the 
formulation from contamination. Other factors which can be of incidence on the efficacy 
of the preservatives are the pH of the system, the presence of micelles and the presence 
of hydrophilic polymers (Jones 2008).  
 The pH of a system determines whether a compound will be present in its ionised 
or unionised form. In some cases only the unionised form of a preservative displays 
antimicrobial activity. As a result increased antimicrobial activity will be seen in acidic 
formulations, an example of such a preservative is benzoic acid. There are other 
preservatives which are less pH dependent include the parabens which thanks to their 
high pKa are suitable for use over a pH range of around 4-8. 
 Micelles can impact preservative activity if the preservative displays hydrophobic 
properties, where this is the case the preservative can pass into the oil phase of the 
micelle leaving concentrations of preservative remaining dissolved in solution which may 
fall below the MIC. If micelles and hydrophobic preservatives are to be used in 
conjunction it is important that the concentration of preservative initially added to the 
formulation is greater than indented for use so as that the concentration of preservative 
present in the solution remains above the MIC (Jones 2008). 
 Hydrophilic polymers have been shown to interact with the preservative dissolved 
in solution via chemical reactions which reduces the availability of preservative. If this is 
the case then as with the presence of micelles the concentration of preservative initially 
added to the formulation must be greater than is indented for use so as that the 
concentration of preservative present in the solution remains above the MIC. 
Electrostatic interactions between the hydrophilic polymers and the preservatives may 
also render the two incompatible. As this is the case then formulations involving cationic 
hydrophilic polymers in formulations along with acidic preservatives should be avoided 
(Jones 2008).        
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1.6.2 Antioxidants  
 Antioxidants are included in pharmaceutical preparations to protect the API when 
there is the possibility of oxidative degradation. Antioxidants are typically either 
compounds that inhibit free radical induced decomposition or they are redox systems 
which exhibit higher oxidative potential than the drug they are protecting. They work to 
protect the drug by being oxidised in preference of the drug itself. Antioxidant 
concentration decreased markedly between production and the end of the shelf life of a 
formulation as the antioxidant is used up over time. Antioxidants are used in low 
concentrations and can be combined with chelating agents which provide added 
protection (Shah et al 2010). 
1.6.3 Additional Excipients Required in the Formulation of Suspensions 
 Suspensions are more complicated formulations than solutions to produce as 
they are inherently unstable formulations. Due to the fact that the insoluble particles in a 
suspension will in most cases sediment at the bottom of the container. If the particles 
sediment in a very compact manner then caking can result where homogenous 
redistribution of the particles into the suspension is impossible. Controlling the interaction 
between the particles so that any aggregation is reversible or preventing any interaction 
between particles makes it possible to prevent caking. In order to do this excipients such 
as; electrolytes, surface active agents and hydrophilic polymers are often included in 
suspension formulations. Electrolytes entirely and surface active agents on the whole 
improve the stability of a suspension by modifying the zeta potential of the suspended 
particles and before their action can be understood explanation of the interaction 
between particles in a suspension is necessary (Jones 2008). 
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1.7 PRODUCTION OF A PALATABLE FORMULATION - CURRENT TECHNIQUES AND 
SHORTCOMINGS OF EXISTING TASTE ASSESSMENT METHODS. 
 One of the most crucial areas to address in the production of a new medicine 
which is intended for oral administration is that of taste. This is of particular importance 
to ensure patient compliance and is of increased importance when formulations are 
intended for paediatric use as children are less likely to be willing to take unpleasant 
tasting medications that an adult may tolerate. The consideration of formulation taste is 
of particular relevance in solutions more so than suspensions as the bitter taste of many 
API’s is only fully prevalent once the API is solubilised whereas when in suspension the 
bitter taste can be somewhat masked by the suspending agent used in the suspension. 
Fortunately there are many modes of taste masking and taste modification which are 
successfully employed on a routine basis by formulation scientists. 
 The inclusion of taste enhancers such as concentrates, fruit juices and 
sweetening agents are widely used however are limited to their capacity in taste masking 
very bitter drugs. Another approach is to coat the drug particles with agents which are 
not pharmaceutically active for example eudragit, polyethylene glycol (PEG) and ethyl 
cellulose. These coatings prevent the interaction of the bitter tasting drug particles with 
the taste receptors in the mouth and thereby mask the bitter taste. It is important that the 
coating of the drug particles does not limit the bioavailability of the drug. Complexation 
of the drug molecule with a host molecule is another method by which the bitter taste of 
a drug can be masked, in this way the whole drug molecule or at least the section of the 
molecule is contained within a host molecule for example cyclodextrin and in a similar 
way to the coating procedure prevents the interaction of the drug with the taste receptors. 
Yet another widely used approach involves the production of solid insoluble poly-
electrolytes which have a high molecular weight known as Ion exchange resins. The 
inclusion of a bitter tasting drug into a solid dispersion, liposomes or emulsions or 
alternatively the combination of the drug with amino acids are four further methods for 
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taste masking with the formation of pro-drugs or salts of the drug being two methods of 
improving palatability via chemical modification (Ayenew et al 2009).      
 The most commonly used sweetening agents included in pharmaceutical 
preparations are sucrose, liquid glucose, glycerol, sorbitol, saccharin sodium and 
aspartame. Increasingly artificial sweeteners are being used in formulations and in 
paediatric formulation the use of sugar is to be avoided. This is also the case for 
formulations intended for use in patients suffering from diabetes mellitus (Jones 2008).  
 In the same manner that sweeteners are included to mask the taste of unpleasant 
tasting formulations, purpose made flavourings can be added. The flavour selected for 
use must be effective at masking the taste and in order to do this the flavours to choose 
from depend on the initial taste of the formulation. For example, when a formulation is 
unpleasant as the result of a salty taste then some of the best flavours to mask this 
include; butterscotch, apricot, peach, vanilla and mint. In the same way, a bitter taste is 
best masked with flavours such as; cherry, mint and anise. Formulations which are 
overly sweet are best improved by including vanilla or fruit and berry flavours while sour 
tasting formulations are best masked using the citrus flavours and raspberry.  
 In most cases a combination of more than one flavouring agent coupled with a 
sweetening agent will produce the most palatable formulation and excipients charged 
with the roll of enhancing the flavours present are often included. Flavour adjuncts are 
at times also included and these have the effect of reducing the sensitivity of the taste 
buds at the same time as adding to the flavour of the formulation. 
 There is however still a problem in the formulation development; due to the 
complexity of taste as a sense, the methods available for assessing the taste 
improvements or taste suitability are limited and are in undoubted need of improvement. 
 Taste transduction begins with taste receptor cells (TRC’s) found in taste bud 
clusters within structures known as taste papillae. These taste bud containing papillae 
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exist in three distinct forms which are located in specific areas on the tongue and they 
are known as fungiform, circumvallate and foliate papillae. Fungiform papillae are 
located on the anterior portion of the tongue while circumvallate and foliate fungiform are 
located in posterior areas of the tongue. The taste buds which are contained within the 
papillae are constructed of four different cell types, the support cells (Type 1 cells, or 
dark cells), account for 50% of the cells present in a taste bud. The sensory cells (Types 
2 &3 or light cells), account for around 25% of the cells present in a taste bud. Basal 
cells (Type 4 cells) account for the remaining 25% of the cells. Of the sensory cells, type 
2 cells are thought to be responsible for the detection of bitter, sweet and umami tastants 
through transduction pathways involving proteins such as gustducin and phospholipase 
C (PLC)-β2, which are used as reliable indicators of type 2 TRC presence in TRC cultures. 
Likewise, neural cell adhesion molecule (NCAM) is a reliable indicator of type 3 sensory 
cells. These are thought to be the cells responsible for the detection of acid taste while 
the cell type responsible for the detection of salty taste is yet to be identified.       
 Bitter compounds are thought to elicit a taste response through two separate 
pathways. The first pathway, as activated by denatonium involves the activation of the 
G-protein coupled receptors T2R/TRB which activates gustducin heterotrimers. Cyclic 
adenosine monophosphate (cAMP) is hydrolysed by phosphodiesterase (PDE) following 
stimulation by the α-gustducin subunit of the heterotrimer. The β and γ subunits which 
are released activate PLC-β2 leading to the generation of inositol trisphosphate (IP3) 
which in turn leads to an increase in intracellular calcium concentrations following the 
release of calcium from internal stores. The second pathway stimulated by bitter 
compounds involves the inhibition of apical K+ channels which leads directly to the 
depolarisation of the TRC and subsequent increase in intracellular calcium (Gilbertson 
et al 2000). 
 Sweet compounds again have multiple taste transduction pathways and the 
cascade mediated is dependent upon whether the compound in question is an artificial 
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sweetener or a natural sugar. Artificial sweeteners activate ionotrophic receptors which 
are linked to cation channels and G-protein coupled receptors. This results in elevated 
levels of IP3 and a subsequent increase in intracellular calcium following the action of 
PLC. Natural sweeteners activate G-protein coupled receptors linked with adenylyl 
cyclase to bring about an increase in intracellular cAMP. This is then thought to bring 
about phosphorylation by cAMP activate protein kinase A and in turn the inhibition of 
basolateral K+ channels. This leads to the depolarisation of the TRC and intracellular 
calcium increase (Gilbertson et al 2000).  
 Umami taste is elicited by the amino acid L-glutamate (L-Glu). L-Glu causes the 
activation of the taste form of the G-protein coupled receptor mGluR4. This causes 
reductions in intracellular cAMP through PDE activation. This reduction in cAMP is 
thought to reopen cyclic nucleotide monophosphate (cNMP) inhibited channels which 
leads to an increase in intracellular calcium. Other amino acids activate ionotrophic 
receptors which leads to the direct depolarisation of the TRC and in turn the increase in 
intracellular level (Gilbertson et al  2000).  
 Salty taste is elicited by sodium salts. These cause direct depolarisation of the 
TRC leading to intracellular calcium increases following the permeation of Na+ ions 
entering the cell through amiloride sensitive epithelial-type Na+ channels (ENaC) 
(Gilbertson et al  2000).  
 Sour taste is a result of protons entering the TRC. There are a variety of proposed 
transduction mechanisms for sour taste however there is still much work required in this 
area to reveal the main transduction components involved in the taste cascade following 
exposure to a sour stimuli. This is due mainly to the pH sensitivity of ion channels, 
intracellular signalling components and transport proteins. Currently proposed ideas are 
similar to the transduction of salty taste through ENaC, where following permeation of 
H+ ions have been shown to cause depolarisation of TRC’s leading to increases in 
intracellular calcium. H+ ions also have the effect of activating proton activated cation 
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channels such as brain type Na+ channel-1 (BNaC1), acid sensing ion channel (ASIC) 
and dorsal root acid-sensing ion channel (DRASIC) all of which may play a role in the 
signalling cascade. Sour stimuli have also been shown to activate an 5-nitro-2-[3-
phenylpropylamino]-benzoic acid (NPPB) sensitive conductance similar to that seen 
through ASIC’s, again suggesting that NPPB may play a role in the transduction of sour 
taste (Gilbertson et al  2000).  
  As it stands, the most common means of assaying taste of new formulations in 
vitro is through the use of in vitro drug release studies or in vitro assay methods. Drug 
release studies examine the release of a tastant from a formulation using modified 
dissolution apparatus or such like, utilising artificial saliva they are used to measure the 
effectiveness of coatings or complexation within a formulation. This method however is 
not applicable to the testing of liquid formulations. In vitro assay methods are currently 
reliant upon the measurement of the activation of transducin and/or gustducin meaning 
that these assays are not applicable to transducin/gustducin independent taste modifiers, 
of which there are many (Ruiz-Avila et al 2000). The most common in vivo method for 
taste assessment is through the use of a taste panel (Anand et al 2007). This involves 
the sensory analysis of tastants using trained healthy human volunteers and although 
being well established and the standard method for the taste assessment of drugs and 
drug products there are significant drawbacks. Finding volunteers who will be available 
on a long term basis is tricky especially when unpleasant tasting samples are being 
tested. Once recruited the volunteers must undergo extensive training and even after 
which the testing is still subjective. In addition the process of testing is time consuming 
and as a result low throughput. Finally potential problems regarding toxicity and 
additional human ethical issues are also limiting factors. Other in vivo test methods 
involve animal preference testing (Tordoff and Bachmanov 2003) and 
electrophysiological methods (Dewis et al 2013), both of which are far from ideal. The 
animal preference testing is a low throughput, qualitative means of taste assessment 
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and the electrophysiological methods involve complicated animal based surgery which 
brings with it significant cost and also animal ethical issues. In addition the data analysis 
and interpretation can be problematic. 
 Most recently advances in biomimetic taste sensing systems (BTSS) have 
provided the first high-throughput techniques which are of use in formulation 
development and optimisation. They employ electrochemical sensing methodologies 
linked to chemometric methodologies to provide both qualitative and quantitative 
analysis (Baldwin et al 2011). There are however still limitations with these systems. It 
is almost impossible to generate absolute statements relating to the taste of a particular 
sample analysed using an electronic tongue and data is susceptible to change as a result 
of changes in analytical conditions and as a result reproducibility of data can be 
hampered (Woertz et al 2011). In addition to the experimental and data analysis 
limitations, the initial setup cost is considerable. 
 One area of interest which is seemingly underexplored and exploited is that of in 
vitro, tissue culture based models. Investigations into taste receptor cell (TRC’s) function 
has been done using explant cultures from rodents (Mbiene 1997), semi-intact taste 
buds in tissue slices (Caicedo 2000) and primary cultures established from freshly 
isolated TRC’s (Ruiz et al 2001, Ookura 2002, Qin 2008). The lack of progress in this 
area is quite likely due to the limitations of primary culture, most notably limited passage 
number typically below P5, which have been encountered by many of the groups who 
have attempted primary culture of TRC’s. One group in particular has reported more 
promising results and have successfully established long term cultures of both rat 
(Ozdener 2006) and human (Ozdener 2011) TRC’s. Both of these cell lines are useful in 
their own right however there are refinements which can be made to significantly reduce 
both the cost and complexity of establishing and maintaining the cultures while at the 
same time maintaining and adding to the reported advantages which each of these 
cultures provide. 
 
 
67 
 
1.8 STABILITY TESTING OF LIQUID FORMULATIONS 
 Once a formulation has been developed it is necessary for it to undergo stability 
testing to provide information with regards to how the quality of a formulation varies over 
time when exposed to environmental factors including temperature, humidity, and light. 
This controlled testing allows for the identification of any degradation in the formulations 
and determine a re-test time or shelf life for the product. Recommended storage 
conditions can also be determined following stability testing.  
 The conditions for storage are set out in the international conference on 
harmonisation (ICH) guidelines (Q1A (R2)) which states that ‘a drug substance should 
be evaluated under storage conditions that test its thermal stability, and if applicable its 
sensitivity to moisture’. There are three studies recommended for general use termed; 
long term, intermediate and accelerated (Table 2); 
Table 2 - Storage conditions for long term, intermediate and accelerated storage 
conditions as detailed by the ICH guidelines 
Study Storage Conditions Minimum Time Period 
Long Term 
25°C ± 2°C  at 60% Relative Humidity ± 
5% 
12 Months or 
30°C ± 2°C at 65% Relative Humidity ± 5% 
Intermediate 30°C ± 2°C at 65% Relative Humidity ± 5% 6 Months 
Accelerated 40°C ± 2°C at 75% Relative Humidity ± 5% 6 Months 
 
 It is necessary to test the formulations at regular time points for the duration of 
the testing period in order to establish the full stability profile of the formulation. For long 
term studies it is recommended that testing should be carried out at least every three 
months over the first twelve months and then every six months thereafter for the duration 
of the study. For the accelerated conditions it is recommended that testing should be 
carried out at least for day zero, the end time point and one other time point during the 
duration. The intermediate study follows the same pattern as the accelerated study 
however requires at least one extra time point between day zero and the end time point.     
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1.9 INTESTINAL DRUG ABSORPTION MODELLING – CURRENT TRENDS IN VITRO, IN VIVO AND 
IN SILICO. 
 The extent of a drug’s ability to successfully traverse from the intestinal lumen 
into the blood is the greatest limiting factor in the absorption of orally administered drugs. 
Physiological components such as tight junctions between intestinal enterocytes and the 
hydrophobicity of cell membranes are combined with biochemical components such as 
enzymes and transporter proteins to provide a barrier function.  
 The passage of drugs across the intestinal membrane can occur in a variety of 
ways (Figure 3) including:-  
1.) Passive diffusion via the paracellular route. 
2.) Transcellular carrier mediated transport across the cell membrane. 
3.) Efflux transporters at the apical membrane may actively drive compounds back 
into the intestinal lumen.  
4.) Apical efflux transporters may facilitate the intestinal clearance of compounds 
that are already present in the blood. 
5.) Intracellular metabolising enzymes may modify compounds before they enter the 
blood. 
6.) Intracellular metabolising enzymes and apical efflux transporters may co-
ordinately metabolise and excrete compounds forming an effective barrier 
against intestinal absorption. 
 With this in mind, a model for the prediction of drug absorption across the 
intestinal membrane should be capable of generating information relating not only to the 
extent to which a drug is absorbed but also the transport pathway by which the drug 
passes across the intestinal membrane. 
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Figure 3 - Potential transport pathways a drug molecule may take in the intestinal 
membrane. (1) Passive diffusion via the paracellular route, (2) Transcellular carrier 
mediated transport across the cell membrane, (3) Efflux transporters at the apical 
membrane may actively drive compounds back into the intestinal lumen, (4) Apical efflux 
transporters may also facilitate the intestinal clearance of compounds that are already 
present in the blood, (5) Intracellular metabolising enzymes may modify compounds 
before they enter the blood, (6) Intracellular metabolising enzymes and apical efflux 
transporters may co-ordinately metabolise and excrete compounds forming an effective 
barrier against intestinal absorption. 
 
 There are many methods which have been developed for the modelling and 
prediction of intestinal absorption and these are categorised broadly into in vitro, in vivo 
and in silico. In vivo investigations involves the use of living humans or animals in order 
to identify the permeability of a drug. In vitro investigations are models of the in vivo 
conditions and are used to produce estimates of the drug permeability. These often do 
not reproduce all of the conditions seen in the intestine and as such the identification of 
correlations between in vivo and in vitro analysis is important to ensure the validity of an 
in vitro analysis. In silico modelling and prediction is computer based models and is 
becoming an increasingly commonly use tool in drug discovery and design.   
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1.9.1 In Vitro Permeability Models 
 In vitro analysis of drug permeability can be done through a multitude of 
techniques which are broadly classified into, excised tissue assays, cell based assays, 
membrane based assays and physiochemical based analysis. Each class of technique 
has its advantages however they all come with limitations also. Selection of the model 
to use is at times determined by the specific parameters relating to the drug permeability 
which are to be investigated.   
 Excised tissue assays involve the use of; isolated intestinal segments, everted 
sacs, intestinal rings and stripped and unstripped mucosal sheets mounted in ussing 
chambers. The main advantage of excised tissue is that there is a full complement of the 
physiological structures present and this provides a very accurate representation of the 
intestinal membrane. The major disadvantage however is that experiments are limited 
in their duration by deterioration of the tissue as cell viability is limited (Table 3). 
 Cell based assays involve the use of cell cultures such as Caco-2, HT-29, T-84 
and primary cultures of isolated epithelial cells. Cell based assays provide many of the 
major features of the intestinal membrane and Caco-2 cells are well established as a 
technique for modelling intestinal permeability. The main limitations of cell based assays 
are that there is often only one cell type present in the culture, mucus production is not 
achieved in well-established models and enzyme levels may be lower than seen in the 
in vivo environment. Primary cultures also carry with them increased complications 
including being technically difficult to culture and having limited viability (Table 4).  
 Membrane based assays involve immobilised artificial membrane (IAM), parallel 
artificial membrane permeation assay (PAMPA), mucosal cell membrane vesicles and 
isolated mucosal cells. The cell free membrane based assays tend to be rapid and high 
throughput techniques and correlation with cell based assays have been shown. There 
is the disadvantage however that in most models, transporter proteins as well as 
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enzymes are not present, also the membrane based assays tend not to provide any 
insight into paracellular absorption (Table 5).    
 Physiochemical methods look at a range of parameters which include, molecular 
weight, atomic make up of drug compounds, partition coefficient and distribution 
coefficient. The logarithm of the partition coefficient (LogP) is the hydrophobicity 
descriptor and it is used in a number of in vitro models and is the logarithm of the 
octanol/water partition coefficient.  Much of this in vitro analysis provides the data used 
in producing in silico models. Lipinski’s rule of five is one example where physiochemical 
properties are used to predict drug absorption. The main limitation of physiochemical 
methods is that they tend to form a basic check rather than an all encapsulating 
predictive model. Many modern API’s do not fit the patterns of the physiochemical 
prediction methods, examples include drugs which are substrates for transporter 
proteins as well as many naturally occurring compounds.  
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Table 3 – Advantages and limitations of the most common in vitro permeability models 
using excised tissue samples.  
In Vitro Permeability Models - Excised Tissue 
Permeability Model Advantages Limitations 
Isolated Intestinal 
Segments 
Full Physiological Profile is 
present. 
Allows for the study of 
specific functions at an organ 
level. 
The effect of Cell alterations 
limits the length of 
experiments. 
Everted Sacs 
All factors involved in the 
Intestinal Barrier are present 
(Cells and Mucus Layer). 
Rapid and Low Cost Method. 
Can be useful in identifying 
the pathway of absorption. 
Allows for the investigation of 
permeability in different 
sections of the Intestine. 
Not a perfused model. 
Low viability of the tissue. 
Drug must cross the whole 
intestinal barrier. 
Ussing Chambers 
Can be used for both human 
and animal tissue. 
Allows for the investigation of 
permeability at in different 
sections of the intestine. 
Both absorption and efflux 
can be investigated. 
Allows for metabolic studies. 
Allows investigation of 
electrophysiological 
behaviour. 
Limited cell viability. 
Human material is limited. 
Not suitable for screening. 
Intestinal Rings 
All factors involved in the 
intestinal barrier are present 
i.e. both cells and mucus 
layer. 
Rapid and low cost method. 
Can be useful in identifying 
the pathway of absorption. 
Allows for the investigation of 
uptake in different sections of 
the Intestine. 
Not a perfused model. 
Low viability of the tissue. 
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Table 4 - Advantages and limitations of the most common in vitro cell based permeability 
models. 
In Vitro Permeability Models  - Cell Models 
Permeability Model Advantages Limitations 
Caco-2 
Displays the major features 
of the intestine. 
Suitably rapid and simple. 
Suitable for a range of 
studies. 
Allows for identification of 
absorption mechanism. 
Models uptake and efflux. 
Allows for Screening. 
Established in drug 
discovery. 
Accurate as uses human 
cells. 
Some physiological factors 
are not present. 
Only one cell type present. 
Low levels of CYP3A4. 
HT-29-MTX/Caco-2 co-
cultures 
MDCK 
Cell combination models 
mucus-secreting cells. 
Rapid and simple method. 
Can be used for screening. 
Allows for the measurement 
of passive diffusion. 
Not a well-established 
method. 
Not an intestinal model. 
Not a human cell line. 
Physiological factors not 
present. 
TC-47 
Derived from Caco-2 cells. 
Express high Levels of 
CYP3A4. 
Physiological factors not 
present. 
Only one cell type present. 
Primary Isolated Epithelial 
Cells 
Displays the major features 
of the site from which cells 
are isolated. 
 
Difficult to culture. 
Limited cell viability. 
Loss of in vivo features. 
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Table 5 - Advantages and limitations of the most common in vitro membrane based 
permeability models. 
In Vitro Permeability Models - Membrane Based Assays 
Permeability Model Advantages Limitations 
Immobilised Artificial 
Membrane (IAM) 
Cell Free Assay. 
Lipids in columns mimic the 
lipid environment of the cell 
membrane. 
Allows high throughput. 
Has been confirmed to show 
correlation with Caco-2 
permeability study findings. 
Uses capacity factor (K) for 
prediction which results in 
polar surface area being the 
stronger predictor of 
absorption as opposed to 
binding capacity and 
molecular size. 
Ignores enzymes, influx and 
efflux transporters and the 
paracellular pathway. 
Parallel Artificial 
Membrane Permeation 
Assay (PAMPA) 
Cell free assay. 
96 Well format allows high 
throughput. 
Small amounts of compound 
needed. 
Can be manipulated to 
investigate the effect of pH 
with ease. 
The presence of co-solvents 
in the system can mislead 
permeability estimations. 
Requires UV absorbance 
which many compounds do 
not exhibit. 
May require long 
experimental times. 
Ignores enzymes, influx and 
efflux transporters and the 
paracellular pathway. 
Mucosal Cell Membrane 
Vesicles 
Useful in the study of specific 
membrane processes. 
Rapid experiments. 
Small amounts of compound 
needed. 
Vesicles produced easily. 
Lack of cellular metabolism 
makes ATP dependent 
investigation difficult. 
Provide no insight into 
paracellular Transport. 
Isolated Mucosal Cells  
Difficult to culture. 
Limited cell viability. 
Loss of in vivo features. 
 
1.9.2 In Vivo Permeability Models 
 In vivo permeability analysis is the most ‘true to life’ means of modelling 
permeability and for the most part involves the use of animal models, rats are the 
preferred species used to model the human intestine. On occasions in vivo permeability 
studies are carried out with the use of human volunteers, this is however not an option 
in cases where there is little toxicological data available for the drug being investigated. 
The main benefit of in vivo testing over in vitro and in silico methods is that the whole 
animal/human is involved in the testing, this means that all of the biological parameters 
such as membrane structure, mucus, transporters, enzymes and drug metabolism are 
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all accounted for. Additionally there is no need to perform experiments to show 
correlations. Added benefits of in vivo permeability investigations using animal models 
is that the animals used in the permeability testing can also be used in pharmacological 
and toxicological evaluations. In vivo experiments are however not without limitation, the 
analytical procedures are usually much more complicated than the equivalents for in 
vitro and in silico, also the use of living organisms brings with it significant costs and 
ethical considerations (Table 6).  
Table 6 - Advantages and limitations of the most common in vivo permeability models. 
In Vivo Permeability Models 
Permeability Model Advantages Limitations 
Animal Model 
Rat Model 
  
Brings together all of the 
factors that can influence the 
uptake of a drug. 
Suitably represents the 
conditions in humans. 
Allows for the measurement 
of bioavailability. 
Animal model. 
Metabolism differences 
between animals and 
humans. 
Hard to identify variables in 
the mechanism of 
absorption. 
Human Model 
Administration of specially 
designed capsules to 
Human Volunteers 
  
Human Model. 
Regulatory authorities are 
recommending the 
importance of this technique 
in developing sustained 
release products. 
Permits regional absorption 
studies. 
  
  
1.9.3 In Silico Permeability Models 
 Recent advances in computing technology has seen the rise of in silico analysis 
which has been limited previously by processing power and data storage constraints. In 
silico models take into consideration the relationship between the structure and activity 
of an API through the Quantitative Structure-Activity Relationships (QSAR). QSAR’s are 
complex mathematical models which find correlation between the biological activity of 
an API and the physiochemical properties of that API.  
 In order to produce an in silico method, existing literature is trawled to collect the 
data used in the construction of the model. Before statistical analysis of the data, 
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methods used in the data gathering are examined to determine if there is the need to 
factor in corrections to counteract any differences in the collection methodology which 
could skew the overall predictions generated. The corrected the data is processed by 
statistical programmes in order to reveal the significant descriptors for the permeability 
of the drug. A mathematical equation is ultimately generated and this is used in the 
prediction of permeability. The predictions made by in silico techniques are able to 
provide guided predictions on a compound’s behaviour but there are multiple reasons 
why the predictions are not exact. 
 The major benefit of in silico modelling techniques is that the results are 
generated rapidly and being computer based there is no need to use the actual drug in 
the investigations thus reducing cost and in some instances the investigations can be 
performed before the API has even been synthesised. The major drawback of in silico 
analysis is that the predicted permeability is only based on the passive transcellular 
pathway. Although it is understood that this is the most active pathway there are also 
transport networks involving the active transport and efflux mechanisms that may affect 
the in vivo permeability of an API. In silico methods for permeability estimation are 
promising techniques for the future, as they have only more recently began to expand 
into a feasible technique they currently only play a relatively limited role in API and 
formulation development (Table 7).  
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Table 7 - Advantages and limitations of the most common in silico permeability models.  
In Silico Permeability Models 
Permeability Model Advantages Limitations 
Rule of Five 
Describes molecular 
properties important for a 
drug’s pharmacokinetics in 
the human body. This 
includes absorption, 
distribution, metabolism, 
excretion and toxicity 
(ADMET).   
The rule does not predict if a 
compound is 
pharmacologically active. 
Solubility Parameters 
Predicts the duration of 
absorption in humans by 
determining the solubility 
parameters for each 
fragment of a drug’s 
structure. 
 
Multiple Calculated 
Molecular Descriptors 
Investigates a number of 
strongly inter-correlated 
physiochemical properties, 
including lipophilicity, 
molecular size, hydrogen 
bonding capability and the 
degree of ionisation at the 
pH level of interest.  
Experimental data can be 
collected to provide more 
reliable data than calculated 
result. 
Dynamic Surface 
Properties 
Allows for the prediction of 
oral absorption, dynamic 
polar surface areas of less 
than 60 A2 suggest good oral 
absorption whereas dynamic 
polar surface areas greater 
than 140 A2 suggest poor 
oral absorption.  
Model does not take into 
account that the compounds 
also need sufficient water 
solubility in order to 
permeate the membrane. 
MolSurf/PLS 
Used to model permeability 
across Caco-2 monolayers 
and differentiate between 
drug’s with poor permeability 
and those with good 
permeability. 
Permeability is modelled for 
an in vitro test and so in vivo 
performance may differ. 
 
1.9.4 Importance of In vitro - In vivo Correlations (IVIVC) and In Silico – IVIVC’s  
 Establishing clear correlations with the observed in vivo behaviour is a vitally 
important part of establishing any method which has been developed for the modelling 
of permeability. In identifying that a correlation exists in the form of a mathematical 
relationship between the predicted results and the expected in vivo observations it is 
possible to use the model as an alternative to human or animal testing.  
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 In the case of IVIVC’s, the correlation between the in vitro findings and the in vivo 
observations should produce a linear relationship with an R2 value close to 1.00. In 
general the findings from the in vitro method are required to be within ± 10% of the 
findings in vivo at each time point for the duration of an investigation. For models where 
this is achieved, the in vitro method is acceptable and becomes a useful tool in both the 
prediction of in vivo permeability and also the quality control of a drug product should it 
progress through the drug development pipeline and make it into production. It is 
important to mention however that any IVIVC, is restricted in its use to the modelling of 
the permeability for the certain drug product. In the same fashion that finding IVIVC’s are 
essential in the production of useable in vitro permeability models, in silico – IVIVC’s are 
necessary to show that permeability predictions produced by any in silico technique are 
representative of the observed in vitro and in vivo findings (Mohammed et al 2011). 
1.10 GENOMICS AS A NOVEL CONTRIBUTOR IN REVEALING AN IVIVC FOR INTESTINAL 
ABSORPTION PREDICTION. 
 Genes are at the hub of so many of the biological events and focusing studies on 
human genetics allows for advances in drug discovery through a multitude of avenues 
including the understanding of disease onset and progression and providing a means to 
the identification of drug targets and even therapeutic agents by observing genes and 
their transcription products. Application of genomics to areas including, biomarkers, 
tissue expression profiling, side effect profiling, pharmacogenomics and genome wide 
epigenetics are some of the main areas through which genomic techniques are already 
contributing to the drug discovery and development processes. Investigation into 
fluctuations in the in vitro gene expression levels of intestinal transporters with the aim 
of producing an IVIVC is one of the ways in which genomic profiling can further contribute 
to drug discovery and development. 
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1.10.1 Membrane Transporters 
 There are two main types of membrane transporters, the first type are membrane 
channels, the second is carrier mediated transporters. Carrier mediated transporters are 
then sub divided based upon the energy needs for the transport process. Carrier 
mediated transporters include transporters active in facilitated diffusion, primary active 
transporters and secondary active transporters (Stenberg et al 2000). Primary active 
transporters transport substrates out of the cell against concentration gradients and are 
driven by the energy released following the conversion of ATP into ADP, the ATP-binding 
cassette (ABC) transporters fall into this group of transporters. Secondary active 
transporters or co-transporters use the energy liberated during the transport of Na+ and 
Ca2+ ions across the membrane by ion pumps. Solute carrier (SLC) transporters fall into 
the secondary active transporter group.   
 ABC Transporters are responsible for the transport of a large number and wide 
variety of substrates. They were initially identified as a result of their role in drug 
resistance when intestinal efflux transporters were recognised as limiting drug 
absorption (Gottesman et al 2002 and Huang et al 2007). The sub classes of ABC 
transporters are arranged into four groups according to their predicted two-dimensional 
structure in which the number of transmembrane regions and the extent of N terminus 
glycosylation varies (Juliano et al 1976).   
 The first group have two symmetrical sub units constructed of 6 transmembrane 
segments and 2 nucleoside-binding domains (NBD) which extend in to the cytoplasm 
and it is to the NBD’s that ATP binds and is hydrolysed. The first extracellular loop of the 
protein is highly glycosylated. The second group is identical in structure to that of the 
first with the only difference being that the glycosylation is present on the fourth 
extracellular loop. The third group exists with an additional transmembrane segment and 
there is additional glycosylation on this region. The final group is the most recently 
discovered and contains breast cancer resistance protein (BCRP), this protein exhibits 
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only one 6 transmembrane segment and glycosylation on the last extracellular loop. 
Having only one sub unit it is referred to as a half-transporter and is believed to be 
involved more in the stabilisation of the cell membrane than in an actual transport role 
(Mohammed et al 2011).  
 The SLC transporters are another superfamily of transporters found in the 
intestinal membrane. Somewhere in the region of 300 genes for SLC transporters have 
been cloned and these have been clustered in to 43 sub families. The SLC transporters 
mediate the uptake of a variety of hydrophilic substrates including sugars, organic 
cations, anions, phosphates, metals, monocarboxylic acids, water soluble vitamins and 
drugs with structures which resemble natural substrates (Huang et al 2006).  
 ABC and SLC transporters are involved in the absorption of many of the drugs 
listed in the EMA/480197/2010 and the NHS specials list for November 2011 tariff 
including the drugs intended for reformulation - lisinopril, ramipril and spironolactone 
(Table 8 and Table 9). 
Table 8 - Drugs listed in the EMA Revised Priority List for Studies into off-patent 
paediatric medicinal products and the transporters with which they interact (Transporter 
information collected from sources listed in the bibliography). 
EMEA Revised Priority List for Studies into off-patent paediatric medicinal 
products 
Drug Transporters 
Amiodarone ABCB1 (Inhibitor, Inducer) 
Dobutamine None 
Milrinone None 
Propanolol SLC22A2 (Inhibitor), ABCB1 (Substrate, Inhibitor) 
Fluoxetine ABCB1 (Inhibitor) 
Androstanolone gel ABCB1 (Substrate(Skin)) 
Cholestyramine None 
Glibenclamide ABCC3 (Inhibitor), ABCB11 (Inhibitor), ABCB1 (Inhibitor), 
ABCC1 (Inhibitor), SLC15A1 (Inhibitor), SLCO1A2 
(Inhibitor), SLC15A2 (Inhibitor), hROAT1 (Inhibitor), 
ABCC2 (Inhibitor), ABCG2 (Inhibitor), SLC22A7 (Inhibitor), 
SLCO2B1 (Substrate).  
Hydorcortisone ABCB1 (Substrate, Inhibitor), ABCG2 (Inhibitor), SLCO1A2 
(Inhibitor). 
Metformin SLC22A2 (Substrate, Inhibitor), SLC22A1 (Substrate, 
Inhibitor), SLC47A1 (Inhibitor) 
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Carbimazole None 
Bisacodyl Not Absorbed 
Macrogol Not Absorbed 
Unfractionated 
Heparin 
None 
Azathioprine None 
Etopophos ABCC3 (Substrate, Inhibitor), ABCC6 (Substrate Inhibitor), 
ABCB1 (Substrate, Inhibitor), ABCC1 (Substrate, Inhibitor), 
ABCC10 (Substrate, Inhibitor), ABCC2 (Substrate, 
Inhibitor), ABCG2 (Substrate) 
Fludarabine SLC29A1 (Substrate) 
Melphalan SLC22A3 (Inhibitor) 
Methotrexate ABCC3 (Substrate, Inhibitor), ABCC4 (Substrate, Inhibitor), 
ABCC1 (Substrate, Inhibitor), hROAT1 (Substrate, 
Inhibitor), ABCC10 (Inhibitor), SLC22A8 (Substrate, 
Inhibitor), ABCC2 (Substrate, Inhibitor), ABCB1 
(Substrate), SLCO1A2 (Substrate), SLC16A1 (Substrate), 
ABCC11 (Substrate), SLCO1B3 (Substrate), SLC22A11 
(Substrate), SLCO1C1 (Substrate), SLCO3A1 (Substrate), 
ABCG2 (Substrate), SLC22A7 (Substrate), SLCO1B1 
(Substrate), SLC46A1 (Substrate, Inhibitor).  
Mycophenolate 
Mofetil 
None 
Amphotericin B None 
Clindamycin None 
Ganciclovir SLC22A1 (Inhibitor), hROAT1 (Inhibitor), SLC22A8 
(Inhibitor), SLC22A7 (Inhibitor) 
Itraconazole ABCB1 (Inhibitor) 
Clonidine SLC22A1 (Inhibitor), SLC22A3 (Inhibitor), SLC22A5 
(Inhibitor), SLC22A4 (Inhibitor), ABCB1 (Substrate) 
Diclofenac ABCC4 (Inhibitor), ABCB1 (Inhibitor), ABCC1 (Inhibitor), 
hROAT1 (Inhibitor), SLC22A8 (Inhibitor), SLCO1C1 
(Inhibitor), SLC22A11 (Inhibitor). 
Propofol None 
Spironolactone ABCC2 (Inducer), ABCB1 (inhibitor), SLCO1A2 (Inhibitor). 
Amiloride SLC22A2 (Inhibitor), SLC22A1 (Inhibitor), SLC22A4 
(Inhibitor) 
Ciclosporin ABCB1 (Substrate, Inhibitor, Inducer), ABCC3 (Inhibitor), 
ABCB11 (Inhibitor), ABCC1 (Inhibitor), SLCO1A2 
(Inhibitor), SLC10A2 (Inhibitor), SLC10A1 (Inhibitor), 
hROAT1 (Inhibitor), ABCC10 (Inhibitor), ABCC2 (Inhibitor), 
ABCG2 (Inhibitor), SLCO1B1 (Inhibitor) 
Deflazacort None 
Captopril ABCB1 (Inhibitor), SLC15A1 (Inhibitor), hROAT1 (Inhibitor) 
Enalapril ABCB1 (Inhibitor), SLC15A1 (Substrate, Inhibitor), 
hROAT1 (Inhibitor), SLC22A8 (Inhibitor), SLC22A7 
(Inhibitor), SLCO1A2 (Substrate). 
Lisinopril ABCB1 (Inhibitor), SLC15A1 (Substrate). 
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Ramipril SLC15A1 (Substrate), SLC15A2 (Substrate) 
Allopurinol SLC22A8 (Substrate), SLC22A7 (Substrate). 
Ethosuximide None 
Lidocaine SCL22A5 (Inhibitor), ABCB1 (Inhibitor) 
Topiramate None 
Cyclophosphamide ABCB1 (Inhibitor) 
Daunorubicin ABCB1 (Substrate, Inhibitor, Inducer), ABCC1 (Substrate, 
Inhibitor), ABCC2 (Inhibitor), SLC22A2 (Substrate), 
ABCC6 (Substrate), ABCB11 (Substrate), ABCC10 
(Substrate), ABCG2 (Substrate). 
Topotecan ABCG2 (Substrate, Inhibitor), ABCB1 (Substrate). 
Granisetron None 
Tropisetron None 
Ondansetron None 
Carbamazepine ABCB1 (Substrate, Inhibitor, Inducer) 
Gabapentin None 
Ibuprofen SLCO2B1 (Substrate), ABCB1 (Substrate), ABCC4 
(Inhibitor), ABCC1 (Inhibitor), SLCO1A2 (Inhibitor), 
hROAT1 (Inhibitor), SLC22A8 (Inhibitor), SLC22A11 
(Inhibitor) 
Azithromycin ABCB1 (Inhibitor) 
Dornase Alfa None 
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Table 9 - Drugs listed in the NHS Specials list for November 2011 Drug Tariff and the 
transporters with which they interact (Transporter information collected from sources 
listed in the bibliography). 
NHS Specials list for November 2011 Drug Tariff 
Drug Transporters 
Amisulpride None 
Amitriptyline ABCB1 (Substrate, Inhibitor) 
Amlodipine ABCB1 (Inhibitor) 
Azathioprine None 
Bendroflumethiazide None 
Captopril ABCB1 (Inhibitor), SLC15A1 (Inhibitor), hROAT1 (Inhibitor) 
Chloral hydrate None 
Clobazam None 
Clonazepam None 
Co-Dydramol None 
Dipyridamole ABCC4 (Inhibitor), ABCC5 (Inhibitor), ABCB1 (Inhibitor) 
Ferrous sulphate None 
Gabapentin None 
Gliclazide None 
Glycopyrronium 
Bromide 
None 
Haloperidol ABCB1 (Substrate, Inhibitor) 
Lorazepam None 
Midazolam ABCB1 (Substrate, Inhibitor, Inducer), SLC22A1 (Inhibitor) 
Primidone None 
Ramipril SLC15A1 (Substrate), SLC15A2 (Substrate) 
Spironolactone ABCC2 (Inducer), ABCB1 (inhibitor), SLCO1A2 (Inhibitor). 
Tarolimus ABCB1 (Substrate, Inhibitor, Inducer), ABCA5 (Substrate) 
Topiramate None 
Zopiclone None 
Glyceryl Trinitrate N/A 
Hypromellose N/A 
Sodium Chloride N/A 
 
1.10.2 Microarrays 
   The development of DNA arrays in the early 1980’s (Augenlicht et al 
1982) was one of the most important advances in the field of genome profiling. Within 
15 years of conception, by 1995 (Schena et al 1995) DNA arrays had been miniaturised 
giving the world the first DNA microarrays which were quickly utilised and in 1997 the 
first full eukaryotic genome microarray for Saccharomyces cerevisiae was reported 
(Lashkari et al 1997). In modern day genomics they find routine application in a broad 
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spectrum of disciplines including advancing areas of drug discovery and development 
through comparative assessment of normal and diseased state tissues, transcription 
and/or expression profiling, side effect profiling, pharmacogenomics and the 
identification of biomarkers (Russell et al 2013). 
 In the production of DNA microarray slides probes are immobilized onto a flat, 
solid support in an organized grid like fashion producing rows and columns. Each probe 
is designed to match and identify its corresponding molecule in an unambiguous fashion 
following hybridization (Karakach et al 2010). Single stranded (ssDNA) and double 
stranded (dsDNA) DNA oligomers as either short length (25 base pairs (bp)) 
oligonucleotide probes (Li et al 2009) or long (50-80bp) oligonucleotide probes (Zhao et 
al 2005 and Barrett et al 2003) can be used. cDNA can also be used in the production 
of microarray probes which are of longer and highly variable cDNA probes (Grover et al 
2010). Although the microarray production procedure varies, the end point of slide 
scanning and fluorescence quantification prior to data analysis are common components 
for all microarrays (Figure 4).  
 In microarray experiments, mRNA isolated from tissue or cell samples is 
fluorescently labelled to produce samples for analysis referred to as targets. These 
targets are then hybridized to their corresponding probes on the microarray slide 
followed by slide scanning allowing for the simultaneous quantification of expression 
levels of thousands of transcripts from each sample facilitating analysis on genome wide 
level. It is this ability which makes microarray such a powerful resource in the high 
throughput assessment of gene expression. Each slide scan generates huge amounts 
of data and it is through the detailed statistical processing of the datasheets that trends 
in the gene expression levels can be revealed. In addition to the specific investigation 
being performed, the data gathered also contributes to the production of genomic 
databases and genetic maps such as the human genome project (Schena et al 1995) 
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and the Kyoto encyclopaedia of genes and genomes (KEGG) (Russell et al 2013, 
Kanehisa and Goto 2000).  
 
Figure 4 – Flow chart illustrating the different processes in the use of cDNA microarrays, 
long oligonucleotide microarrays and short oligonucleotide microarrays. cDNA 
microarrays begin by growing libraries of cDNA clones in bacterium, this cDNA is then 
transferred to glass slides to form the array. In contrast, oligonucleotide arrays start with 
bioinformatic oligonucleotide design to produce the array slides. Once microarray slides 
are produced, the fluorescent labelling, hybridisation and data analysis processes are 
the same for both types of array.  
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 Various software programs such as TMEV have been developed perform 
hierarchical clustering (HCA), principal component analysis (PCA) and statistical 
analysis of microarray (SAM) to facilitate the comparison of gene expression leading to 
the identification of potentially important genes.  
 HCA clusters data from samples or investigations in order of closeness of the 
gene expression profiles. That is samples showing the largest difference to controls are 
clustered furthest from the controls and likewise samples showing the least difference 
are clustered closest. HCA allows for the visual identification of samples or genes which 
are providing similar degrees of expression in the experimental conditions (Heyer et al., 
1999; Tefferi et al., 2002). The main limitation of this technique is the data set is not 
reduced in any way therefore there are still tens of thousands of data points for 
consideration and thus identifying specific correlations in the data is complex and time 
consuming.  
 Data reduction techniques such as PCA overcome the limitations of HCA by 
separating the data set into multiple principal components, PCA is multivariate data 
analysis (MVDA) tool, the likes of which have been used extensively in the past, it is only 
within the last decade or so however that they have found application in cellular biology 
analysis (Orr & Scherf, 2002; Michaud et al., 2003).  
 PCA is a tool used to simplify the data analysis procedure making large scale 
data easier to handle, and crucially without the loss of information. This is achieved by 
assessing principal components in a three dimensional space. The term principal 
component describes how we choose to describe our data in a more concise or 
convenient way, redefining variables by combining factors showing correlation (Orr & 
Scherf, 2002; van der Werf et al., 2005). Eigenvalue decomposition (EVD) is one of the 
most popular ways to define principal components. Principal components are required 
to be mathematically orthogonal to each other, this means that there is no linear 
correlation between components. This is useful as variables in raw data are not 
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independent and any variables which display correlation to one another result in 
redundancy. It is in this way PCA minimises variables without the loss of information. 
Principal components are numbered in order of the magnitude of variance meaning that 
component 1 has the largest degree of variance in the data followed by component 2 
then 3 and so on and it is the separation along a component between data sets that 
illustrates the degree of variation between them. It is common that there are large 
numbers of components however so to simplify the data analysis further components 
which contribute to low levels of variance can be discarded without impacting the findings.  
 SAM algorithms are also a useful tool in the analysis of genomic data as they are 
capable of identifying individual genes as significant based on the differential expression 
between sample sets. The statistical analysis can be tuned to the data set being 
investigated to maximise the data mining process. An additional benefit of SAM which is 
not provided by other techniques is the identification of the false discovery rate (FDR), 
this reveals what percentage of the significant genes have been identified by chance. 
The incorporation of SAM into microarray data analysis means that gene lists can be 
produced for significantly different genes and used in pathway analysis investigations 
with the confidence that the findings are statistically relevant.     
 KEGG is one of the many online resources in existence alongside databases the 
human genome project and METLIN amongst others which are utilised across a range 
of genomic, proteomic and metabolomic applications where it is used to build genome 
wide models of pathways and processes. The key to its usefulness is in the integration 
of information recorded regarding molecular pathways, genome projects and compound 
databases which is complimented by the logging of information referring to cellular 
pathways, both metabolic and signalling and also information on human disease and 
drug development in a largely open access manner (Russell et al 2013). 
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1.11 REFORMULATION 
 Reformulation of existing medicinal products is performed for a variety of reasons. 
Pharmaceutical companies ‘tweak’ their own products so as to allow for re-patenting and 
in doing so maintain their market exclusivity in that area, to expanding the scope of an 
existing drug to better target other patient segments (Yoshitani and Cooper 2007). Also 
there are many factors of existing formulations which can be improved in an effort to 
maximise their potential for targeting specific patient groups. Where paediatric 
reformulations are concerned some of the most common areas for improvement are; 
increasing the understanding of a drug’s pharmacokinetics, improving a drug’s safety 
and developing an age appropriate formulation. 
 Reformulation of off-patent medications in an attempt to improve the availability 
of medication to children is a much more attractive proposition when compared to 
developing a completely NCE as using an existing API which is recognised by the FDA 
means that all of data collection via clinical trials associated with the production of a NCE 
will already have to have been carried out in order for the FDA advisory committee to 
approve the product (Bhattaram et al 2005). This will remove much of the cost associated 
with the formulation of a new drug. Reformulation is generally categorised into three sub 
categories including; the reformulation of a molecular entity, new deliveries and new 
indications (Yoshitani and Cooper 2007). 
 The reformulation of molecular entities involves the modification of an existing 
API just enough so as that the changed molecule can be patented however not enough 
to alter how it behaves in the body. In this way the FDA views the modified API as the 
same drug under the guidelines regarding bioequivalence. In the area of molecular entity 
reformulation there are three further subsections which involve metabolites, polymorphs 
and chiral switching. 
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 Metabolites are the molecules produced following a chemical reaction in the body, 
the modification implemented with regards to metabolites is the creation of prodrugs 
which enter the body in an inactive form and following metabolism the active form of the 
drug is produced (Yoshitani and Cooper 2007).  
 Polymorphs which exist with different crystalline structures, waters of hydration, 
solvents and amorphous forms come into play where reformulation is concerned as the 
FDA recognise a modified API so long as there is no change in its physical form and that 
it is also bioequivalent to the original drug (Yoshitani and Cooper 2007). It is often difficult 
to produce reformulations which display characteristics which are bioequivalent to the 
original product as changes in the polymorphism often bring about changes in the 
solubility of the drug which in turn can result in changes in the drugs dissolution 
properties (Wiliams et al 2008). 
 Chiral switching is implemented in reformulation as the ratio of each chiral version 
can be changed resulting in a more pure S- enantiomer or a more pure R- enantiomer 
and as each chiral version bring about very different responses in the body (Fleming and 
Ma 2002). A more pure mix would produce a more effective response in favour of one 
or other enantiomer depending on which was present in the highest concentration. In 
this way the efficacy of a drug is improved without altering the molecule itself (Yoshitani 
and Cooper 2007).    
 Reformulation to produce new delivery methods is fairly self-explanatory with 
factors such as the alteration of the dosage form say from an oral liquid such as a 
suspension to an oral solid such as a tablet or a capsule. Alternatively reformulating to 
change the route of entry into the body for example changing from a nasal spray to an 
oral tablet or a capsule. In both cases it is essential that the behaviour of the drug once 
inside the body is identical to the original formulation (Yoshitani and Cooper 2007).  
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 New indications involves the production of an existing drug however using the 
existing medication to treat a disease or condition not covered in an existing drug patent 
(Ashburn and Thor 2004). If this is achieved then there are no changes to the existing 
API and it is just a new method of use for an existing medication. This is a relatively 
uncommon occurrence as drug companies go to great lengths to protect their products 
in order to maintain market exclusivity (Yoshitani and Cooper 2007).  
1.12 AIMS AND OBJECTIVES OF THESIS 
 As discussed above it is recognized globally that the drug products currently 
available for treating the paediatric population, which suitably meet the needs of the 
patient segment are lacking in their coverage. In order to improve on this situation bodies 
such as the FDA and the EMA have devised legislation to guide the research and 
development of paediatric medicines through priority listings. By selecting and 
reformulating off patent medications as oral liquids in cases where oral liquids are not 
already available the paediatric population can be more appropriately targeted.    
 Additionally, previous research has shown how the gene expression of intestinal 
membrane transporters changes in response to drug transport. It is therefore considered 
worthwhile investigating if there is a correlation between the expressional changes seen 
and the extent of drug absorption. The development of an in vitro – in vivo correlation 
would be of benefit to a number of fields, potentially aiding in the areas of drug discovery 
and development as well as potentially reducing the need for animal based drug 
absorption studies.  
The objectives of the work can be categorized into three main areas of research; 
1. Reformulation of the angiotensin converting enzyme (ACE) inhibitors lisinopril 
and ramipril and potassium-sparing diuretic spironolactone to produce oral liquid 
formulations better targeting the paediatric patient segment.  
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2. Using the model formulations produced in the first stage of the project, an in vitro 
– in vivo correlation between changes in gene expression following in vitro 
transport studies and in vivo absorption will be investigated using microarray 
technology.        
3. During the production of any oral formulation targeting any patient segment the 
palatability of the formulation is an important consideration. It became apparent 
during the formulation development stages of the project that the available 
analytical techniques for taste assessment are inadequate. As such initial stages 
into the development of an in vitro cell based taste assessment method merited 
investigation.  
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2 REFORMULATION OF LISINOPRIL TO PRODUCE AN AGE APPROPRIATE 
ORAL LIQUID DOSAGE FORM TARGETING THE PAEDIATRIC PATIENT 
SEGMENT 
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2.1 CHAPTER AIMS AND OBJECTIVES 
- Develop a HPLC method for the detection of Lisinopril and validate according to 
ICH guidelines. 
- Formulate Lisinopril as an oral liquid dosage form with a particular focus on 
effectively targeting the paediatric patient segment. 
- Characterise formulations including stability testing in long term and accelerated 
conditions as specified by ICH guidelines.   
2.2 INTRODUCTION 
 According to the BNF for children September 2013 edition, the use of Lisinopril 
is limited to treatment, under specialist supervision, of hypertension and proteinuria in 
nephritis, diabetic nephropathy and heart failure. The recommended dosage varies 
significantly depending upon the desired application. For the treatment of hypertension 
and proteinuria in nephritis in children aged 6-12 years the recommended initial dose is 
70µg/kg (Max 5mg) being administered once daily increasing in intervals of 1-2 weeks 
to 600µg/kg (Max 40mg) given once daily. In children aged 12-18 years the 
recommended dose is initially 5mg given once daily with a usual maintenance dose of 
10-20mg given once daily with a maximum of 80mg given once daily. In the case of 
diabetic nephropathy, the recommendation is only for the treatment of children aged 12-
18 years and again the dosage is initially 5mg given once daily with a usual maintenance 
dose of 10-20mg given once daily with a maximum of 80mg given once daily. For the 
treatment of heart failure the recommendation is only for children aged 12-18 and the 
dosage is initially 2.5mg given once daily which is increased by no greater than 10mg at 
a time and at intervals of at least two weeks up to a maximum of 35mg given once daily 
if tolerated by the patient (Paediatric Formulary Committee 2012).  
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 Lisinopril (Table 10), along with Captopril is one of the few ACE inhibitors which 
in administered in its active form and not as a pro-drug. Lisinopril is not currently 
available as a liquid dosage form (Table 11) and the existing formulations are not 
currently licensed for use in pediatrics. 
 
Table 10 - Lisinopril Monograph listing important physiochemical properties which should 
be considered before formulation. 
Lisinopril Monograph 
Chemical Name 
(2S)-1-[(2S)-6-Amino-2-[[(1S)-1-carboxy-3-
phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic 
acid dehydrate 
Other Names Prinivil, Zestril 
Molecular Formula C21H31N3O5.2H2O 
Molecular Weight 441.5 
CAS Number 83915-83-7 
Lisinopril Structure 
 
Appearance White Crystalline Powder 
Solubility 
Lisinopril is soluble in water (100mg/ml), soluble in 
methanol (14.3mg/ml). Lisinopril is practically insoluble in 
alcohol, acetone, chloroform and ether. 
Sensitivities 
Lisinopril is sensitive to Oxidation and Alkaline 
conditions. 
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Table 11 - Available Lisinopril dosage forms detailing product name, drug dosage and 
dosage form. 
Available Lisinopril Dosage Forms 
Prinivil 90 20 mg tablet Bottle Prinzide 10-12.5 mg tablet 
Prinzide 30 20-12.5 mg tablet Bottle Zestril 20 mg tablet 
Prinivil 30 2.5 mg tablet Bottle Zestril 10 mg tablet 
Lisinopril 100% powder Zestoretic 20-25 tablet 
Zestril 40 mg tablet Zestril 5 mg tablet 
Zestril 30 mg tablet Zestoretic 20-12.5 tablet 
Prinivil 40 mg tablet Lisinopril 20 mg tablet 
Zestoretic 20-25 mg tablet Prinivil 20 mg tablet 
Zestoretic 20-12.5 mg tablet Zestril 2.5 mg tablet 
Prinzide 20-25 mg tablet Lisinopril 10 mg tablet 
Zestoretic 10-12.5 mg tablet Prinivil 10 mg tablet 
Zestoretic 10-12.5 tablet Lisinopril 5 mg tablet 
Lisinopril 30 mg tablet Prinivil 5 mg tablet 
Lisinopril 40 mg tablet Apo-Lisinopril 20 mg Tablet 
Prinzide 20-12.5 mg tablet Mylan-Lisinopril 20 mg Tablet 
 
 Given the recommendation for the production of an age appropriate formulation, 
coupled with the need for dose flexibility and the lack of an oral liquid formulation, the 
production of an oral liquid formulation created with a focus on paediatric use would be 
highly advantageous. 
 Detailed herein is the formulation of, and characterization of an oral Lisinopril 
solution, including details of the production of a suitable HPLC method, excipient 
selection and stability assessment of the formulations in accordance with ICH guidelines. 
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2.3 MATERIALS AND METHODS  
2.3.1 HPLC Method Development for the Detection of Lisinopril 
 The Lisinopril HPLC method was developed using a Dionex GP50 Gradient 
Pump coupled to a Dionex UVD170U detector and a Dionex A550 auto sampler. The 
stationary phase is a Phenomenex Gemini 5µ C18 reverse phase HPLC column (150 x 
4.5mm with 5µm Particle Size). The detection wavelength was set at 228nm. The 
injection volume is 20µl with a run time of 10 minutes. Preparation of Calibration 
Standards involves the production of six standards produced via serial dilution in mobile 
phase. Standards at 2.0, 1.0, 0.5, 0.25, 0.125 and 0.0625mg/ml and samples are 
prepared for analysis by dilution so as to fall within the calibration range and are diluted 
with Lisinopril mobile phase. Method validation was carried out following ICH Guidelines 
(Q2(R1)). 
2.3.2 Formulation Development 
 The Lisinopril for the formulation was purchased from Discovery fine chemicals 
while citric acid, Propyl Paraben, Butyl Paraben and Xylitol were all supplied by Sigma. 
The flavour concentrates used in the formulation development were free samples 
provided by S. Black’s (Azelis). Formulations were produced using volumetric glassware. 
Ultrapure water was first added into which excipients were dissolved with the aid of a 
magnetic stir bar before it was removed and the solutions made up to volume. Upon 
production formulations were transferred to amber glass bottles.  
2.3.3 Stability Analysis 
 The conditions for storage are set out in the ICH Harmonisation Guidelines 
(Q1A(R2)) 2003 (Table 12) which states that ‘a drug substance should be evaluated 
under storage conditions that test its thermal stability, and if applicable its sensitivity to 
moisture’. The conditions are listed below; 
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Table 12 - Storage conditions for stability testing as outlined in the ICH guidelines (ICH 
Guidelines Q1A(R2) 2003). (R.H = Relative Humidity) 
Study Storage Conditions 
Minimum Time 
Period 
Long Term 
25°C ± 2°C  at 60% 
12 Months 
R.H ± 5% 
or 
30°C ± 2°C at 65% R.H ± 5% 
Accelerated 40°C ± 2°C at 75% R.H ± 5% 6 Months 
 
 Samples were stored in Firlabo SP-BVEHF stability cabinets and analysed on a 
monthly basis, quantitatively for drug recovery via HPLC and pH and qualitatively for 
colour and odor.   
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2.4 RESULTS AND DISCUSSION  
 The content of this chapter comprises of two key areas of investigation, firstly 
there is the development stages and secondly there is the assessment stages. 
2.4.1 HPLC Method Development for the Detection of Lisinopril 
 The development of a HPLC method for the detection of Lisinopril was initially 
carried out following the method described by Nahata and Morosco (2004). This involved 
the use of a reverse phase Phenomenex Gemini C18 column (150 × 4.6 mm) 5µm particle 
size at 27°C, using a mobile phase of 0.8% diethylamine in water and acetonitrile (43:57, 
v/v). The flow rate was 0.4 mL/min. UV detection was carried out at 220nm. The Lisinopril 
stock solution was prepared in methanol at 2mg/ml and further calibration standards 
were produced from this via serial dilution. Six standards were produced in total and 
these were ran using the above conditions. 
 The trace (Figure 5) produced by following the method described by Nahata and 
Morosco (2004) was very noisy and a large solvent front was present close to the 
Lisinopril peak with the Lisinopril peak appearing ahead of the solvent front.  
 
Figure 5 - HPLC trace for 2mg/ml Lisinopril calibration standard ran using the method 
described by Nahata and Morosco (2004). 
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 In order to reduce the noise on the trace the stock solution and subsequent serial 
dilutions were produced using mobile phase in place of the methanol. The resulting trace 
(Figure 6) displayed a much smoother readout as desired however the large solvent 
front was still present with the Lisinopril peak appearing ahead of the solvent front.  
 
 
Figure 6 -HPLC trace for 2mg/ml Lisinopril calibration standard ran following modification 
to the method described by Nahata and Morosco (2004). Calibration standards produced 
in mobile phase rather than in methanol. 
 
 To correct this problem the mobile phase used was adjusted from 0.8% 
diethylamine in water and acetonitrile (43:57, v/v) to 0.8% diethylamine in water and 
acetonitrile (20:80, v/v). This was designed to increase the polarity of the mobile phase 
which would lead to an increase in the retention time of the Lisinopril. Running the 
Lisinopril standards using the modified mobile phase resolved the problem of the solvent 
front and improved the detection of the Lisinopril (Figure 7). 
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Figure 7 - HPLC trace for Lisinopril calibration standards ran following modification to 
the method described by Nahata and Morosco (2004). Mobile phase altered from 0.8% 
diethylamine in water and acetonitrile (43:57, v/v) to 0.8% diethylamine in water and 
acetonitrile (20:80, v/v). Calibration standards produced in mobile phase rather than in 
methanol. 
 
 Although the trace displayed vast improvement there still remained some 
variation in the retention time and the peaks produced were larger than desired. In order 
to maximize the detection of Lisinopril and reduce the variation in retention time a 
Lisinopril solution produced using the modified mobile phase was analysed using UV 
spectroscopy to identify λmax. This was found to be 228nm. The injection volume was 
reduced to decrease the peak size and following adjustment of the detection wavelength 
the calibration standards were re-ran and the resulting retention times were found to be 
more consistent (Figure 8) 
-0.36 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.14
-279
0
200
400
600
800
1,000
1,277
1 - Lisinopril Calibration 02.11.2010 #1 Lisinopril Calibration 02.11.2010 UV_VIS_1
2 - Lisinopril Calibration 02.11.2010 #2 Lisinopril Calibration 02.11.2010 UV_VIS_1
3 - Lisinopril Calibration 02.11.2010 #3 Lisinopril Calibration 02.11.2010 UV_VIS_1
4 - Lisinopril Calibration 02.11.2010 #4 [modified by Administrator] Lisinopril Calibration 02.11.2010 UV_VIS_1
5 - Lisinopril Calibration 02.11.2010 #5 [modified by Administrator] Lisinopril Calibration 02.11.2010 UV_VIS_1
6 - Lisinopril Calibration 02.11.2010 #6 [modified by Administrator] Lisinopril Calibration 02.11.2010 UV_VIS_1
7 - Lisinopril Calibration 02.11.2010 #7 [modified by Administrator] Lisinopril Calibration 02.11.2010 UV_VIS_1
mAU
min
7
6
5
4
3
2
1
WVL:220 nm
 
 
101 
 
 
 
Figure 8 - HPLC trace for calibration standards ran following modification to the method 
described by Nahata and Morosco (2004). Mobile phase altered from 0.8% diethylamine 
in water and acetonitrile (43:57, v/v) to 0.8% diethylamine in water and acetonitrile (20:80, 
v/v). Calibration standards produced in mobile phase rather than in methanol. Reduction 
of the injection volume to 20µl and adjustment of the detection wavelength to 228nm.     
 
 With the detection optimized the method was investigated for its ability to resolve 
Lisinopril from a preliminary formulation. The first stage in this was to produce a 
calibration curve for the method using the calibration standards produced from the stock 
solution. The calibration curve (Figure 9) displayed good linearity with an R2 value of 
0.9979. 
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Figure 9 - HPLC calibration curve for Lisinopril following modification to the method 
described by Nahata and Morosco (2004). Mobile phase altered from 0.8% diethylamine 
in water and acetonitrile (43:57, v/v) to 0.8% diethylamine in water and acetonitrile (20:80, 
v/v). Calibration standards produced in mobile phase rather than in methanol. Reduction 
of the injection volume to 20µl and adjustment of the detection wavelength to 228nm.     
 
 Following the production of a suitable calibration curve, two preliminary 
formulations were produced and contained 2mg/ml and 0.5mg/ml Lisinopril, 1mg/ml 
Ascorbic acid and 1mg/ml Benzoic acid as a common antioxidant and preservative. 
These formulations were then ran following the modified method with the sample 
formulation being diluted 1:5 in mobile phase (Figure 10 and Figure 11). 
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Figure 10 - HPLC trace for a preliminary Lisinopril formulation containing 0.5mg/ml 
Lisinopril, 1mg/ml Ascorbic acid and 1mg/ml Benzoic acid. 
 
 
Figure 11 - HPLC trace for a preliminary Lisinopril formulation containing 2.0mg/ml 
Lisinopril, 1mg/ml Ascorbic acid and 1mg/ml Benzoic acid. 
 
 Although the HPLC method produced a good calibration curve the Lisinopril 
recovery from the preliminary formulations was found to be >500% of the expected. This 
indicates that the excipients in the formulation are interfering with the Lisinopril peak. To 
confirm this an ascorbic acid (Figure 12) and a benzoic acid (Figure 13) solution were 
both ran using the Lisinopril HPLC method.  
 
 
104 
 
 
 
Figure 12 - HPLC trace for the detection of ascorbic acid using the Lisinopril HPLC 
method. 
 
 
Figure 13 - HPLC trace for the detection of benzoic acid using the Lisinopril HPLC 
method 
 
 As the two traces confirm the retention time of ascorbic acid and benzoic acid 
(2.9 minutes) are at the same time as the lisinopril retention time, the only way to avoid 
this problem was to again modify the mobile phase composition. To do this the ratio of 
0.8% diethylamine to acetonitrile was reversed and increased from (20:80) to (90:10). 
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Although it was expected that the solvent front previously present would re-appear, 
increasing the polarity of the mobile phase sufficiently may separate the sample peak 
suitably from the solvent front. Repeating the HPLC for the preliminary formulation with 
the modified mobile phase produced the following trace (Figure 14). 
 
 
Figure 14 - HPLC trace for preliminary formulation using modified mobile phase of 0.8% 
diethylamine and acetonitrile (90:10). 
 
 This produced a clear peak and following the production of a calibration curve 
(Figure 15) the recovery was found to be 102.71%. With a suitable method developed 
the next stage was the validation of the method. This was performed as detailed in the 
ICH Guidelines Q2(R1).  
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Figure 15 - HPLC calibration curve for Lisinopril using modified mobile phase of 0.8% 
diethylamine and acetonitrile (90:10). Results are generated from triplicate repeats (n=3) 
and error bars indicate standard deviation (RSD). 
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To provide indication of the method’s selectivity the Mobile Phase (0.8% diethylamine 
and acetonitrile (90:10)) was used as a blank (Figure 16) in order to show that there are 
no placebo peaks eluting at the same retention time as Lisinopril (Figure 17).  
 
 
Figure 16 - Mobile Phase Blank 
 
 
Figure 17 - Lisinopril Spiked Mobile Phase (2mg/ml) 
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 The Accuracy of the method was determined by spiking mobile phase solution 
with known amounts of Lisinopril (2mg/ml, 1mg/ml and 0.5mg/ml). Three different 
concentrations within the calibration range were ran in triplicate. The recoveries ranged 
from 97.14% to 106.86% with a relative standard deviation (RSD) of 4.13%. Response 
for the detector was determined to be linear over a range of 2mg/ml to 65.5µg/ml. 
Correlation coefficients and slopes were obtained by plotting standard concentration 
(mg/ml) against peak area (mAU*min) (Figure 18).  
 
 
Figure 18 - Lisinopril Calibration chart illustrating good linearity with an R2 value of 0.9988 
and an equation (y = 38.57x – 0.8227) to be used in the calculation of sample 
concentrations. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
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 The method precision is determined via 3 intraday HPLC runs, running six 
standards each in triplicate (Figure 19, Figure 20 and Figure 21). The intermediate 
precision for the method is determined via 3 interday HPLC runs, running six standards 
each in triplicate (Figure 22, Figure 23 and Figure 24). 
 
Figure 19 - Lisinopril Validation - Intraday Run A. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 20 - Lisinopril Validation - Intraday Run B. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 21 - Lisinopril Validation - Intraday Run C. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 22 - Lisinopril Validation - Interday Run A. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 23 - Lisinopril Validation - Interday Run B. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 24 - Lisinopril Validation - Interday Run C. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 The Limit of Detection (LOD) for the method is the lowest amount of analyte in a 
sample which can not necessarily be used in order to calculate an exact value but the 
lowest amount which can be detected by the detector. The LOD can be expressed as; 
𝐿𝑂𝐷 =  
3.3𝜎
𝑆
 
σ = is standard deviation of the response. 
S = the slope of the calibration curve. 
For the Lisinopril method the LOD was 0.12mg/ml. 
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 The Limit of Quantification (LOQ) for the method is the lowest amount of analyte 
in a sample which can be used in order to calculate a suitably accurate and precise value 
for the amount of analyte in the sample. The LOQ can be expressed as;  
𝐿𝑂𝑄 =  
10𝜎
𝑆
 
σ = is standard deviation of the response. 
S = the slope of the calibration curve. 
For the Lisinopril method the LOQ was 0.38mg/ml. 
 Having preformed the validation for the Lisinopril HPLC method it was 
determined that the method was not sensitive enough for the purpose required. In order 
to overcome this problem a second HPLC method for the detection of Lisinopril was 
investigated. 
 The new method was adapted from a method described by Beasley et al (2005). 
The new mobile phase consisted of a Potassium Phosphate Buffer mixed 80:20 with 
acetonitrile. Standards were produced using the Potassium Phosphate mobile phase 
ranging from 2mg/ml – 62.5µg/ml and these were ran at a wavelength of 228nm using a 
flow rate of 1.0ml/min and an injection volume of 20µl through a Phenomenex Gemini 
C18 column (150 × 4.6 mm) 5µm particle size at 27°C.  
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Figure 25 - HPLC trace for Beasley et al (2005) Lisinopril HPLC method. 
 
 The Beasley et al (2005) Lisinopril HPLC method produced a clean peak at 
around 2 minutes retention time (Figure 25). The peak produced was very narrow and 
the difference in peak area between standards was relatively small. In an effort to 
broaden the peak to increase the peak area and also potentially increase the separation 
of peaks produced by excipients the flow rate was reduced from 1ml/min to 0.5ml/min. 
The standards were re-ran with the flow rate reduced and this produced the following 
trace (Figure 26).  
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Figure 26 - HPLC trace for Beasley et al (2005) Lisinopril HPLC method implementing 
reduction to the flow rate from 1ml/min to 0.5ml/min.  
 
 The modification to the flow rate increased the peak area by around 100% and 
increased the retention time to approximately 4 minutes. As a result the separation of 
any excipient peaks will also be doubled. The calibration curve for this method produced 
good linearity with an R2 value of 0.9996 (Figure 27). The gradient of the calibration 
curve was also increased which indicates improved LOD and LOQ values.  
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Figure 27 - Calibration curve for second Lisinopril HPLC method illustrating improved 
linearity with an R2 value of 0.9996 and an equation with a steeper gradient (y = 105.55x 
– 1.383) to be used in the calculation of sample concentrations. Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD).   
 
 The Lisinopril preliminary formulation was ran on this method in order to ensure 
there was no interference from the excipients and also to ensure that the recoveries 
were 100%. This was proven to be the case (Figure 28).  
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Figure 28 - HPLC trace for preliminary Lisinopril HPLC formulation. 
  
 Validation of this method was performed as previously described and as per the 
ICH guidelines. A summary of the validation is shown below (Table 13); 
Table 13 - Validation Summary for improved Lisinopril HPLC method 
Lisinopril Validation 
Selectivity 
The Method was deemed to be selective for Lisinopril 
by running 'blank' samples and Lisinopril spiked 
samples 
Accuracy 
Determined by spiking mobile phase with known 
amounts of Lisinopril (2.0mg/ml, 1.0mg/ml and 
0.5mg/ml). The recoveries ranged from 98.34% to 
103.15% with an average standard deviation of 2.43%. 
Linearity 
Response for the detector was determined to be linear 
over a range of 2mg/ml to 62.5µg/ml. Correlation 
coefficients and slopes were obtained by plotting 
standard concentration (mg/ml) against peak area 
(mAU*min). R2=0.9996 m=105.55 
Precision  
Precision and intermediate precision were tested via 
the comparison of three intraday and interday 
calibration curves. These showed suitable 
repeatability. 
Limit Of Detection LOD is 13.5µg/ml. 
Limit Of Quantification LOQ is 40.92µg/ml 
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     The improved HPLC method produced a greatly improved standard deviation of 
2.43%, the Linearity was also improved with an R2 value of 0.9996. The gradient of the 
line was also increased which lead to improved LOD and LOQ values of 13.55µg/ml and 
40.925µg/ml respectively. Following the development of a suitable method of detection 
the next stage in the production of the Lisinopril oral liquid formulation was the excipient 
selection.  
2.4.2 Formulation Development 
 As Lisinopril is sensitive to oxidation then it was necessary to include antioxidants 
to protect the drug from degradation as a result of oxidation over the life of the 
formulation. Similarly it was necessary to include preservatives which protect the 
formulations from microbial infection over the shelf life of a product. Also to be included 
were sweeteners and flavours to improve the palatability of the formulation owing to the 
bitter taste of the drug. The key criteria for the excipients selected were that; they must 
be generally recognised as safe (GRAS) listed by the FDA and also compatible with the 
drug, the other excipients and also the formulation conditions the drug requires. Through 
investigation into existing literature detailing information on potential excipients, 
summary tables were produced to allow directed selection of excipients for inclusion in 
formulations.  
 The inclusion of preservatives in pharmaceutical preparations has long been 
known as a necessary means of protecting a product from microbial contamination. 
Preservatives are not universal and some are better suited to one dosage form more so 
than another (Table 14); 
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Table 14 - Preservative Options  
Preservative Advantages Disadvantages Application 
Acids (organic): 
benzoic acid, 
parabens, sorbic 
acid 
Active against 
bacteria and fungi 
Highly pH 
dependent 
Oral and topical 
formulations; gums 
and syrups 
Alcohols: ethyl or 
isopropyl, 
chlorbutol, 
bronopol 
Broad spectrum, 
including that 
against acid-fast 
bacteria 
Volatile; poor 
penetration of 
organic matter 
Solvent; eye drops 
and injections; 
synergistic 
properties 
Aldehydes: 
formaldehyde, 
gluteraldehyde 
Broad spectrum 
antibacterial, 
antifungal, and 
sporicidal activity 
Acid solutions 
inactivated with 
temperature; toxic 
and carcinogenic 
Chemical 
sterilization and 
storage of surgical 
instruments (e.g., 
endoscopes) 
Biguanides: 
chlorhexidine, 
polyhexamethylene 
biguanide 
Mainly active in 
cationic form 
against gram-
positive bacteria 
Water insoluble; 
inactivated by 
organic matter; 
limited antifungal 
activity 
Solution for hard 
contact lenses and 
other opthalmic 
products 
Halogens: 
hypochlorite, 
povidone-iodine, 
chloroform 
Broad spectrum of 
antibacterial, 
fungal, and viral 
activity 
Unstable; 
corrosive; 
inactivated by 
organic matter 
Limited use 
nowadays 
Organic 
mercurials: 
mercury, silver, 
thiomersal, 
phenylmercuric 
acetate 
Broad spectrum of 
antibacterial 
activity 
Low capacity to 
organic matter, 
ionic and some 
non-ionic 
surfactants; 
toxicity 
Eye drops; contact 
lens solutions 
Phenolics: cresol, 
chlorocresol, 
bisphenol 
Cheap, rapid 
activity against 
gram-positive 
bacteria and fungi 
Low water 
solubility; 
adsorbed by 
rubber; volatile, 
irritant, pH 
dependent 
Creams 
Quaternary 
ammonium 
compounds: 
cetrimide, 
benzalkonium 
chloride 
Narrow spectrum 
(gram-positive 
bacteria) of 
activity; surfactant 
properties 
Low capacity to 
organic matter; low 
activity at acidic 
pH; incompatible 
with soaps, ionic 
and non-ionic 
surfactants 
Eye drops; 
surgical creams; 
ointments 
 
 For the Lisinopril formulations the selected preservative/s needed to be suitable 
for use in an oral preparation. As such and using the information provided in the table 
above (Table 14), Benzoic Acid, Sorbic Acid and the Paraben group of preservatives 
were further investigated (Table 15, Table 16 and Table 17) (Gilbert and Allison, 2006).  
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Table 15 - Summary Table for Parabens intended for use as preservatives. 
Parabens 
  
Methyl 
Paraben 
Ethyl Paraben 
Propyl 
Paraben 
Butyl Paraben 
Solubility in 
Water (%w/v) 
0.25 0.08 0.02 0.02 
pH Range  3-6 4-8 4-8 4-8 
Stability at 
20°C 
4 Years 4 Years 4 Years 4 Years 
RDA 
10mg/kg 
Bodyweight 
10mg/kg 
Bodyweight 
10mg/kg 
Bodyweight 
10mg/kg 
Bodyweight 
Buffer 
Required 
No No No No 
Antioxidants 
Required 
No No No No 
Limiting 
Factors 
Activity Reduced by use of micelles 
Advantages 
Non-toxic, Acid when dissolved in water, Effective at Low 
Concentrations 
GRAS Listed Yes Yes Yes Yes 
Amount for 
Use (mg/ml) 
4 4 4 4 
 
Table 16 - Summary Table for Benzoic Acid intended for use as a preservative. 
Benzoic Acid 
Solubility in Water 
(%w/v) 
0.33 
pH Range  2.5-4.5 
Stability at 20°C 8 Weeks 
RDA 5mg/Kg Body Weight 
Buffer Required No 
Antioxidants Required Yes 
Limiting Factors Inactive above pH5 
Advantages 
GRAS listed. Accepted as a food additive in Europe. 
Included in the FDA Inactive Ingredients Database. 
GRAS Listed Yes 
Amount for Use 
(mg/ml) 
0.1 
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Table 17 - Summary Table for Sorbic Acid intended for use as a preservative 
Sorbic Acid 
Solubility in Water 
(%w/v) 
0.25 
pH Range  Optimum 4.5 
Stability at 20°C 
Sensitive to light, Oxidising agents, Some loss of 
antimicrobial activity occurs in the presence of non-ionic 
surfactants and plastics. 
RDA 25mg/Kg Body Weight 
Buffer Required No 
Antioxidants Required Yes 
Limiting Factors 
Sensitive to oxidation, Particularly in the presence of 
light. Oxidation occurs more readily in an aqueous 
solution than in the solid form. When stored in glass 
containers, solutions become very ph sensitive, Aqueous 
Solutions of sorbic acid without the addition of 
antioxidants are rapidly decomposed when stored in 
polypropylene, polyvinylchloride and polyethylene 
containers. No activity above pH 6. 
Advantages 
Optimum pH in suitable range for lisinopril preparation, 
GRAS Listed 
GRAS Listed Yes 
Amount for Use 
(mg/ml) 
2 
 
 Investigation into the properties of benzoic acid, sorbic acid and the parabens 
allowed for sorbic acid to be discounted as an option due to more complicated conditions 
for storage and the maintenance of stability than benzoic acid and the parabens with no 
extra benefit as a preservative.  At this parabens are the preservative of choice as they 
fit all of the necessary criteria and have no limitations which will be of consequence in 
this application. It should be noted however that parabens should be used together to 
improve their activity, e.g. methyl and propyl parabens used in conjunction.  
 As discussed, antioxidants are necessary for inclusion in the Lisinopril 
formulation as lisinopril is sensitive to oxidation. Excipients included in the formulations 
may also be sensitive to oxidation and therefore the presence of antioxidants may be 
necessary to maintain the effect of preservatives or flavours for example. In the same 
was as for the selection of a preservative, the antioxidant chosen must be compatible 
with the active ingredient and also feature in the GRAS database. Investigation into 
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possible antioxidants  for use in an oral liquid preparation lead to the short listing of Citric 
Acid, Ascorbic Acid, Sodium Metabisulphate and α-Tocopherol. Investigation into the 
individual properties of these antioxidants (Table 18, Table 19 and Table 20) allowed for 
the elimination of α-Tocopherol as it has a low solubility in water.  
Table 18 - Summary Table for Citric Acid intended for use as an antioxidant. 
Citric Acid 
Solubility in 
Water (%w/v) 
61.8 
pH Range  2-6 
Stability at 
20°C 
Citric Acid Anhydrous is stable if stored under cool and dry 
conditions 
RDA None Specified 
Buffer 
Required 
No 
Limiting 
Factors 
On storage, sucrose may crystallize from syrups in the presence of 
citric acid. 
Advantages Correct pH range for use. Has some taste masking properties 
GRAS Listed Yes 
Amount for 
Use (mg/ml) 
3 
 
Table 19 - Summary Table for Ascorbic Acid intended for use as an antioxidant. 
Ascorbic Acid 
Solubility in Water 
(%w/v) 
28.57 
pH Range  Acid 
Stability at 20°C 
Powder Form = Stable. Unstable in solution, especially 
alkaline solution, made worse by light and heat. In the 
absence of oxygen and other oxidizing agents it is also heat 
stable 
RDA 15mg/kg Bodyweight 
Buffer Required No 
Limiting Factors Can be unstable in solution  
Advantages Active in correct pH range 
GRAS Listed Yes 
Amount for Use 
(mg/ml) 
1 
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Table 20 - Summary Table for sodium metabisulphate intended for use as an antioxidant. 
Sodium Metabisulphate 
Solubility in Water 
(%w/v) 
52.63 
pH Range  Acid 
Stability at 20°C 
Powder Form = Slowly oxidised in air. Aqueous sodium 
metabisulphate solutions decompose in air, especially on 
heating. Photosensitive. 
RDA 3.5mg/kg Bodyweight 
Buffer Required No 
Limiting Factors Links with allergic reactions, Potential irritant. 
Advantages 
Correct pH, GRAS listed, Has some antimicrobial properties, 
Used in acidic preparations. 
GRAS Listed Yes 
Amount for Use 
(mg/ml) 
10 
 
 All of the summarised antioxidants would be suitable for use however Citric acid 
was selected as it is already used extensively as an antioxidant in pharmaceutical 
preparations and has no limiting factors that will be of consequence in this investigation. 
It also has the added advantage that citric acid can improve the taste of a formulation. 
 For the selection of flavours and sweeteners, flavours were provided by S. 
Black’s and included at concentrations based upon manufacturer recommendations. 
Where sweeteners are concerned, artificial sweeteners were targeted to avoid using 
sugar, both for the age appropriate dosage form and also to produce a formulation which 
would be suitable for diabetics. Numerous sweeteners were investigated, all of which 
would have been suitable however Xylitol was selected for its multiple advantages which 
are discussed below. 
 Xylitol is a non-cariogenic sweetening agent in a variety of pharmaceutical 
dosage forms, including tablets, syrups, and coatings. It is also widely used as an 
alternative to sucrose in foods and as a base for medicated confectionery. Unlike 
sucrose, Xylitol is not fermented into cariogenic acid end products and does not 
contribute to the formation of dental caries. As Xylitol has an equal sweetness intensity 
to sucrose, combined with a distinct cooling effect upon dissolution of the crystal, it is 
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highly effective in enhancing the flavour of tablets and syrups and masking the 
unpleasant or bitter flavours associated with some pharmaceutical actives and 
excipients. In liquid preparations, Xylitol is used as a sweetening agent and vehicle for 
sugar-free formulations. In syrups, it has a reduced tendency to 'cap-lock' by effectively 
preventing crystallization around the closures of bottles. Xylitol also has a lower water 
activity and a higher osmotic pressure than sucrose, therefore enhancing product 
stability and freshness. In addition, Xylitol has also been demonstrated to exert certain 
specific bacteriostatic and bactericidal effects, particularly against common spoilage 
organisms. 
 As the API and all excipients are soluble in water the production of the formulation 
is simple. Following excipient selection the constituent parts for Lisinopril solutions are 
as follows;  
 Lisinopril (2mg/ml) 
 Citric Acid (3mg/ml) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (30% w/v in sweetened formulation) (10% w/v in flavoured formulation) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
2.4.3 Stability Analysis 
 With the formulation produced the next stage in the investigation was to proceed 
into stability testing. This is done by simulating an environment which a drug product 
would be likely to experience during its production, distribution and storage. Stability 
testing is important as it not only ensures that the drug content of the product remains 
constant over the duration of the products life in storage, but also that the organoleptic 
properties of the product remain unchanged. Something as simple as a colour change 
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with may be harmless can be detrimental as a patient may be reluctant to take the 
medication.  
2.4.3.1 Accelerated Conditions 
 Over the six month course of the stability testing in accelerated conditions with 
40°C and 75% relative humidity, the drug content of the formulations dropped below 
95% of the starting dose by the third month of testing falling to a low of approximately 
80% of the starting dose after six month (Figure 29). The pH remained constant for the 
duration (Figure 30). 
 
Figure 29 - Lisinopril recovery following HPLC for formulations in accelerated storage 
conditions. Before the third month of testing the formulations proved stable with little 
variation in drug content and consistent drug content between samples of the same 
batch. From the third month onwards a reduction of up to approximately 20% of the drug 
content was seen when compared with the starting concentration and in addition the 
variation between samples also increased. Results are generated from triplicate repeats 
(n=3) and error bars indicate standard deviation (RSD). 
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Figure 30 - Lisinopril pH stability for formulations in Accelerated storage conditions. For 
the duration of testing the formulations proved stable with little variation in pH seen for 
all samples. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
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2.4.3.2 Long Term Conditions 
 Over the twelve month course of the stability testing in long term conditions with 
25°C and 60% relative humidity, the drug content of all of the formulations remained 
>95% of the starting dose (Figure 31) and the pH remained constant for the duration 
(Figure 32).   
 
Figure 31 - Lisinopril recovery following HPLC for formulations in Long Term storage 
conditions. For the duration of testing the formulations proved stable with little variation 
in drug content and consistent drug content between samples of the same batch. Results 
are generated from triplicate repeats (n=3) and error bars indicate standard deviation 
(RSD).  
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Figure 32 - Lisinopril pH stability for formulations in Long Term storage conditions. For 
the duration of testing the formulations proved stable with little variation in pH seen for 
all samples. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
  
 According to the parameters outlined by the ICH harmonised tripartite guideline 
stability testing of new drug substances and products Q1A(R2), “significant change” for 
a drug product is defined as:  
1. A 5% change in assay from its initial value; or failure to meet the acceptance 
criteria for potency when using biological or immunological procedures;  
2. Any degradation product’s exceeding its acceptance criterion;  
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hardness, dose delivery per actuation); however, some changes in physical 
attributes (e.g., softening of suppositories, melting of creams) may be expected 
under accelerated conditions;  
and, as appropriate for the dosage form:  
4. Failure to meet the acceptance criterion for pH; or  
5. Failure to meet the acceptance criteria for dissolution for 12 dosage units. 
 The Lisinopril formulations tested under accelerated conditions showed 
significant decrease in the drug assayed in comparison to the day zero analysis (Figure 
29). The formulations in long term storage conditions (Figure 31) did not show any 
significant decrease in the drug assayed even after 12 months in storage. This suggests 
that the degradation seen under accelerated conditions is a result of the elevated 
temperature.  It is known that Lisinopril diketopiperazine (DKP) degradate is the primary 
degradation compound for Lisinopril. Degradation occurs through intramolecular 
condensation and sees the formation of a second amide bond (Figure 33).  
A.  
B.  
Figure 33 – Lisinopril DKP Structure (B) - primary degradation product of Lisinopril (A). 
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 This reaction is known to occur when Lisinopril experiences conditions of 
elevated temperature (Demeter et al 1998), as such the advice for storage of the 
medication would have to emphasise storage in a cool location (<25°C). The humidity of 
the storage conditions is not a large issue as the medication will be contained within 
bottles impervious to moisture. With regards to excursions outside of the storage 
conditions such as transport during distribution, degradation due to temperature should 
not be a concern so long as excursions are short in duration and infrequent. This is as 
degradation was only seen to be significant after >1 month and the temperature at which 
degradation was seen is higher than most environmental temperatures the medication 
would experience.     
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3 REFORMULATION OF RAMIPRIL TO PRODUCE AN AGE APPROPRIATE 
ORAL LIQUID DOSAGE FORM TARGETING THE PAEDIATRIC PATIENT 
SEGMENT 
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3.1 CHAPTER AIMS AND OBJECTIVES 
- Develop a HPLC method for the detection of Ramipril and validate according to 
ICH guidelines. 
- Formulate Ramipril as an oral liquid dosage form with a particular focus on 
effectively targeting the paediatric patient segment. 
- Characterise formulations including stability testing in long term and accelerated 
conditions as specified by ICH guidelines.   
3.2 INTRODUCTION 
 Ramipril is one of the many ACE Inhibitors which is produced as a pro-drug 
(Figure 34). Similar in nature to other pro-drug ACE Inhibitors such as Quinapril, 
Fosinapril and Benazepril, Ramipril is converted into its active form Ramiprilat (Figure 
35) following metabolism by esterase enzymes in the liver. This is the main site of 
activation although there is a small degree of activation which occurs in the kidneys.   
 
 
Figure 34 - Ramipril Structure 
 
 
 
133 
 
 
Figure 35 - Ramiprilat Structure 
 
 Ramiprilat competes with angiotensin I for binding with ACE and in doing so 
prevents the production of angiotensin II. In this way the conversion of Angiotensin I to 
Angiotensin II is prevented which in turn leads to the suppression of Angiotensin II 
activity resulting in the reduction of blood pressure. This effect is complemented via the 
prevention of bradykinin inactivation allowing for vasodilatation resulting in increased 
blood pressure reduction (Betzing et al 1999).   
 Ramipril is used mainly in the treatment of mild to severe hypertension but is also 
used to reduce the incidence of fatality following heart attacks in patients who develop 
indications of congestive heart failure. Also Ramipril is used to reduce the risk of heart 
attack and strokes in patients who are at high risk. As with all ACE Inhibitors Ramipril 
may be used to slow the progression of kidney disease in patients who suffer from high 
blood pressure whilst at the same time suffering from conditions such as diabetes (Ravid 
et al 1998, Lewis et al 2001, Molitch et al 2001), microalbuminuria (albumin in the urine) 
(Lewis et al 2001) or nephropathy (Molitch et al 2001). Once administered maximum 
absorption tends to be approximately 50-60% (Senthilkumar et al 2011) and is through 
the PEPT1 transporters in the small intestine (Knutter el al 2008). In the paediatric 
population Ramipril is used most commonly for the treatment of heart failure, 
hypertension in children with type 1 diabetes with nephropathy and also in the treatment 
of diabetic nephropathy (Paediatric Formulary Committee 2012). At the time of this 
research there was no liquid Ramipril formulation available (Table 21).   
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Table 21 - Ramipril Dosage Forms 
Ramipril Dosage Forms 
Altace 1.25 mg Tablet Novo-Ramipril 10 mg Tablet 
Altace 10 mg Tablet Novo-Ramipril 2.5 mg Tablet 
Altace 2.5 mg Tablet Novo-Ramipril 5 mg Tablet 
Altace 5 mg Tablet Pms-Ramipril 1.25 mg Tablet 
Altace 1.25 mg capsule Pms-Ramipril 10 mg Tablet 
Altace 1.25 mg tablet Pms-Ramipril 2.5 mg Tablet 
Altace 10 mg capsule Pms-Ramipril 5 mg Tablet 
Altace 10 mg tablet Ramipril 1.25 mg Tablet 
Altace 2.5 mg capsule Ramipril 10 mg Tablet 
Altace 2.5 mg tablet Ramipril 2.5 mg Tablet 
Altace 5 mg capsule Ramipril 5 mg Tablet 
Altace 5 mg tablet Ramipril 1.25 mg capsule 
Apo-Ramipril 1.25 mg Tablet Ramipril 10 mg capsule 
Apo-Ramipril 10 mg Tablet Ramipril 2.5 mg capsule 
Apo-Ramipril 2.5 mg Tablet Ramipril 5 mg capsule 
Apo-Ramipril 5 mg Tablet Ran-Ramipril 1.25 mg Tablet 
Co Ramipril 1.25 mg Tablet Ran-Ramipril 10 mg Tablet 
Co Ramipril 10 mg Tablet Ran-Ramipril 2.5 mg Tablet 
Co Ramipril 2.5 mg Tablet Ran-Ramipril 5 mg Tablet 
Co Ramipril 5 mg Tablet Ratio-Ramipril 1.25 mg Tablet 
Jamp-Ramipril 1.25 mg Tablet Ratio-Ramipril 10 mg Tablet 
Jamp-Ramipril 10 mg Tablet Ratio-Ramipril 2.5 mg Tablet 
Jamp-Ramipril 2.5 mg Tablet Ratio-Ramipril 5 mg Tablet 
Jamp-Ramipril 5 mg Tablet Sandoz Ramipril 1.25 mg Tablet 
Mylan-Ramipril 1.25 mg Tablet Sandoz Ramipril 10 mg Tablet 
Mylan-Ramipril 10 mg Tablet Sandoz Ramipril 2.5 mg Tablet 
Mylan-Ramipril 2.5 mg Tablet Sandoz Ramipril 5 mg Tablet 
Mylan-Ramipril 5 mg Tablet  
  
 The aim of this investigation was to reformulate Ramipril as an Oral liquid dosage 
form overcoming the various hurdles, such as poor solubility and drug stability, which 
are present in between the selection of the drug to the production of the final formulation. 
The main limitation to the formulation of an oral solution is the poor aqueous solubility of 
Ramipril. The physiochemical properties of Ramipril (Table 22) as with any drug guide 
the formulation development.  
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Table 22 - Ramipril Monograph listing important physiochemical properties which should 
be considered before formulation. 
Ramipril Monograph 
Chemical Name 
[2S-[1[R*(R*)],2α,3aβ,6aβ]]-1-[2-[[1-(Ethoxycarbonyl)-3-
phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-
2-carboxylic acid 
Other Names Altace 
Molecular 
Formula 
C23H32N2O5 
Molecular Weight 416.5 
CAS Number 87333-19-5 
Ramipril Structure 
 
Appearance White Crystalline Powder 
Solubility 
Ramipril is soluble in polar organic solvents and in buffered 
aqueous solutions. Ramipril is practically insoluble in water. 
Sensitivities 
Ramipril is sensitive to photodegradation, oxidation and alkaline 
conditions.  
 
 There are numerous methods for solubilising drugs with poor aqueous solubility 
such as; salt formation (Serajuddin 2007), micelle formation (Sezgin et al 2006), co-
solvency (Li et al 1999) and cyclodextrin complexation (Lockwood et al 2003) to name a 
few. For the purpose of the Ramipril formulation it was decided that the implementation 
of cyclodextrin complexation and also the use of co-solvency were the two best suited 
avenues of investigation. This was based on the desire to develop simple formulations 
containing the minimum amounts of excipients in order to best target paediatrics.   
 Detailed herein is the production of three oral liquid Ramipril formulations. A 
solution produced implementing cyclodextrins, a solution produced implementing a co-
solvency approach and also the production of a suspension in which excipient selection 
is optimised to overcome the limitations of a suspensions incipient instability. 
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3.3 MATERIALS AND METHODS  
3.3.1 HPLC Method for the Detection of Ramipril 
 The HPLC method for Ramipril was developed from a combination of the stability 
indicating HPLC methods described by Allen et al (1995) and Patil et al (2008). The 
method developed used a Dionex GP50 Gradient Pump coupled to a Dionex UVD170U 
detector and a Dionex A550 auto sampler. Perchlorate Buffer and Acetonitrile (55:45) 
formed the mobile phase and the stationary phase was a C18 reverse phase HPLC 
column (150 x 4.5mm with 5µm Particle Size) with a flow rate of 1mg/min and a detection 
wavelength of 216nm. The injection Volume was 50µl and the run time was 10 minutes. 
Six calibration standards produced via serial dilution in methanol and acetonitrile (Diluent 
A) (50:50). The standards are then diluted 1:5 in Diluent B (Water and Acetonitrile, 45:55). 
Samples were diluted to be within calibration standards using Diluent B. The Mobile 
Phase (Perchlorate Buffer and Acetonitrile (55:45)) was used as a blank in order to show 
that there are no placebo peaks eluting at the same retention time as Ramipril. A suitably 
linear calibration was produced (Figure 36) and the method was validated (Table 23) 
following ICH guidelines (ICH Topic Q 2 (R1) 1995). 
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Figure 36 - Ramipril HPLC calibration. Results are generated from triplicate repeats 
(n=3) and error bars indicate standard deviation (RSD). 
 
Table 23 - Ramipril HPLC Validation 
Ramipril Validation 
Selectivity 
The Method was deemed to be selective for Ramipril by 
running 'blank' samples and Ramipril spiked samples 
Accuracy 
Determined by spiking mobile phase solution with known 
amounts of Ramipril (0.5mg/ml, 0.25mg/ml and 0.125mg/ml). 
Three different concentrations within the calibration range 
were ran in triplicate. The recoveries ranged from 96.22% to 
106.33% with an R.S.D of 4.68%.  
Linearity 
Response for the detector was determined to be linear over a 
range of 1mg/ml to 31.25µg/ml. Correlation coefficients and 
slopes were obtained by plotting standard concentration 
(mg/ml) against peak area (mAU*min). R2 = 0.9996 m = 
826.51.  
Precision  
Precision and intermediate precision were tested via the 
comparison of three intraday and interday calibration curves. 
These showed suitable repeatability. 
Limit Of Detection LOD is 4.0µg/ml. 
Limit Of 
Quantification 
LOQ is 13.4µg/ml  
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3.3.2 Co-solvent Approach to Dissolve Ramipril 
 Ramipril (Discovery fine Chemicals, UK) was added (1mg/ml) to acetic acid 
(Fisher Scientific) solutions at concentrations of 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 
0.04%, 0.03%, 0.02% and 0.01%. The solutions were stirred using magnetic stirrers for 
1 hour. The speed at which the solubilisation of Ramipril occurred was observed during 
this period. Samples were then taken and filtered before analysis by HPLC to confirm 
the complete solubilisation of Ramipril.  
3.3.3 Cyclodextrin Approach to Dissolve Ramipril 
3.3.3.1 Phase Solubility 
 To investigate the phase solubility of Ramipril and HP-β-CD (Sigma) the method 
implemented was described by Higuchi and Connors (1965). Here, increasing 
concentrations of HP-β-CD were added to water. To each solution excess Ramipril was 
added and the system was stirred for 24 hours. At this point samples were taken from 
each solution, passed through a 0.45µm filter and then analysed via HPLC. 
3.3.3.2 Effect of Temperature and pH on Solubility following complexation.  
 Effect of pH and Temperature on the ability of HP-β-CD to dissolve Ramipril - In 
order to investigate the effect of pH and Temperature on the ability of HP-β-CD to 
solubilise Ramipril the phase solubility method described by Higuchi and Connors (1965) 
was adapted. To assay the effect of temperature, six concentrations of cyclodextrin were 
produced in distilled water from 1.2mM down to 3.75µM using serial dilution. These 
solutions were cooled to 15°C using ice and to each solution excess Ramipril was added. 
The solutions were then maintained at this temperature for 1 hour at which point a 
sample was taken from each solution, filtered to remove undissolved Ramipril and then 
diluted 1:10 in water with acetonitrile (45:55). These were then transferred to HPLC vials. 
The solutions were moved to a water bath set at 30°C and incubated for a further hour 
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at which point samples were again taken and transferred to HPLC vials as before. This 
process was repeated at temperatures of 45°C, 60°C and 75°C.  
 To assay the effect of pH six concentrations of Cyclodextrin were produced in 
from 1.2mM down to 3.75µM using serial dilution. These were produced in solutions of 
pH 3, 5 and 7 and to these excess Ramipril was added. This pH range was selected on 
the grounds that formulations will not be produced with a pH lower than 3 to ensure the 
compatibility of excipients and will not be produced with a pH greater than 7 as Ramipril 
is known to degrade in alkaline conditions.   Solutions were left stirring for 1 hour before 
samples were filtered to remove undissolved Ramipril and prepared for HPLC analysis. 
3.3.3.3 Effect of Complexation on Ramipril Stability 
 Accelerated degradation studies were developed from the methods described by 
Belal et al (2001) and Patil et al (2008) to test the effect of complexation of Ramipril with 
HP-β-CD on the drug stability. Solutions of 0.1M NaOH and 1.0M HCL were prepared. 
For each of these one batch of solution containing Ramipril (0.24mM) only, and one 
batch of solution containing Ramipril (0.24mM) and HP-β-CD (0.24mM) were produced. 
These were stirred for two hours and samples were taken at time 0 and then every 20 
minutes thereafter. Samples were analysed via HPLC. Photostability was assayed with 
exposure of test solutions to UV light at 254nm for 24 hours. Once solution contained 
complexed drug (Ramipril and HP-β-CD) and the other solution contained Ramipril only. 
Samples were taken at the six hour time point and after 24 hours. Samples were 
analysed via HPLC. 
3.3.3.4 Determination of Ramipril – HP-β-CD Binding Constant and Stoichiometry 
 The binding constant for the complexation of Ramipril and HP-β-CD was 
determined. This involved production of a 4.8x10-3M solution of HP-β-CD in water. The 
conductivity of this cyclodextrin solution was measured to determine a base line. Then, 
known amounts of Ramipril were added at increasing increments of 1.0x10-3M up to 
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1.0x10-2M. Temperature was maintained at 25°C and pH was recorded throughout to 
ensure no variation occurred as varying pH affects the conductance measured. 
Conductometry readings were taken after each addition of drug. In this way a graph of 
the conductance readings was produced. Plotting two lines for each section of the graph 
and calculating their point of convergence allows for the determination of the 
concentration of cyclodextrin at which complete complexation occurs. In this way the 
stoichiometry can be determined allowing for the calculation of the binding constant. 
3.3.4 Suspension Approach to Ramipril Formulation 
3.3.4.1 Xantham Gum and Xanatural 180 Comparison 
 Xantham Gum (Sigma) and Xanatural 180 (Azelis) were analysed for viscosity 
using a Brookfield DV – I + Viscometer at a shear rate of 1.7s-1. Measurements were 
taken from solutions of Xantham Gum and Xanatural at concentrations of 0.1-0.5% for 
each polymer and compared. 
3.3.4.2 Investigation into the Rate and Volume of Sedimentation 
 The theoretical rate and volume of sedimentation was calculated using Stokes 
equation;  
𝛿𝑉
𝛿𝑇
=  
𝑑2(𝜌𝑠 − 𝜌𝑡)𝑔
9𝑛1
 
Where: 
𝛿𝑉
𝛿𝑇
 - Rate of Sedimentation (Velocity/Time) 
𝑑2 - Average Particle Diameter  
𝜌𝑠  - Solid Particle Density  𝜌𝑡 - Vehicle Density 
 𝑛1 - Viscosity of the Vehicle   𝑔 – Gravity   
 The average particle diameter was determined using Sympatec HELIOS particle 
size analysis. This returned an average particle size of around 70µm. The vehicle 
viscosity was taken to be viscosity recorded at the lowest shear rate investigated in the 
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rheology experiment to simulate storage conditions and the vehicle density was 
calculated via measuring the weight of 1ml of vehicle. The solid particle density was 
calculated by weighing out a known amount of powder (Wp) followed by weighing out a 
known volume (Vl) of distilled water (Wl). The ratio of Vl/Wl provides the density (Dl w/v 
g/dm3) of the liquid. By adding sufficient water to make the powder and water 
combination the same volume as Vl and measuring the amount of unused water allows 
for the calculation of how much volume is take up by the powder. As the weight of the 
powder was recorded at the start and the volume is now known, the density of the 
powder was calculated. Gravity was taken to be 980.7cm/s. 
 For investigation into the actual rate and volume of sedimentation Ramipril 
suspensions in concentrations of Xanatural from 0.1-0.5%w/v were prepared and were 
allowed to stand undisturbed for the four weeks. Assessment of the actual sedimentation 
is obtained by measuring the sedimentation volume (F). This is the ratio of the sediment 
volume (Vs) to the initial volume of the suspension (Vi); 
𝐹 =  
𝑉𝑠
𝑉𝑖
 
Where:  
Vs = Sediment volume  Vi  = The initial volume of the suspension  
 
3.3.4.3 Particle Size and Investigation into Ostwald Ripening 
 Ramipril suspensions were produced using concentrations of Xanatural 180 at 
concentrations of 0.1-0.5% w/v and these were measured for particle size using a 
Sympatec HELIOS/BF particle size analyser. These suspensions were then be heated 
and cooled repeatedly with particle size being measured after each cycle. Microscope 
images were also recorded to document any crystal growth that may have been evident. 
Each cycle involves heating to 40°C of 24 hours then cooling to 4°C for 24 hours. Three 
cycles were completed. 
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3.3.4.4 Analysis of Zeta Potential 
 The Zeta potential of Ramipril suspensions produced using 0.1-0.5% Xanatural 
180 were analysed using a Brookhaven instruments corporation zeta plus zeta potential 
analyser in conjunction with a BI-ZEL electrode assembly (Brookhaven Instruments).  
3.3.4.5 Wettability and Investigation into Surfactant Use 
 The wettability of Ramipril was investigated using a Camtel Ltd CT-100, CCA-
100 contact angle tensiometer. The liquid phases for the Ramipril coated slide to be 
immersed into consisted of water as a control and then Tween 20, 40, 60 and 80 (Sigma) 
solutions at concentrations of 0.1, 1.5 and 3.0% were produced and also Span 20, 40, 
60 and 80 (Sigma) at concentrations of 0.1, 1.5 and 3.0% were produced in order to 
determine the effect of surfactant presence on contact angle. 
3.3.4.6 Suspension Rheology 
 Suspension Rheology was investigated to provide information on flow properties 
by measuring suspension viscosity at different shear rates using a Brookfield DV – I + 
Viscometer at shear rates of 0.08, 0.16, 0.32, 0.83 and 1.67 reciprocal seconds.  
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3.3.5 Stability Analysis 
 The conditions for storage are set out in the ICH Harmonisation Guidelines 
(Q1A(R2)) (2003) (Table 24) which states that ‘a drug substance should be evaluated 
under storage conditions that test its thermal stability, and if applicable its sensitivity to 
moisture’. The conditions are listed below; 
Table 24 - Storage conditions for stability testing as outlined in the ICH guidelines (ICH 
Guidelines Q1A(R2) 2003). (R.H = Relative Humidity) 
Study Storage Conditions Minimum Time Period 
Long Term 
25°C ± 2°C  at 60%  
12 Months 
R.H ± 5% 
 or 
30°C ± 2°C at 65% R.H ± 
5% 
Accelerated 
40°C ± 2°C at 75% R.H ± 
5% 
6 Months 
 
 The formulations were tested on a monthly basis and assessed quantitatively by 
HPLC and for pH. The formulations were also assessed qualitatively for colour and smell.   
3.4 RESULTS AND DISCUSSION 
3.4.1 Co-solvent Approach to the Solubilisation of Ramipril 
 Following the Solubilisation of 1mg/ml of Ramipril in Acetic acid solutions, the 
solutions were characterised (Table 25) in order to identify the optimum co-solvent 
concentration. The colour, smell, pH and the solubilising potential of the solutions was 
compared. All of the Acetic acid solutions achieved the complete solubilisation of 
Ramipril to form colourless solutions. It was noted however that the 0.01% (v/v) took 
considerably longer to achieve solubilisation. As expected the pH of the solutions also 
became less acidic as the Acetic acid concentration decreased. For all of the solutions, 
the smell of the acetic acid was negligible.   
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Table 25 - Co-solvent solution characterisation 
Acetic Acid 
Concentration Colour pH 
1mg/ml Ramipril 
Solubilised 
4.00% Colourless 2.4 Yes 
3.00% Colourless 2.5 Yes 
2.00% Colourless 2.6 Yes 
1.00% Colourless 2.7 Yes 
0.50% Colourless 2.9 Yes 
0.10% Colourless 3.2 Yes 
0.05% Colourless 3.4 Yes 
0.04% Colourless 3.5 Yes 
0.03% Colourless 3.6 Yes 
0.02% Colourless 3.7 Yes 
0.01% Colourless 3.8 Yes (Slowly) 
 
 Acetic acid was selected for use as a co-solvent in the solubilisation of Ramipril 
as it dissolves Ramipril freely, is GRAS listed and is inexpensive. Also in the production 
of age appropriate formulations the use of harsh co-solvents and alcohols is to be 
avoided. Ramipril was successfully solubilised (Table 25) using acetic acid as a co-
solvent even at concentrations as low as 0.01% (v/v). This lends itself to use in the 
production of an oral liquid dosage form as low levels of co-solvent are preferred. This 
is particularly the case with acetic acid as the unpleasant taste and smell are significant 
factors. Low concentrations of acetic acid mean that in turn less taste and odour masking 
agents need be used.  Also the use of a low concentration of acetic acid results in a less 
acidic pH than if high concentrations were required (Table 25). This is beneficial in that 
it increases the choice of excipients such as antioxidants, preservatives and flavours. 
The optimum concentration of acetic acid solution for use in disolving Ramipril is 0.02% 
(v/v) (Table 25). This is the lowest concentration at which rapid solubilisation is achieved 
at the same time as yielding a suitable pH, colour and odour. 
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3.4.1.1 Final Formulation for Ramipril Solution Implementing a Co-solvency Approach to Achieve 
Solubilisation.  
 Following development of a Ramipril solution using acetic acid as a co-solvent 
the final formulation is as follows; 
 Ramipril (1mg/ml) 
 Acetic Acid (0.02% v/v) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (20%) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
 For the production of the formulation, a 0.02% v/v acetic acid solution was 
produced. Into this Ramipril was added and under stirring allowed to fully dissolve before 
any further excipients were added. With Ramipril dissolved in the acetic acid solution the 
other excipients were added with flavouring being added as the final excipient. 
3.4.2 Cyclodextrin Approach to Solubilising Ramipril 
3.4.2.1 Phase Solubility  
 The phase solubility profile for Ramipril complexed with HP-β-CD is that of a AL 
curve over the concentration ranges investigated (Figure 37). 
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Figure 37 - Phase solubility profile for Ramipril complexed with HP-β-CD. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
   This demonstrates a linear relationship between the increase in concentration of 
drug solubilised and the increase in cyclodextrin required to bring about this increase. 
 HP-β-CD is a modified β-CD and as a result has improved solubility. This 
improved solubility means that Bs profiles indicating limited solubility of the complex and 
BI profiles indicating insolubility of the complex are rarely seen. More likely are AL, AP 
and AN type profiles which indicate a linear relationship between the improvement in 
solubility with increasing cyclodextrin concentration, a positively deviating isotherm and 
a negatively deviating isotherm respectively (Brewster and Loftsson 2007). The Phase 
solubility profile for Ramipril complexed with HP-β-CD is that of the AL type (Figure 37). 
This is particularly useful as the linear relationship allows for close estimation of the 
concentration of cyclodextrin needed to solubilise a chosen concentration of Ramipril. 
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Indications regarding the stoichiometry of the complexation can also be determined from 
the phase solubility profiles although this requires confirmation using conductometry. 
Using the gradient from the equation for the line it can be estimated that there is a 1:1 
ratio of the binding between Ramipril and cyclodextrin molecules. As the target dosage 
of the formulation is 1mg/ml which equates to 0.24mM, it can be estimated that 0.24mM 
of cyclodextrin will be required to solubilise the drug. 0.24mM equates to 3.5mg/ml. 
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3.4.2.2 Effect of Temperature and pH on Solubilisation following complexation. 
  Increasing the temperature of the Ramipril-HP-β-CD system in the presence of 
excess Ramipril increased the amount of Ramipril solubilised over the whole 
temperature range and for all concentrations of cyclodextrin (Figure 38). The increase is 
greatest between 15°C and 30°C for the 1.2mM cyclodextrin solution.   
 
Figure 38 - Effect of temperature on Ramipril solubility in the presence of HP-β-CD. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard 
deviation (RSD).  
  
 As shown below (Figure 39) the optimum pH for the solubilisation of Ramipril 
using HP-β-CD is pH 3. The pH 5 solution showed slightly poorer solubilisation of 
Ramipril with pH 7 showing the same reduction again.   
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Figure 39 - Effect of pH on Ramipril solubility in the presence of HP-β-CD. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 It has been shown that in some cases, increasing temperature can decrease 
drug-cyclodextrin complex stability, possibly due to the loss of hydrophobic forces and 
other forces of interaction. This effect however is not universal and in situations where 
the drug-cyclodextrin complexation reaction is entropy driven then the effect may be 
negligible (Challa et al. 2005). As seen in Figure 6, increasing temperature does not 
decrease the amount of Ramipril solubilised meaning the drug molecules are forming 
complexes with HP-β-CD even at elevated temperatures. This would suggest that there 
is no decrease in hydrophobic forces or other forces of interaction up to and including 
75°C. As the results show there is in fact an increase in the amount of drug solubilized 
at increasing temperature. This is again potentially further evidence of an entropy driven 
reaction and also may be contributed to by the increased kinetic energy in the system.  
 Drug solubility following complexation with cyclodextrin has been show to 
increase upon modification of the pH of a system. This occurs as a result of the alteration 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.20E+006.00E-013.00E-011.50E-017.50E-023.75E-02
R
am
ip
ri
l C
o
n
ce
n
tr
at
io
n
 (
m
M
)
Cyclodextrin Concentration (mM)
The Effect of pH on Cyclodextrin Activity in Solubilizing 
Ramipril
pH 3
pH 5
pH 7
 
 
150 
 
to the complexation constant following the adjustment of pH. If solubility increases then 
this resembles an increase in the complexation constant (Kim et al. 1998). As (Figure 
39) illustrates the amount of Ramipril solubilized by HP-β-CD increases with decreasing 
pH down to pH 3. This is possibly due to the drug existing in an increasingly more 
dissociated form at more neutral pH levels. HP-β-CD has been shown by Zia et al (2001) 
to complex to a lesser degree with ionised molecules when compared with their 
uncharged form. The negative charge present following ionisation of Ramipril could 
result in repulsion forces between the cyclodextrin and the drug molecule and also 
between drug molecules and this in turn could lead to a reduction in complexation. 
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3.4.2.3 Effect of Complexation on Ramipril Stability  
 As the below chart (Figure 40) shows there is no significant difference in the 
stability of Ramipril in acid or alkali conditions following complexation with HP-β-CD. 
Ramipril remains stable in both acidic solutions and Ramipril degrades rapidly in both 
alkali solutions. 
 
Figure 40 - Effect of complexation on Ramipril stability. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
  
 The photostability (Figure 41) of Ramipril is unaffected by complexation with HP-
β-CD as there is no significant difference in the stability of Ramipril in either solution 
following exposure to UV light (254nm) for 24 hours.  
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Figure 41 - Effect of HP-β-CD on Ramipril Photostability. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 Cyclodextrins have in the past been shown to improve the stability of several 
liable drugs against dehydration, hydrolysis, oxidation, and photodecomposition (Challa 
et al 2005) (Zhang et al 2009). There have also been some cases in which complexation 
of a drug with a cyclodextrin has resulted in decreased stability when cyclodextrins have 
catalysed de-acetylation (Jarho et al 2000) or when drugs have undergone a structural 
change up on complexation with cyclodextrin (Sortino et al 2001). Other investigations 
have found the complexation of the drug with cyclodextrins to have no effect on stability. 
When this occurs it is possible that there is only partial inclusion of the drug inside the 
cyclodextrin (Koester et al 2001). Understanding the effect of complexation on the drug 
is important as if the stability of a drug is affected then this will have an impact on the 
shelf life of the product. As figure 40 shows, for the complexation of Ramipril with HP-β-
CD there is no significant difference in drug stability in either 0.1M NaOH or 1.0M HCL 
over time. Ramipril is rapidly degraded in alkali conditions and this is confirmed in the 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0 6 24
P
er
ce
n
ta
ge
 o
f 
R
am
ip
ri
l P
re
se
n
t
Time (h) of exposure  of solutions to UV light (254nm) 
The Effect of Cyclodextrin on Ramipril Photostability
No Cyclodextrin Cyclodextrin
 
 
153 
 
findings presented here. The fact that Ramipril is still rapidly degraded even in the 
presence of cyclodextrin suggests that the Ramipril molecules are only partly included 
in the cyclodextrin leaving some of the molecule susceptible. Ramipril is known to be 
stable in acid conditions, the findings here show that complexation with HP-β-CD does 
not contribute to the degradation of Ramipril. Figure 41 illustrates that following the 
complexation of Ramipril with HP-β-CD there is no significant effect on the Photostability 
of the drug. Degradation is seen to a small degree for both solutions which again lends 
strength to the argument that the drug is not completely encapsulated by HP-β-CD. 
3.4.2.4 Determination of Ramipril – HP-β-CD Binding Constant and Stoichiometry 
 Solving the equations of the straight lines produced from the conductometry 
investigation (Figure 42) simultaneously allows for the accurate determination of the 
point of convergence. This yields an x value of 5.16mM which is the concentration of 
Ramipril. 
 
Figure 42 - Conductometry and pH for Ramipril and HP-β-CD complexation. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD).  
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The stoichiometric ratio is then calculated using; 
𝐷𝑟𝑢𝑔: 𝐶𝑦𝑐𝑙𝑜𝑑𝑒𝑥𝑡𝑟𝑖𝑛 𝑅𝑎𝑡𝑖𝑜 =  
[𝐷𝑟𝑢𝑔 𝑐𝑜𝑚𝑝𝑙𝑒𝑥𝑒𝑑 (𝑚𝑀)]
[𝐶𝑦𝑐𝑙𝑜𝑑𝑒𝑥𝑡𝑟𝑖𝑛 𝑢𝑠𝑒𝑑 (𝑚𝑀)]
 
D:CD = 5.16/4.8 
D:CD = 1.07 
 This leads to the determination of a 1:1 ratio for the complexation of Ramipril and 
HP-β-CD. It is now possible to calculate the binding constant (K) for the Ramipril-HP-β-
CD system. Where a 1:1 stoichiometry is observed; 
Drug (D) + HP-β-CD (CD) 
 
Drug-CD Complex (D•CD) 
With this considered, the equation for the binding constant becomes; 
𝐾1:1 =  
[D • CD]
[𝐷][𝐶𝐷]
 
[D] = Concentration of Free Drug (1.07M) 
[CD] = Concentration of Free CD (1.00M) 
[D•CD] = Concentration of Drug-CD complex (2.07M) 
Applying this gives; 
𝐾1:1 =  1.93 𝑀
−1 
 In order to understand more about the drug-cyclodextrin interaction it is important 
to understand the stoichiometry of the complexation. That is the ratio of the number of 
drug molecules complexed with the number of cyclodextrin molecules. The ratio seen in 
most drug-cyclodextrin complexation is a 1:1 ratio although ratios of 2:1 and 1:2 are not 
uncommon. Ratios greater than this have been observed however are very rare. Once 
the stoichiometry is determined then calculations can be performed which allow for the 
determination of the binding constant (Zarzycki et al 1998). The findings from the 
conductometry investigation (Figure 42) show that Ramipril complexes with HP-β-CD in 
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a 1:1 ratio and this further supports the conclusions drawn from the phase solubility 
investigation.  
 There are a wide range of values for binding constants depending upon the host 
and guest molecules in question with the majority of the values falling between 50 and 
2000M-1 with α-CD, β-CD and γ-CD having mean binding constant values of 130, 490 
and 350M-1 respectively when a stoichiometric ratio of 1:1 is observed (Brewster and 
Loftsson 2007). Calculation of the binding constant is the main method by which host-
guest affinity in solution is assessed. For Ramipril - HP-β-CD complexation the binding 
constant was calculated to be 1.93M-1. The binding constant is also referred to as the 
stability constant and a value of 1.93M-1 is a relatively low value although there are other 
examples of low binding constants for example Imidazole with β-CD has a binding 
constant of 1.9M-1 (Tran and Lacerda, 2002). A low binding constant is not necessarily 
a detrimental factor as although complexation of Ramipril with HP-β-CD is necessary for 
solubilisation of the drug, the release of the drug from the cyclodextrin is essential for 
the absorption of the drug. 
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3.4.2.5 Final Formulation for Ramipril Solution Implementing a Complexation Approach to 
Achieve Solubilisation.  
 Following development of a Ramipril solution using cyclodextrins, the final 
formulation is as follows; 
 Ramipril (1mg/ml) 
 HP-β-CD (3.51mg/ml) 
 Ascorbic Acid (0.1mg/ml) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (20%w/v) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
 For the production of the formulation a cyclodextrin solution is first produced by 
dissolving 3.51mg/ml in distilled water. With this produced the next stage is to add the 
Ramipril until it is completely dissolved. Following this the other excipients are added 
until fully dissolved with flavour being added last. 
3.4.3 Suspension Formulation Development 
3.4.3.1 Selection of a Suspending Agent 
 Hydrophilic polymers including cellulose derivatives such as Methylcellulose, 
Ethylcellulose, Hydroxyethylcellulose, Hydroxypropylmethylcellulose and Sodium 
Carboxymethylcellulose along with Sodium Alginate, Acacia gum, Tragacanth Gum and 
Xantham Gum were investigated for their usefulness as a suspending agent. 
  Following investigation into the scientific literature Xantham gum looked the most 
promising for use in a Ramipril suspension having been proven to display pseudoplastic 
properties, produce colourless solutions and be soluble in water. Xantham gum is 
suitable for use in a pH range of 3-12 which has benefits over hydrophilic polymers such 
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as Ethylcellulose which are sensitive to acid conditions as Ramipril is most stable in an 
acidic environment. Also in comparison to preparation of some hydrophilic polymer 
solutions such as methylcellulose which requires careful heating and cooling cycles to 
achieve solubilisation, Xantham gum solutions can be prepared following simple addition 
and stirring.    
 A modified Xantham Gum is available from Azelis under the trade name of 
Xanatural 180 which provides improved aesthetics and is comparable to the Xantham 
gum from sigma. Xantham Gum (Table 26) and Xanatural 180 (Table 27) were analysed 
for viscosity to compare their viscosity modifying properties.  
 
Table 26 - Viscosity table for Xantham Gum at concentrations between 0.5 and 0.1%. 
Xantham Gum Viscosity Table (Temperature 25 degrees C) 
Concentration (%w/v) Viscosity (mPas) STDEV 
0.5 21.6 0.3 
0.4 19.8 0.25 
0.3 15 0.36 
0.2 5.3 0.04 
0.1 2.2 0.01 
0 0.3 0.03 
 
Table 27 - Viscosity table for Xanatural 180 at concentrations between 0.5 and 0.1%. 
Xanatural 180 Viscosity Table (Temperature 25 degrees C) 
Concentration (%w/v) Viscosity (mPas) STDEV 
0.5 22.3 0.15 
0.4 20.1 0.15 
0.3 15.1 0.3 
0.2 5.6 0.04 
0.1 2.4 0.04 
0 0.4 0.03 
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Figure 43 - Comparison of Xantham Gum and Xanatural 180 viscosity at 0.1, 0.2, 0.3, 
0.4 and 0.5% w/v. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
 
 Following the comparison of Xantham gum and Xanatural 180 there was similar 
viscosity across the range of concentrations investigated (Figure 43). As the only 
difference between the two polymers was that Xanatural 180 produced a clear vehicle 
and Xantham gum produced a vehicle which was turbid in nature, Xanatural 180 was 
selected for use in the Ramipril suspension. One important concern of suspension 
production is their aesthetics and the clear suspension is more pleasing on the eye.  
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3.4.3.2 Suspension Rheology 
 For oral suspensions hydrophilic polymers such as Xanatural 180 are used as 
suspending agents and have the effect of increasing the viscosity of the liquid vehicle. 
This is useful for prolonging the suspension of particles but can at times in the same way 
make it more difficult to re-suspend any particles which do sediment.  
 To get the best results from the addition of hydrophilic polymers, the ideal 
properties for a suspensions resulting flow profile are pseudoplastic or shear thinning 
and thixotropic. These are non-Newtonian liquids for which the rate of shear is not 
proportional to the shear stress exerted. This is particularly useful as the relatively high 
viscosity under low shear conditions e.g. during storage slows the sedimentation process 
and the relatively low viscosity under high shear conditions e.g. shaking or pouring, 
allows for the easy re-dispersion of any sediment and also the easy dispensation of the 
medication. 
 The shear rate response to changes in shear stress is measured using a 
viscometer. Five different suspensions were produced using different concentrations of 
Xanatural between the recommended limits for use. These were analysed at 25°C and 
at 5 different shear stresses and the results are shown below (Figure 44).       
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Figure 44 - Chart for the comparison of viscosity under variable shear stress in Ramipril 
suspensions produced using five different concentrations of Xanatural 180. As expected 
all concentrations of Xanatural 180 displayed pseudoplastic flow with the viscosity at 
each measurement point being proportional to the concentration of Xanatural 180 
present in the solution. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD).   
 
 As the chart clearly shows, the suspensions produced using Xanatural 180 all 
display pseudoplastic properties for their rheology. These findings indicate desirable flow 
properties with the largest change in apparent viscosity observed for the highest 
concentration of Xanatural (0.5%). All concentrations of Xanatural produced suspension 
vehicles suitable for use and the selection of the concentration to be used required 
further development of the suspensions. As such the next stage was to investigate the 
rate and volume of sedimentation for Ramipril in each concentration of Xanatural. 
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3.4.3.3 Investigation into the Rate and Volume of Sedimentation 
 Before producing any suspensions in the lab the theoretical rate of sedimentation 
was calculated for Ramipril in each concentration of Xanatural (Table 28). This was 
calculated using Stokes’ equation;  
 
Table 28 - Theoretical Rate and Volume of Sedimentation of Ramipril in various 
concentrations of Xanatural 180. 
Theoretical Rate and Volume of Sedimentation 
Xanatural 
(%w/v) 
Particle 
diameter 
(cm) 
Solid 
Particle 
Density 
(g/cm3) 
Vehicle 
Density 
(g/cm3) 
Vehicle 
Viscosity 
(g/cm sec) 
Gravity 
(cm/s2) 
Theoretical 
Rate of 
Sedimentation 
(cm/sec) 
0.1 0.007 0.43 1.009 0.4 980.7 -0.01 
0.2 0.007 0.43 1.012 0.8 980.7 0 
0.3 0.007 0.43 1.02 1.54 980.7 0 
0.4 0.007 0.43 1.029 2.1 980.7 0 
0.5 0.007 0.43 1.034 2.57 980.7 0 
 
  
 As the results suggest then there should be no sedimentation seen in the system 
however there are more than just the factors of density and viscosity which are 
responsible for sedimentation in a suspension. As such lab based experiments to 
confirm that there is no sedimentation were necessary. The suspensions were inspected 
at time points over a four week period and the results are as follows (Table 29); 
  
 
 
162 
 
Table 29 - Experimental Rate and Volume of Sedimentation of Ramipril in various 
concentrations of Xanatural 180. 
Time Point 
Volume Of 
Suspension (ml) 
Volume Of 
Sediment (cm2) 
Ratio of 
Suspension 
volume to 
Sediment Volume 
1 (20 Minutes) 1.5 0 0 
2 (40 Minutes) 1.5 0 0 
3 (60 Minutes) 1.5 0 0 
4 (80 Minutes) 1.5 0 0 
5 (100 Minutes) 1.5 0 0 
6 (120 Minutes) 1.5 0 0 
7 (140 Minutes) 1.5 0 0 
8 (160 Minutes) 1.5 0 0 
9 (180 Minutes) 1.5 0 0 
10 (4 Hours) 1.5 0 0 
11 (5 Hours) 1.5 0 0 
12 (1 Day) 1.5 0 0 
13 (2 Days) 1.5 0 0 
14 (3 Days) 1.5 0 0 
15 (4 Days) 1.5 0 0 
16 (5 Days) 1.5 0 0 
17 (1 Week) 1.5 0 0 
18 (2 Weeks) 1.5 0 0 
19 (3 Weeks) 1.5 0 0 
20 (4 Weeks) 1.5 0 0 
 
 Following analysis of the sedimentation volume no sedimentation was observed 
at any of the time points. This has also been reported in previous suspensions using 
Xanthan Gum as a suspending agent (Nep and Conway 2011). This investigation 
showed the suspension to remain stable at up to four weeks in storage.  
3.4.3.4 Particle Size and Investigation into Ostwald Ripening 
 A problem with particles in a suspension is the possibility of Ostwald Ripening or 
crystal growth occurring. This occurs when compounds are suspended in a vehicle in 
which they are slightly soluble. Upon a temperature increase the smaller particles in the 
system become soluble. This can lead to the crystallisation of the dissolved drug onto 
the surface of the larger drug molecules increasing the particle size further. As discussed 
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previously particle size is directly related to the rate of sedimentation and so an increase 
in particle size via Ostwald ripening will lead to destabilisation of a stable suspension.  
 Particle size measurement was performed after heating and cooling cycles to 
investigate the possibility of Ostwald ripening (Figure 45). The findings from this showed 
there was no increase in particle size.   
 
Figure 45 - Particle Size analysis for the investigation into Ostwald ripening. There is no 
statistical difference in the particle size at each concentration of Xanatural 180 for the 
duration of the investigation at each Xanatural concentration. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 Images of the Ramipril crystals were also taken at each time point for the duration 
of the Ostwald ripening investigation in an effort to visibly identify any crystal growth that 
may have been observed. The microscope images follow below (Figures 46 – 65) and it 
is evident that there is no visibly discernable change in the particles supporting the 
findings from the particle size measurement.  
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Time Point 0 
 
Figure 46 - Time Point 0 - 0.1% 
Xanatural 
 
Figure 47 - Time Point 0 - 0.2% 
Xanatural 
 
Figure 48 - Time Point 0 - 0.3% 
Xanatural 
 
Figure 49 - Time Point 0 - 0.4% 
Xanatural 
 
Figure 50 - Time Point 0 - 0.5% 
Xanatural 
 
 
Time Point 1 
 
Figure 51 - Time Point 1 - 0.1% 
Xanatural 
 
Figure 52 - Time Point 1 - 0.2% 
Xanatural 
 
Figure 53 - Time Point 1 - 0.3% 
Xanatural 
 
Figure 54 - Time Point 1 - 0.4% 
Xanatural 
 
Figure 55 - Time Point 1 - 0.5% 
Xanatural 
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Time Point 2 
 
Figure 56 - Time Point 2 - 0.1% 
Xanatural 
 
Figure 57 - Time Point 2 - 0.2% 
Xanatural 
 
Figure 58 - Time Point 2 - 0.3% 
Xanatural 
 
Figure 59 - Time Point 2 - 0.4% 
Xanatural 
 
Figure 60 - Time Point 2 - 0.5% 
Xanatural 
 
 
Time Point 3 
 
Figure 61 - Time Point 3 - 0.1% 
Xanatural 
 
Figure 62 - Time Point 3 - 0.2% 
Xanatural 
 
Figure 63 - Time Point 3 - 0.3% 
Xanatural 
 
Figure 64 - Time Point 3 - 0.4% 
Xanatural 
 
Figure 65 - Time Point 3 - 0.5% 
Xanatural 
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 If Ostwald ripening had occurred then altering the amount of hydrophilic polymer 
or implementing the use of a different hydrophilic polymer may have been required for 
use in the formulation as hydrophilic polymers form a protective layer around drug 
molecules which should protect the formulation from Ostwald ripening.  
3.4.3.5 Analysis of Zeta Potential 
  The Zeta potential of a suspension can be carefully modified if necessary in 
order to produce floccules which sediment reversibly and therefore stabilize formulations 
which display sedimentation. The use of electrolytes are the main method of modifying 
zeta potential. In order to identify the most useful concentration of electrolyte, the rate 
and volume of sedimentation must be assessed. Following electrolyte modification the 
suspension which displayed the largest sediment volume would be deemed the most 
stable as the particles in the suspension would be interacting the most weakly. There is 
however, no sedimentation observed for the Ramipril suspension using Xanatural 180 
then this process cannot be investigated. The zeta potential for the suspension can 
however be measured in order to see if Xanatural concentration has any effect.  
 Measuring the Zeta potential in suspensions made using concentrations of 
Xanatural at 0.1, 0.2, 0.3, 0.4 and 0.5% would indicate if the concentration of hydrophilic 
polymer had any effect on the zeta potential. The larger the magnitude of the Zeta 
potential the better the stability of a suspension. Following analysis of the Zeta potential 
in suspensions made using concentrations of Xanatural at 0.1, 0.2, 0.3, 0.4 and 0.5% 
the results were as follows (Figure 66).  
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Figure 66 - Zeta potential of Ramipril suspension using different concentrations of 
Xanatural 180. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
 
 There was no significant difference between the Zeta potential measured in each 
suspension regardless of the Xanatural concentration present. The Zeta potential 
measured is within +/-25mV and this is in the range where suspensions are known to 
produce non-caking suspensions (Greenwood & Kendall 1999). This is confirmed by the 
finding of a lack of sedimentation seen in the rate and volume of sedimentation 
investigation. As such the modification of the zeta potential to control flocculation is 
deemed to be unnecessary in the production of the Ramipril suspension.  
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3.4.3.6 Wettability and Investigation into Surfactant Use  
 An insoluble or poorly soluble drug may not be easily wetted, that is that the 
vehicle in which the particles are suspended may not easily form a layer around the 
suspended drug particle. In order for maximum Wettability the angle at which the liquid 
meets the solid particles surface needs to be low. The contact angle is defined in terms 
of the tensions between three phases, these being; 
 Solid/Vapour (γ s/v) 
 Liquid/Vapour (γ l/v) 
 Solid/Liquid (γ s/l) 
Young’s equation is used to describe Wettability;  
𝛾𝑙/𝑣 𝑐𝑜𝑠𝜃 =  𝛾𝑠/𝑣 −  𝛾𝑠/𝑙 
 Decreasing the interfacial tensions in the Liquid/Vapour and the Solid/Liquid will 
lead to a reduction in the contact angle. This is attained by the addition of surfactants 
into the formulation which adsorb at the Liquid/Vapour and the Solid/Liquid interfaces 
reducing the tension.   
 Poorly wetted drug particles have a tendency to clump together in an attempt to 
thermodynamically stabilise the system by lowering the Gibb’s free energy. This clearly 
would cause problems in the stability of a suspension. Sufficiently wetted particles are 
also necessary for the production of homogenous suspensions and this is essential for 
the correct dosage. A final consideration is that increased wetting has the added benefit 
of improved absorption which can lead to better drug performance. 
 Wettability of a drug is investigated using a surface tensiometer to determine the 
contact angle for that compound. If the contact angle requires improvement then the use 
of surface active agents in the formulation may be necessary. If any alterations are made 
to the formulation the rate of sedimentation and zeta potential should be re-investigated 
to provide a comparison.  The surfactants selected for use were SPAN 20, 40, 60 and 
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80 and also TWEEN 20, 40, 60 and 80. Both of these are widely used in the 
pharmaceutical industry and are readily available. The Wettability of Ramipril was first 
investigated using only distilled water to provide a reference. Surfactants producing a 
reduced receding contact angle would be considered to have improved the Wettability 
of the drug. The results are shown below (Figure 67); 
 
Figure 67 - Investigation into improving the wettability of Ramipril using various 
surfactants. (**) Indicates significant difference at p=0.001 when compared to distilled 
water. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
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 As the above chart indicates the wettability was improved most effectively by 
SPAN 40 at a concentration of 3% v/v. As such if there had been and problems 
experienced which involved the clumping of Ramipril in the suspension then the use of 
SPAN 40 as a surfactant to prevent this would be the first choice. 
3.4.3.7 Final Suspension Formulation 
 The final composition of the suspensions are as follows; 
Flavoured Suspension: 
 Ramipril (1mg/ml) 
 Xanatural 180 (0.1% w/v)  
 Sodium Metabisulphate (1.0% w/v) 
 Sodium Benzoate (0.5% w/v) 
 Xylitol (40% w/v) 
 Strawberry Concentrate (0.2%v/v) 
 
Sweetened Suspension: 
 Ramipril (1mg/ml) 
 Xanatural 180 (0.1% w/v) 
 Sodium Metabisulphate (1.0% w/v)  
 Sodium Benzoate (0.5% w/v) 
 Xylitol (40%w/v) 
 
 The suspensions are produced by first producing a 0.1% Xanatural 180 solution. 
Into this Ramipril is then added slowly during vigorous stirring and evenly distributed 
throughout the vehicle. The remaining excipients are then added to the formulation with 
the strawberry concentrate being added as the last ingredient. 
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3.4.4 Stability Analysis 
3.4.4.1 Accelerated Conditions 
 Over the six month course of the stability testing in accelerated conditions with 
40°C and 75% relative humidity, the drug content of the formulations fell below 95% of 
the starting dose indicating that the formulations failed to display adequate stability in 
accordance with ICH guidelines (Figure 68). The solutions produced behaved in a 
comparable manner however the suspension formulation showed a greater degree of 
degradation by the 6 month time point. The pH remained constant for the duration of the 
stability testing (Figure 69). 
 
Figure 68 - Ramipril recovery following HPLC for formulations in Accelerated storage 
conditions. Before the third month of testing the formulations proved stable with little 
variation in drug content and consistent drug content between samples of the same 
batch. From the third month onwards a reduction of 30% to 80% of the drug content was 
seen when compared with the starting concentration. The variation between samples 
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also increased. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
 
 
Figure 69 - Ramipril pH stability for formulations in Accelerated storage conditions. For 
the duration of testing the formulations proved stable with little variation in pH seen for 
all samples. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
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3.4.4.2 Long Term Conditions 
 The twelve month testing course of the formulations stability in long term 
conditions, 25°C and 60% relative humidity, the drug content of all of the formulations 
remained >95% of the starting dose (Figure 70) and the pH remained constant for the 
duration (Figure 71). 
 
Figure 70 – Ramipril recovery following HPLC for formulations in Long Term storage 
conditions. For the duration of testing the formulations proved stable with little variation 
in drug content and consistent drug content between samples of the same batch. Results 
are generated from triplicate repeats (n=3) and error bars indicate standard deviation 
(RSD). 
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Figure 71 - Ramipril pH stability for formulations in Long Term storage conditions. For 
the duration of testing the formulations proved stable with little variation in pH seen for 
all samples. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD). 
 
 According to the parameters outlined by the ICH harmonised tripartite guideline 
stability testing of new drug substances and products Q1A(R2), “significant change” for 
a drug product is defined as:  
1. A 5% change in assay from its initial value; or failure to meet the acceptance 
criteria for potency when using biological or immunological procedures;  
2. Any degradation products exceeding its acceptance criterion;  
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3. Failure to meet the acceptance criteria for appearance, physical attributes, and 
functionality test (e.g., colour, phase separation, resuspendibility, caking, 
hardness, dose delivery per actuation); however, some changes in physical 
attributes (e.g., softening of suppositories, melting of creams) may be expected 
under accelerated conditions;  
and, as appropriate for the dosage form:  
4. Failure to meet the acceptance criterion for pH; or  
5. Failure to meet the acceptance criteria for dissolution for 12 dosage units. 
 The Ramipril formulations tested under accelerated conditions showed 
significant decrease in the drug assayed in comparison to the day zero analysis (Figure 
68). This was seen in all formulations regardless of the method of formulation. The 
formulations in long term storage conditions (Figure 70) did not show any significant 
decrease in the drug assayed even after 12 months in storage. This suggests that the 
degradation seen under accelerated conditions is a result of the elevated temperature. 
It is known that Ramipril diketopiperazine (DKP) degradate is the primary degradation 
compound for Ramipril. Degradation occurs through intramolecular condensation and 
sees the formation of a second amide bond (Figure 72).  
 
Figure 72 - Ramipril DKP – The primary degradation compound for Ramipril. 
 
 
 
176 
 
  This reaction is known to occur with Ramipril as was seen with Lisinopril when 
the drug experiences conditions of elevated temperature (Diego et al 2010). The pH of 
the formulation in both accelerated (Figure 69) and long term conditions (Figure 71) did 
not change beyond the acceptance levels for the formulation. In addition, the 
appearance and odour of the formulations remained acceptable for the duration of the 
stability testing and in both long term and accelerated conditions. The advice for storage 
of the medication would have to emphasise storage in a cool location (<25°C), the 
humidity of the storage conditions is not a large issue as the medication will be contained 
within glass bottles impervious to moisture. With regards to excursions outside of the 
storage conditions such as transport during distribution, degradation due to temperature 
should not be a concern so long as excursions are short in duration and infrequent. This 
is as degradation was only considered significant after >1 month and the temperature at 
which degradation was seen is higher than most environmental temperatures the 
medication would experience.    
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4 REFORMULATION OF SPIRONOLACTONE TO PRODUCE AN AGE 
APPROPRIATE ORAL LIQUID DOSAGE FORM TARGETING THE 
PAEDIATRIC PATIENT SEGMENT 
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4.1 CHAPTER AIMS AND OBJECTIVES 
- Develop a HPLC method for the detection of Spironolactone and validate 
according to ICH guidelines. 
- Formulate Spironolactone as an oral liquid dosage form with a particular focus 
on effectively targeting the paediatric patient segment. 
- Characterise formulations including stability testing in long term and accelerated 
conditions as specified by ICH guidelines.   
4.2 INTRODUCTION 
 Spironolactone is a competitive aldosterone antagonist, acting at the distal 
convoluting renal tubule, thus increasing sodium and water excretion and reducing 
potassium elimination. It is extensively used in medicine, though until recently it was 
considered only as a potassium-sparing diuretic and antihypertensive drug. 
Spironolactone is used in adults for the treatment of oedema and ascites in cirrhosis of 
the liver, malignant ascites, nephrotic syndrome, oedema in congestive heart failure, 
moderate to severe heart failure (adjunct), resistant hypertension (adjunct) and primary 
hyperaldosteronism in patients awaiting surgery. It is used in neonates, infants and 
children with congestive heart failure secondary to congenital heart disease. In children 
under 18 years of age it is used for oedema in heart failure and in ascites, nephrotic 
syndrome and reduction of hypokalaemia induced by diuretics or amphotericin.  In 
addition to licenced uses, it may also reverse aldosterone-induced cardiac fibrosis, 
improve morbidity and survival of patients with congestive heart failure (Paediatric 
Formulary Committee 2012).  
 As with many other frequently used drugs, spironolactone is available only as 
tablets (Table 30), rather than in liquid dosage form suitable for paediatric use. Over the 
last 25 years, many extemporaneously prepared spironolactone containing oral liquid 
formulations have been reported in the literature, as well as their physical and chemical 
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stability. The latter is an important issue in pharmaceutical compounding because 
medicines must remain stable and efficacious during the course of their use. To improve 
stability, or even drug solubility, most of the described spironolactone formulations 
contain complex vehicle mixtures, including propyleneglycol, glycerine and alcohol. 
However, the use of these excipients in the concentrations described is not desirable in 
infants. 
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Table 30 - Currently Available Spironolactone Dosage Forms 
Available Dosage Forms 
Aldactazide 25-25 mg tablet Novo-Spiroton 100 mg Tablet 
Aldactazide 25-25 tablet Novo-Spiroton 25 mg Tablet 
Aldactazide 50-50 mg tablet Spironolactone 100 mg tablet 
Aldactazide 50-50 tablet Spironolactone 25 mg tablet 
Aldactone 100 mg tablet Spironolactone 50 mg tablet 
Aldactone 25 mg tablet Spironolactone powder 
Aldactone 50 mg tablet Spironolactone-HCTZ 25-25 mg tablet 
 
 As discussed in the introduction, given the recommendation for the production of 
an age appropriate formulation, coupled with the need for dose flexibility and the lack of 
an oral liquid formulation, the production of an oral liquid formulation created with a focus 
on paediatric use would be highly advantageous. The physiochemical properties of 
Spironolactone (Table 31) as with any drug guide the formulation development.   
Table 31 - Spironolactone Monograph listing important physiochemical properties which 
should be considered before formulation. 
Spironolactone Monograph 
Chemical Name 
(7α,17α)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-
21-carboxylic acid γ-lactone  
Other Names Aldactone 
Molecular Formula C24H32O4S 
Molecular Weight 416.6 
CAS Number 52-01-7 
Spironolactone Structure 
 
Appearance Light cream to light tan crystalline powder 
Solubility 
Spironolactone is practically insoluble in water but is 
soluble in alcohol. 
Sensitivities Spironolactone is sensitive to strong oxidising agents.  
 
 The aim of the presented research encapsulates the formulation of, and 
characterization of an oral Spironolactone suspension, including the production of a 
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suitable HPLC method, excipient selection and stability assessment of the formulations 
in accordance with ICH guidelines. 
4.3 MATERIALS AND METHODS 
4.3.1 HPLC Method Development for the Detection of Spironolactone 
 The Spironolactone HPLC method was developed using a Dionex GP50 Gradient 
Pump coupled to a Dionex UVD170U detector and a Dionex A550 auto sampler. The 
stationary phase is a Phenomenex Gemini 5µ C18 reverse phase HPLC column (150 x 
4.5mm with 5µm Particle Size). The detection wavelength was set at 254nm. The 
injection volume is 20µl with a run time of 10 minutes. Preparation of Calibration 
Standards involves the production of six standards produced via serial dilution in mobile 
phase. Standards at 2.0, 1.0, 0.5, 0.25, 0.125 and 0.0625mg/ml and samples are 
prepared for analysis by dilution so as to fall within the calibration range and were diluted 
with Spironolactone mobile phase. Method validation was carried out following ICH 
Guidelines (Q2(R1)). 
4.3.2 Formulation Development 
 The Spironolactone for the formulation was purchased from Discovery fine 
chemicals while citric acid, Propyl Paraben, Butyl Paraben and Xylitol were all supplied 
by Sigma. The flavour concentrates used in the formulation development were free 
samples provided by S. Black’s (Azelis). Formulations were produced using volumetric 
glassware. Ultrapure water was first added into which excipients were dissolved with the 
aid of a magnetic stir bar before it was removed and the solutions made up to volume. 
Upon production formulations were transferred to amber glass bottles.  
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4.3.3 Sol-Gel Transition Temperature 
 Pluronic was used at concentrations of 0, 1, 2, 3, 4 and 5%w/v and Xanatural 
was used at concentrations of 0, 0.1, 0.2, 0.3, 0.4 and 0.5%w/v. Samples were heated 
to 15, 25, 35, 45, 55, 65, 75 and 85°C and observed for any change in the liquid state.  
4.3.4 Suspension Rheology 
 Suspension Rheology was investigated to provide information on flow properties 
by measuring suspension viscosity at different shear rates using a Brookfield DV – I + 
Viscometer at shear rates of 0.08, 0.16, 0.32, 0.83 and 1.67 reciprocal seconds. 
4.3.5 Rate and Volume of Sedimentation 
 For investigation into the rate and volume of sedimentation spironolactone 
suspensions in concentrations of Xanatural from 0.1-0.5%w/v and Pluronic F127 from 
1-5%w/v were prepared and were allowed to stand undisturbed for 24 hours. 
Assessment of the actual sedimentation is obtained by measuring the depth of 
sedimentation. 
4.3.6 Particle Size Measurement and Investigation into Ostwald Ripening 
 Ramipril suspensions were produced using concentrations of Xanatural 180 at 
concentrations of 0.1-0.5% w/v and Pluronic F127 from 1-5%w/v, these were measured 
for particle size using a Sympatec HELIOS/BF particle size analyser. These suspensions 
were then be heated and cooled repeatedly with particle size being measured after each 
cycle. Microscope images were also recorded to document any crystal growth that may 
have been evident. Each cycle involves heating to 40°C of 24 hours then cooling to 4°C 
for 24 hours. Three cycles were completed. 
4.3.7 Analysis of Zeta Potential 
 The Zeta potential of Ramipril suspensions produced using 0.1-0.5% Xanatural 
180 Pluronic F127 from 1-5%w/v were analysed using a Brookhaven instruments 
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corporation zeta plus zeta potential analyser in conjunction with a BI-ZEL electrode 
assembly (Brookhaven Instruments). 
4.3.8 Stability Analysis 
 The conditions for storage are set out in the ICH Harmonisation Guidelines 
(Q1A(R2)) (2003) (Table 32) which states that ‘a drug substance should be evaluated 
under storage conditions that test its thermal stability, and if applicable its sensitivity to 
moisture’. The conditions are listed below; 
Table 32 - Storage conditions for stability testing as outlined in the ICH guidelines (ICH 
Guidelines Q1A(R2) 2003). (R.H = Relative Humidity) 
Study Storage Conditions Minimum Time Period 
Long Term 
25°C ± 2°C  at 60% 
12 Months 
R.H ± 5% 
or 
30°C ± 2°C at 65% R.H ± 5% 
Accelerated 40°C ± 2°C at 75% R.H ± 5% 6 Months 
  
 Samples were stored in Firlabo SP-BVEHF stability cabinets and analysed on a 
monthly basis, quantitatively for drug recovery via HPLC and pH and qualitatively for 
colour and odor.   
4.4 RESULTS AND DISCUSSION 
4.4.1 HPLC Method Development for the Detection of Spironolactone 
 The Spironolactone HPLC method developed was based loosely around the 
method developed by Allen and Erickson (1996) in which using HPLC, the stability of 
Spironolactone 5 mg/mL in extemporaneously compounded oral liquids was evaluated. 
The system was a Hewlett-Packard series 1050 liquid chromatograph, including a 
multisolvent mixing and pumping system, an autoinjector, a diode-array detector, and a 
computer with Chem Station software. The stationary phase was a Bakerbond C18 
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analytical column (250 × 4.6 mm, 5-µm particle size). The mobile phase was 79% 
methanol in water; it was delivered isocratically at 1.0 mL/min.  
 Initial runs involved alterations to the Allen method described above in that the 
mobile phase was changed from methanol and water to acetonitrile and water (70:30). 
It is widely recognized that acetonitrile is a preferential solvent over methanol in HPLC 
applications thanks to its reduction of retention time and improvement in UV absorption 
properties. Also the preliminary injection volume was 20µl. Using a Thermofisher C18 
column and a flow rate of 1.00ml/ml with the absorption wavelength set to 254nm the 
following trace was produced (Figure 73); 
 
Figure 73 – Spironolactone HPLC method development. Trace produced following 
modification to the method described by Allen and Erickson (1996).  
 
 As is evident this trace produced a tall narrow peak at shortly after 2 minutes. 
This is however relatively close to the solvent front indicating poor retention of the 
compound on the column. This can be problematic when analysing samples consisting 
of multiple compounds as poor retention can lead to co-elution of multiple compounds. 
In order to improve the retention of the column, the mobile phase can be altered to be 
more polar. This involves reducing the acetonitrile content from 70% to 50%. This will 
result in the Spironolactone having a lower affinity for the mobile phase and thus a higher 
 
 
185 
 
apparent affinity for the column. The injection volume was also increased to produce a 
greater peak area. This is possible thanks to the narrow peaks. If broad peaks were in 
presence then increasing the injection volume may increase the peak width more than 
the peak height and so increase the chance of peaks overlapping. 
 Following modification of the mobile phase to acetonitrile and water (50:50), and 
increasing the injection volume to 50µl, the following trace was produced (Figure 74); 
 
 
Figure 74 - Spironolactone HPLC method development following modification of the 
mobile phase to acetonitrile and water (50:50), and increasing the injection volume to 
50µl 
  
 The changes made had the desired effect with the retention time increased 
slightly but still providing a relatively fast analysis procedure. This will maximize 
separation of the drug peak from peaks produced by other excipients in the formulation. 
Coupled with the modified mobile phase, the increased injection volume also had a large 
impact increasing the peak area from 34mAU*min to 284mAU*min for the 0.5mg/ml 
standard. This increase in peak area will improve LOD and LOQ by increasing the 
gradient of the calibration curve.  
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 With a suitable method developed the next stage was to validate the method via 
intraday and interday repeats (Figures 75 – 80). Producing a final calibration chart 
(Figure 81) and validation (Table 33).  
 
 
Figure 75 - Spironolactone Validation - Intraday Run A. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 76 - Spironolactone Validation - Intraday Run B. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 77 - Spironolactone Validation - Intraday Run C. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 78 - Spironolactone Validation - Interday Run A. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 79 - Spironolactone Validation - Interday Run B. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 80 - Spironolactone Validation - Interday Run C. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 81 – Final calibration for Spironolactone HPLC method. Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Table 33 – Spironolactone Validation Summary 
Spironolactone Validation 
Selectivity 
The Method was deemed to be selective for 
Spironolactone by running 'blank' samples and 
Spironolactone spiked samples 
Accuracy 
Determined by spiking mobile phase with known amounts 
of Spironolactone (0.5mg/ml, 0.25mg/ml and 
0.125mg/ml). The recoveries ranged from 97.18% to 
102.84% with an average standard deviation of 4.13%.  
Linearity 
Response for the detector was determined to be linear 
over a range of 0mg/ml to 0.5mg/ml. Correlation 
coefficients and slopes were obtained by plotting 
standard concentration (mg/ml) against peak area 
(mAU*min). R2=0.9994 m=2957.6  
Precision  
Precision and intermediate precision were tested via the 
comparison of three intraday and interday calibration 
curves. These showed suitable repeatability. 
Limit Of Detection LOD is 0.4µg/ml. 
Limit Of Quantification LOQ is 1.39µg/ml  
  
 With the Spironolactone HPLC method validated then next stage was to produce 
an oral liquid formulation. As Spironolactone is insoluble the formulation will have to 
allow for this. Also the concentrations at which the formulation must be produced were 
also cause for consideration. 10mg/ml and less so 5mg/ml are high concentrations of 
drug to be included in a formulation. 
4.4.2 Formulation Development 
 Spironolactone has a solubility of only 22µg/ml in water and the desired dosages 
for a liquid Spironolactone formulation are 10mg/ml and 5mg/ml, in order to produce a 
solution the solubility would need to be increased 227 fold. Additionally, Spironolactone 
has been shown to be degraded by cyclodextrins meaning that this common method of 
solubilising insoluble drugs cannot be used. As such and with an onus on simplicity, 
complex methods of solubilising the insoluble drug were rejected in favour of producing 
a suspension. 
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4.4.2.1 Buffer Production 
 It is known that Spironolactone is most stable at pH4.5 (Pramar & Gupta 1991) 
and as such the formulation pH was controlled so as to maintain optimum conditions for 
drug stability. There are many buffer systems which could be implemented for this task 
however it was decided that a citric acid/trisodium citrate buffer would be the best option 
as this system has a buffering capacity in the range of pH3-6.2 and is widely used in oral 
liquid formulations. Orally ingested citric acid is absorbed and is generally regarded as 
a nontoxic material, when used as an excipient trisodium citrate is generally regarded 
as a nontoxic and non-irritant excipient. Excessive consumption may cause 
gastrointestinal discomfort or diarrhoea however, concentrations used in the production 
of a buffer will be far too low to induce these adverse effects. Investigation into the buffer 
production revealed that the ratio of 0.1M citric acid to 0.1M trisodium citrate which 
produced a pH in the desired range was between 49.5:50.5 and 44.5:55.5 (Table 34).   
Table 34 – Buffer production – Ratios of citric acid and trisodium citrate. 
pH x ml 0.1M-citric acid y ml 0.1M-trisodium citrate 
3 82 18 
3.2 77.5 22.5 
3.4 73 27 
3.6 68.5 31.5 
3.8 63.5 36.5 
4 59 41 
4.2 54 46 
4.4 49.5 50.5 
4.6 44.5 55.5 
4.8 40 60 
5 35 65 
5.2 30.5 69.5 
5.4 25.5 74.5 
5.6 21 79 
5.8 16 84 
6 11.5 88.5 
6.2 
 
 
6.2 
8 92 
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4.4.2.2 Inclusion of Pluronic F127 and Xanatural 180. 
 During preliminary work carried out with the view to solubilising Spironolactone it 
was observed that upon addition to water the Spironolactone powder clumped and a 
homogenous mix was impossible to achieve. Pluronic F127 was used in an effort to 
solubilise the Spironolactone and although it failed to achieve this it proved very useful 
as a dispersing agent. In the presence of Pluronic F127, Spironolactone dispersed well 
and produced homogenous suspensions. Although the inclusion of Pluronic F127 
prevented clumping, sedimentation occurred rapidly and irreversibly. To combat the 
sedimentation Xanatural 180 was implemented as a suspending agent. Pluronic was 
used at concentrations of 0, 1, 2, 3, 4 and 5%w/v and Xanatural was used at 
concentrations of 0, 0.1, 0.2, 0.3, 0.4 and 0.5%w/v. 
 Pluronic is known to undergo transition from a solution to a gel at the sol-gel 
transition temperature. This normally only occurs at high concentrations, well over 5% 
and increased temperature. Although the pluronic solution itself would not be expected 
to form a gel, the presence of Xanatural may alter its behaviour. All combinations of 
Pluronic and Xanatural were investigated at temperatures up to 85°C (Table 35). 
 All of the various combinations remained liquid throughout the temperature range 
and so were then investigated at both 10mg/ml and 5mg/ml concentrations of 
Spironolactone for the Rate and Volume of sedimentation, Particle Size and Zeta 
potential. From this the Optimum combination of dispersing agent and suspending agent 
was determined. 
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Table 35 – Sol-gel transition temperature investigation for all combinations of Pluronic 
and Xanatural investigated up to 85°C 
  
 
 
194 
 
4.4.2.3  Rate and Volume of Sedimentation 
 The rate and volume of sedimentation was investigated at a range of Pluronic 
and Xanatural concentrations for 10mg/ml (Table 36) and 5mg/ml (Table 37) 
Spironolactone suspensions. Measurements were taken at 5, 10, 15, 20, 30, 60, 120, 
240 and 480 minutes. 
Table 36 – Rate and volume of sedimentation for 10mg/ml Spironolactone Suspension 
10mg/ml Spironolactone 
Sedimentation depth (mm) after time 
(Minutes) 
Pluronic Conc 
(%w/v) 
Xanatural Conc 
(%w/v) 
5 10 15 20 30 1h 2h 4h 8h 
0 0 2 4 6 8 8 8 8 8 6 
1 0 0 1 1 2 2 3 3 2 2 
2 0 0 1 1 2 2 3 3 2 2 
3 0 0 1 1 2 2 3 3 2 2 
4 0 0 1 1 2 2 3 3 2 2 
5 0 0 1 1 2 2 3 3 2 2 
1 0.1 0 0 2 2 3 3 3 4 4 
2 0.1 0 0 2 2 3 3 3 4 4 
3 0.1 0 0 2 2 3 3 3 4 4 
4 0.1 0 0 2 2 3 3 3 4 4 
5 0.1 0 0 2 2 3 3 3 4 4 
1 0.2 0 0 0 2 2 3 3 4 4 
2 0.2 0 0 0 2 2 3 3 4 4 
3 0.2 0 0 0 2 2 3 3 4 4 
4 0.2 0 0 0 2 2 3 3 4 4 
5 0.2 0 0 0 2 2 3 3 4 4 
1 0.3 0 0 0 0 0 2 2 3 3 
2 0.3 0 0 0 0 0 2 2 3 3 
3 0.3 0 0 0 0 0 2 2 3 3 
4 0.3 0 0 0 0 0 2 2 3 3 
5 0.3 0 0 0 0 0 2 2 3 3 
1 0.4 0 0 0 0 0 0 0 0 0 
2 0.4 0 0 0 0 0 0 0 0 0 
3 0.4 0 0 0 0 0 0 0 0 0 
4 0.4 0 0 0 0 0 0 0 0 0 
5 0.4 0 0 0 0 0 0 0 0 0 
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Table 37 - Rate and volume of sedimentation for 5mg/ml Spironolactone Suspension 
5mg/ml Spironolactone 
Sedimentation depth (mm) after time 
(Minutes) 
Pluronic Conc 
(%w/v) 
Xanatural Conc 
(%w/v) 
5 10 15 20 30 1h 2h 4h 8h 
0 0 0 1 1 1 1 2 2 1 1 
1 0 0 1 1 1 1 2 2 1 1 
2 0 0 1 1 1 1 2 2 1 1 
3 0 0 1 1 1 1 2 2 1 1 
4 0 0 1 1 1 1 2 2 1 1 
5 0 0 0 1 1 2 2 2 3 3 
1 0.1 0 0 1 1 2 2 2 3 3 
2 0.1 0 0 1 1 2 2 2 3 3 
3 0.1 0 0 1 1 2 2 2 3 3 
4 0.1 0 0 1 1 2 2 2 3 3 
5 0.1 0 0 0 1 1 2 2 3 3 
1 0.2 0 0 0 1 1 2 2 3 3 
2 0.2 0 0 0 1 1 2 2 3 3 
3 0.2 0 0 0 1 1 2 2 3 3 
4 0.2 0 0 0 1 1 2 2 3 3 
5 0.2 0 0 0 0 0 1 1 2 2 
1 0.3 0 0 0 0 0 1 1 2 2 
2 0.3 0 0 0 0 0 1 1 2 2 
3 0.3 0 0 0 0 0 1 1 2 2 
4 0.3 0 0 0 0 0 1 1 2 2 
5 0.3 0 0 0 0 0 0 0 0 0 
1 0.4 0 0 0 0 0 0 0 0 0 
2 0.4 0 0 0 0 0 0 0 0 0 
3 0.4 0 0 0 0 0 0 0 0 0 
4 0.4 0 0 0 0 0 0 0 0 0 
5 0.4 0 0 0 0 0 0 0 0 0 
 
 From the observation of the Spironolactone sedimentation in different 
concentrations of Pluronic and Xanatural it was determined that increasing the 
concentration of Pluronic above 1% to 2, 3, 4 or 5% had no significant effect on 
sedimentation. Increasing the Xanatural concentration up to 0.4% gradually reduces the 
amount of sedimentation until at 0.4%w/v sedimentation no longer occurs. The 
differences in the formulations are illustrated below (Figure 82 and 83). 
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Figure 82 - Spironolactone in (A) Buffer Solution, (B) 1% Pluronic, (C) 2% Pluronic, (D) 
3% Pluronic, (E) 4% Pluronic and (F) 5% Pluronic after 24h of standing following 
vigorous initial shaking 
 
 
Figure 83 - Spironolactone in (A) Buffer Solution + 0.4% Xanatural, (B) 1% Pluronic + 
0.4% Xanatural, (C) 2% Pluronic + 0.4% Xanatural, (D) 3% Pluronic + 0.4% Xanatural, 
(E) 4% Pluronic + 0.4% Xanatural and (F) 5% Pluronic + 0.4% Xanatural after 24h of 
standing following vigorous initial shaking. 
. 
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4.4.2.4 Particle Size 
 The particle size is also an important consideration and as such the particle size 
was investigated for all concentration combinations of Pluronic and Xanatural (Table 38 
and 39).  
Table 38 – Particle size analysis for 10mg/ml formulation at different ratios of Pluronic 
and Xanatural. 
Particle Size (µm) (10mg/ml 
Spironolactone) 
Xanatural Concentration 
Pluronic F127  Concentration 0.00% 0.10% 0.20% 0.30% 0.40% 0.50% 
0.00% 42 44 42 43 42 42 
1.00% 22 23 22 23 23 22 
2.00% 21 23 22 21 22 23 
3.00% 22 22 23 22 21 22 
4.00% 24 22 21 22 24 22 
5.00% 23 22 22 24 25 22 
 
Table 39 - Particle size analysis for 5mg/ml formulation at different ratios of Pluronic and 
Xanatural. 
Particle Size (µm) (5mg/ml 
Spironolactone) 
Xanatural Concentration 
Pluronic F127  Concentration 0.00% 0.10% 0.20% 0.30% 0.40% 0.50% 
0.00% 42 44 42 43 42 42 
1.00% 21 22 23 22 22 22 
2.00% 21 20 22 21 23 22 
3.00% 22 23 22 22 22 21 
4.00% 23 23 22 21 23 21 
5.00% 21 20 23 22 23 21 
   
 The presence of pluronic reduced the particle size of the Spironolactone by 
approximately 50% in both the 10mg/ml and 5mg/ml suspensions, all concentrations of 
Pluronic had the same effect and so the concentration of choice is 0.1%. The presence 
and concentration of Xanatural had no impact on the particle size and so from the 
sedimentation work the 0.4% concentration still appears to be the optimum concentration. 
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4.4.2.5 Zeta Potential 
 Zeta potential analysis for all combinations of the Pluronic and Xanthan Gum 
showed no significant difference in response to increasing concentrations (Table 40 and 
41). With the information gathered so far it was decided to carry forward the use of 
Pluronic F127 and Xanatural at concentrations of 1%w/v and 0.4%w/v.  
Table 40 – Zeta potential analysis for 10mg/ml formulation at different ratios of Pluronic 
and Xanatural 
Zeta Potential (mV) 
(10mg/ml Spironolactone) 
Xanatural Concentration 
Pluronic F127 
Concentration 
0.00% 0.10% 0.20% 0.30% 0.40% 0.50% 
0.00% -8 -7 -7 -8 -7 -7 
1.00% -7 -8 -8 -7 -8 -7 
2.00% -7 -6 -8 -7 -7 -6 
3.00% -8 -7 -7 -8 -7 -8 
4.00% -7 -6 -8 -6 -7 -7 
5.00% -6 -7 -8 -7 -8 -7 
 
Table 41- Zeta potential analysis for 5mg/ml formulation at different ratios of Pluronic 
and Xanatural 
Zeta Potential (mV) (5mg/ml 
Spironolactone) 
Xanatural Concentration 
Pluronic F127 
Concentration 
0.00% 0.10% 0.20% 0.30% 0.40% 0.50% 
0.00% -8 -7 -7 -8 -7 -7 
1.00% -8 -7 -7 -7 -8 -7 
2.00% -6 -7 -7 -6 -7 -6 
3.00% -7 -8 -6 -6 -7 -7 
4.00% -7 -6 -7 -7 -8 -7 
5.00% -7 -6 -7 -8 -8 -6 
  
4.4.3 Final Formulations  
 From the investigations carried out it was clear that Xanatural 180 and Pluronic 
F127 would be essential components in the formulation to produce a vehicle providing 
suitable characteristics to maintain stability of the dosage form through the control of 
sedimentation and the prevention of caking. Based on knowledge gained in the Ramipril 
and Lisinopril formulations, the other excipients selected for the formulation were Sodium 
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Metabisulphate and Sodium benzoate to act as an antioxidant and preservative 
respectively. Flavouring would be present in the form of Xylitol as a sweetener and 
strawberry flavour included in a flavoured variety. 
The final ingredients for the formulation are as follows; 
 Spironolactone (10mg/ml or 5mg/ml) 
 Xanatural 180 (0.4%w/v) 
 Pluronic F127 (1.0%w/v) 
 Sodium Metabisulphate (1.0%w/v) 
 Sodium Benzoate (0.5%w/v) 
 Xylitol (40%w/v) 
 Strawberry Flavour (0.2%) (Flavoured Formulation Only) 
4.4.4 Formulation Characterisation 
  With the formulation completed, investigation into its physical properties 
were carried out with investigations into the suspension rheology, Ostwald ripening and 
suspension stability. 
4.4.4.1 Suspension Rheology 
 For oral suspensions hydrophilic polymers such as Xanatural 180 are used as 
suspending agents and have the effect of increasing the viscosity of the liquid vehicle. 
This is useful for prolonging the suspension of particles but can at times in the same way 
make it more difficult to re-suspend any particles which do sediment. To get the best 
results from the addition of hydrophilic polymers, the ideal properties for a suspensions 
flow profile are pseudoplastic or shear thinning. These are non-Newtonian liquids for 
which the rate of shear is not proportional to the shear stress exerted. This is particularly 
useful as the relatively high viscosity under low shear conditions e.g. during storage 
slows the sedimentation process and the relatively low viscosity under high shear 
 
 
200 
 
conditions e.g. shaking or pouring, allows for the easy re-dispersion of any sediment and 
also the easy dispensation of the medication. 
 The Spironolactone suspensions showed the desired pseudoplastic flow 
properties for both dosage concentrations with the 10mg/ml dosage resulting in higher 
viscosity than the 5mg/ml dosage (Figure 84). 
 
Figure 84 - Pseudoplastic flow properties for both dosage concentrations with the 
10mg/ml dosage resulting in higher viscosity than the 5mg/ml dosage. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
4.4.4.2 Ostwald Ripening  
 A common problem with particles in a suspension is the possibility of Ostwald 
ripening (crystal growth) occurring. This has been shown to be a problem previously with 
Spironolactone and occurs when compounds are suspended in a vehicle in which they 
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are slightly soluble. Upon a temperature increase the smaller particles in the system 
become soluble. This can lead to the crystallisation of the dissolved drug onto the surface 
of the larger drug molecules increasing the particle size further. As particle size is directly 
related to the rate of sedimentation an increase in particle size via Ostwald ripening will 
lead to destabilisation of a stable suspension. As Ostwald ripening has been shown to 
affect Spironolactone in the past, an increased number of heat/cool cycles was 
performed (Figure 85 and 86); 
 
Figure 85 – Particle size analysis for Ostwald ripening observation in 10mg/ml 
Spironolactone suspension. Results are generated from triplicate repeats (n=3) and 
error bars indicate standard deviation (RSD). 
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Figure 86 - Particle size analysis for Ostwald ripening observation in 5mg/ml 
Spironolactone suspension. Results are generated from triplicate repeats (n=3) and 
error bars indicate standard deviation (RSD). 
 
 Ostwald Ripening was shown not to be a problem for either of the Spironolactone 
dosage concentrations. It has been previously reported that hydrophobic polymers can 
be implemented to prevent Ostwald ripening, as such it is reasonable to conclude that 
the Xanatural 180 present in the Spironolactone formulations has provided a degree of 
protection against the crystal growth which has been reported in previous attempts to 
formulate spironolactone.   
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4.4.5 Stability Analysis 
4.4.5.1 Accelerated Conditions 
 Over the six month course of the stability testing in accelerated conditions with 
40°C and 75% relative humidity, the drug content of the formulations remained above 
95% of the starting dose indicating that the formulations display adequate stability in 
accordance with ICH guidelines (Figure 87). The pH remained constant for the duration 
of the stability testing (Figure 88). 
Figure 87 – Spironolactone recovery following HPLC for formulations in accelerated 
storage conditions. The drug content of the formulations remained above 95% of the 
starting dose indicating that the formulations display adequate stability in accordance 
with ICH guidelines. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
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Figure 88 – Spironolactone pH stability for formulations in accelerated storage conditions. 
For the duration of testing the formulations proved stable with little variation in pH seen 
for all samples. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
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4.4.5.2 Long Term Conditions 
 As seen in the accelerated conditions, for the twelve month testing course of the 
formulations stability in long term conditions, 25°C and 60% relative humidity, the drug 
content of all of the formulations remained >95% of the starting dose and the pH 
remained constant for the duration. 
 
Figure 89 – Spironolactone recovery following HPLC for formulations in long term 
storage conditions. The drug content of the formulations remained above 95% of the 
starting dose indicating that the formulations display adequate stability in accordance 
with ICH guidelines. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
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Figure 90 - Spironolactone pH stability for formulations in long term storage conditions. 
For the duration of testing the formulations proved stable with little variation in pH seen 
for all samples. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
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2. Any degradation product’s exceeding its acceptance criterion;  
3. Failure to meet the acceptance criteria for appearance, physical attributes, and 
functionality test (e.g., colour, phase separation, resuspendibility, caking, 
hardness, dose delivery per actuation); however, some changes in physical 
attributes (e.g., softening of suppositories, melting of creams) may be expected 
under accelerated conditions;  
and, as appropriate for the dosage form:  
4. Failure to meet the acceptance criterion for pH; or  
5. Failure to meet the acceptance criteria for dissolution for 12 dosage units. 
 The Spironolactone formulations tested under all conditions showed no 
significant decrease in the drug assayed in comparison to the day zero analysis. This 
was seen in all formulation types and at all dosages. In addition, the appearance and 
odour of the formulations remained acceptable for the duration of the stability testing and 
in both long term and accelerated conditions. Sedimentation did not occur in formulations 
stored in long term storage conditions and some degree of sedimentation was observed 
in formulations stored in accelerated storage conditions. The reason behind the 
sedimentation seen is most likely the increased temperature decreasing the viscosity of 
the vehicle and thus allowing particles to gravitate more easily. Caking did not occur 
however and the suspension was returned to a homogenous state easily and with 
minimal agitation meaning that the physical stability of the formulations in all conditions 
was maintained for the duration of testing. The advice for storage of the medication 
would have to advise against storage in hot conditions and directions for the procedure 
of re-suspension would have to be provided to ensure formulation homogeneity 
immediately prior to administration. With regards to excursions outside of the storage 
conditions such as transport during distribution, degradation and lack of physical stability 
should not be a concern.  
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5 IN VITRO AND IN VIVO PERMEABILITY ASSESSMENT OF LIQUID 
RAMIPRIL, LISINOPRIL AND SPIRONOLACTONE FORMULATIONS 
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5.1 CHAPTER AIMS AND OBJECTIVES 
- Caco-2 cells grown on transwell inserts are used to perform in vitro drug transport 
studies for the formulations developed in chapters 2, 3 and 4. 
- Wistar rats are used to perform in vivo drug transport studies for the formulations 
developed in chapters 2, 3 and 4. 
- Analyse samples from drug transport studies via HPLC. 
- Compare in vitro and in vivo findings to identify any in vitro – in vivo correlation 
which can later be combined with genomic studies to investigate the application 
of microarrays in the production of an in vitro – in vivo correlation screening 
toolbox.          
5.2 INTRODUCTION 
 Where drug absorption is concerned, the barrier function of human intestine is 
the largest obstacle in the absorption of orally administered drugs. There are two 
components to this barrier function which can be classified as physical and biochemical. 
The physical barrier is present as a result of tight junctions which form between the 
enterocytes in the intestine and also the hydrophobic nature of the cell membranes while 
the biochemical barrier is a result of enzymes and transporter proteins. A model which 
predicts the absorption of a drug needs to replicate these barriers as closely as possible 
(Mohammed et al 2011).  
 Varieties of cell monolayer models that mimic in vivo intestinal epithelium in 
humans have been developed and are now used in many applications. Unlike 
enterocytes, human immortalized (tumor) cells grow rapidly into confluent monolayers 
that exhibit several characteristics of differentiated epithelial cells. As such the cell 
culture model provides an ideal system for the rapid assessment of the intestinal 
permeability of drug candidates. The Caco-2 cell model has been the most extensively 
characterized and useful cell model in the field of drug permeability studies. Caco-2 cells, 
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a human colon adenocarcinoma, undergo spontaneous enterocytic differentiation in 
culture and are polarized with well-established tight junctions. Due to the permeation 
characteristics of drugs across Caco-2 cell monolayers correlating with their human 
intestinal mucosa permeation characteristics, Caco-2 cells can be used to predict the 
oral absorption of drugs in humans. In the past 10–15 years, there has been a 
tremendous growth in the use of Caco-2 cells for mechanistic studies, and as a rapid in 
vitro screening tool in support of drug discovery within the pharmaceutical industry. In 
order to assay the permeability of drugs, Caco-2 cells are grown on membrane supports 
which create an apical and basal chamber inside each well of a six well plate. Following 
addition of the drug substance to the apical chamber, its arrival in the basal chamber is 
measured at various time points to produce a profile for the drug’s permeability. This is 
expressed as apparent permeability which correlates to in vivo absorption.   
 One of the limitations of a cell model is that the cells only represent one obstacle 
in the absorption of the drug and the model requires correlations to be produced with the 
in vivo performance. Factors such as gastrointestinal transit time, first pass metabolism, 
fasted/fed absorption differences and mucus production are all largely unaccounted for. 
In vivo permeability analysis is the most ‘true to life’ means of modelling permeability 
and for the most part involves the use of animal models, rats are the preferred species 
used to model the human intestine, Zhao et al 2003 reported a correlation of R2=0.88 
when they investigated the correlation of drug absorption between humans and rats. 
Also in 2003, Cao et al reported that drug absorption in the small intestine of humans 
and rats showed a linear correlation (R2=0.8) for both passive and carrier mediated 
absorption pathways. They also investigated the genetic expression levels of intestinal 
transporters in the duodenum for both species, this did not correlate as well as the values 
for drug absorption however an R2 value of 0.56 indicated that there was some level of 
correlation. Transporters such as PepT1, SGLT-1, GLUT5, MRP2, NT2, and high affinity 
glutamate transporter were shown to display similar expression levels in both humans 
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and rats while in contrast, other transporters such as MDR1, MRP3, GLUT1, and GLUT3 
were shown to be expressed at different levels. Finally they investigated the expression 
levels of metabolising enzymes present in the intestine of both species such as 
CYP3A4/CYP3A9 and UDPG and it was revealed that here there was no correlation, 
providing reasoning for differences seen in drug metabolism and oral bioavailability seen 
between rats and humans (Cao et al 2003). These correlations and the similarity 
between rats and humans in the undelaying mechanisms playing a part in oral drug 
absorption through the intestinal membrane are the reason the rat model is preferred for 
use in vivo and widely used.  
 Results generated from in vivo permeability experiments can provide information 
on a variety of parameters which are dependent upon experimental design, three 
functions which are common to almost all in vivo data analysis are the area under the 
curve (AUC), peak concentration (CMAX) and peak time (TMAX).  
 The area under the plasma drug concentration-time curve (AUC) reflects the 
actual body exposure to drug after administration of a dose of the drug and is expressed 
in mg*h/L. The AUC is governed by the initial dose given and the rate at which the drug 
in question is eliminated from the body. Total drug elimination may be calculated through 
the cumulative amount eliminated in each time interval, from time zero (time of the 
administration of the drug) to time infinity. This total amount corresponds to the fraction 
of the dose administered that reaches the systemic circulation. The AUC is directly 
proportional to the dose when the drug follows linear kinetics and the AUC is inversely 
proportional to the clearance of the drug (Urso et al 2002).  
 Following oral administration CMAX and TMAX are dependent on the extent, and 
the rate of drug absorption and on the disposition profile of the drug. The peak time 
(TMAX) and the peak concentration (CMAX) may be directly obtained from the experimental 
observations (Urso et al 2002). 
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 In this chapter, investigation into the in vitro and in vivo drug absorption of 
Lisinopril, Ramipril and Spironolactone from developed formulations is reported with the 
aim of finding a correlation between the Log Papp produced from in vitro assays and the 
information derived from in vivo assays.     
5.3 MATERIALS AND METHODS 
5.3.1 Assessment of Absorption In Vitro 
5.3.1.1 Culture of Caco-2 Cells for permeability assay  
 Caco-2 cells (passage 45) (A kind gift from Dr A. Collett and Dr Daniel Patten at 
the University of Huddersfield) were seeded at a density of 1.3x105 cells/cm2 onto 
permeability supports (Appleton Woods Ltd). Cells were cultured in an incubator (Sanyo) 
37°C in a humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days 
over a three week period. During this time TEER measurements were taken following 
each media change using an EVOM – Epithelial Voltohmmeter (World Precision 
Instruments Ltd) to develop a profile for tight junction formation and development and to 
ensure monolayer integrity. Additionally, TEER was measured immediately before and 
after experiments to ensure that monolayer integrity had been maintained for the 
duration of the investigation. 
 For the determination of Trans-epithelial flux of Ramipril, Lisinopril and 
Spironolactone across Caco-2 monolayers, culture media was removed and the 
monolayers washed with HBSS before the monolayers were incubated at 37°C for 30 
minutes with 2.5ml of HBSS in the basolateral compartment and 1.5ml of HBSS in the 
apical compartment. After 30 minutes the HBSS was removed from the apical 
compartment and replaced with 1.5ml of the formulation to be tested. 200µl samples 
were then taken from the basolateral compartment of each well at time points of 5, 10, 
15, 20, 30, 60, 90, and 120 minutes. 200µl samples were also taken from the apical 
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compartment of each well at the 120 minute time point. In each case where sample was 
taken from the basolateral compartment a matching volume of HBSS was added. This 
was corrected for in calculations. The samples were analysed via HPLC. All of the 
experiments were performed in triplicate and the level of transport is described as the 
percentage of drug arriving in the basolateral compartment.   
5.3.1.2 HPLC Methods Adapted for inclusion of HBSS 
 HPLC Methods were repeated using HBSS in standard production to account for 
any changes to the retention time, peak size or peak shape that the addition of a salt 
solution may cause. 
5.3.1.3 Lisinopril HPLC Method 
 The Lisinopril HPLC method for permeability assays was modified from a method 
previously developed in house and used a Dionex GP50 Gradient Pump coupled to a 
Dionex UVD170U detector and a Dionex A550 auto sampler. The stationary phase is a 
Phenomenex Gemini 5µ C18 reverse phase HPLC column (150 x 4.5mm with 5µm 
Particle Size). The detection wavelength was set at 228nm. The injection volume is 20µl 
with a run time of 10 minutes. Preparation of Calibration Standards involves the 
production of a stock solution 4mg/gml in HBSS followed but the production of six 
standards, initially with a 1:1 dilution and then subsequent serial dilution of the stock 
solution using mobile phase. Standards at 2.0, 1.0, 0.5, 0.25, 0.125 and 0.0625mg/ml. 
Samples were prepared for analysis by dilution so as to fall within the calibration range 
and were diluted with Lisinopril mobile phase. 
5.3.1.4 Ramipril HPLC Method 
 The HPLC method for Ramipril permeability assays was adapted from the 
method previously developed in house which had been based upon a combination of 
the stability indicating HPLC methods described by Allen et al (1995) and Patil et al 
(2008). The method developed used a Perchlorate Buffer and Acetonitrile (55:45) mobile 
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phase and C18 reverse phase HPLC column (150 x 4.5mm with 5µm Particle Size) with 
a flow rate of 1mg/min and a detection wavelength of 216nm. The injection Volume was 
50µl and the run time was 10 minutes. Six calibration standards produced via serial 
dilution in HBSS. The standards were then diluted 1:5 in water and acetonitrile (45:55). 
Samples were diluted to be within calibration standards using water and acetonitrile 
(45:55).  
5.3.1.5 Spironolactone HPLC Method 
 The Spironolactone HPLC method for permeability assays was developed in 
house using from the existing method using a Dionex GP50 Gradient Pump coupled to 
a Dionex UVD170U detector and a Dionex A550 auto sampler. The stationary phase is 
a Phenomenex Gemini 5µ C18 reverse phase HPLC column (150 x 4.5mm with 5µm 
Particle Size). The detection wavelength was set at 254nm. The injection volume is 20µl 
with a run time of 10 minutes. Preparation of Calibration Standards involves the 
production of six standards. A 4mg/ml Spironolactone stock is produced in HBSS 
followed but the production of six standards, initially with a 1:1 dilution and then 
subsequent serial dilution of the stock solution using mobile phase. Standards at 2.0, 
1.0, 0.5, 0.25, 0.125 and 0.0625mg/ml. serial dilution in mobile phase. Samples were 
prepared for analysis by dilution so as to fall within the calibration range and are diluted 
with mobile phase.  
5.3.1.6 Calculation of apparent permeability (Papp) 
 The apparent permeability of a molecule (Papp) determined following permeability 
assay through Caco-2 has been shown in previous studies to correlate reasonably well 
with the associated human absorption coefficients. Studies to determine Papp of a 
molecule in formulation are incredibly useful in the drug discovery and development area 
as Papp is often the first indicator of a molecule’s potential to pass from the intestine into 
the blood. As a result Papp can be used to identify molecules which are suitable for oral 
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administration and also it allows for the comparison of different formulations containing 
the same active ingredient. 
Following the production of a transport/time graph which displays the rate of drug 
transport from the apical to basolateral chamber of the permeability support over the 
time of the assay, Papp is calculated using the following equation (Yang 2007); 
𝑃𝑎𝑝𝑝 =   (
𝑉𝑟
𝐴𝐶𝑜
) (
𝑑𝐶
𝑑𝑡
) 
Where; 
Vr – is the volume of the basolateral chamber (ml) 
A – is the filter surface area available for transport (cm2). 
C0 – is the initial concentration of drug (mg/µl). 
𝑑𝐶
𝑑𝑡
 - is the initial slope of the cumulative concentration (dC) of drug in the basolateral 
chamber (mg/µl) with time (dt) (s).  
    
5.3.2 Assessment of Absorption in Vivo. 
 Rats were Wistar rats with a body weight of approximately 250g-300g. Once 
prepared the formulations were loaded into a 1ml syringe and administered via oral 
gavage. Dosing was calculated depending upon the weight of each individual animal 
and formulations were diluted in H2O, Lisinopril was dosed at 10mg/kg, Ramipril was 
dosed at 5mg/kg and Spironolactone was dosed at 40mg/kg. Following dosing, an 
additional 1ml of H2O was administered to rinse in the formulations. Blood samples (45µl) 
were taken via tail bleeds at 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hour, 2 
hour, 2.5 hour, 3 hour and 4 hour time points following administration. Plasma was 
extracted from blood samples by centrifugation at 2800 x g for 10minutes followed by 
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liquid-liquid extraction using hexane and methylene chloride. Samples were then diluted 
1:5 in mobile phase and analysed using HPLC. 
5.3.2.1 Calculation of AUC 
 Area under the curve for drug absorption in vivo was performed using the 
trapezoidal rule where the plasma concentration against time profile is split into multiple 
trapezoids and the area of each trapezoid is added to provide the overall AUC (Figure 
91).  
 
Figure 91 - Trapezoidal calculation of the area under the curve (AUC). The area under 
the curve is separated into trapezoids where each time point forms the vertical 
boundaries. To calculate the area of each trapezoid for example trapezoid A is given by 
(Cn-1 - Cn) x (tn – tn-1)/2. Where the plasma concentration has not returned to 0 before the 
final time point, extrapolation to work out AUC to time infinity, trapezoid B, is calculated 
using (Clast/0.693/t1/2). AUC is given by the sum of all of the trapezoids and the units are 
expressed as ng*h/ml. 
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5.4 RESULTS AND DISCUSSION 
5.4.1 Culture of Caco-2 cells for permeability investigation.  
 For the permeability investigation of Lisinopril, Ramipril and Spironolactone, 
membrane supports were seeded at a density of 1.3x105 cells/cm2 and allowed to 
develop. TEER was measured at each media change to monitor the integrity of the 
developing monolayers. At a density of 1.3x105 cells/cm2 it takes roughly 7 days for 
Caco-2 cells to reach confluence in 6 well and 24 well plates, however for the tight 
junctions to form fully between these cells producing a fully selectively permeable 
membrane it takes much longer. Sources in literature generally report that Caco-2 
monolayers grown on permeable supports are suitable for use between 2 and 4 weeks 
following seeding (Fleck et al 2014, Parker et al 2014, Inaba et al 2014). As it is not 
possible to inspect the Caco-2 cells on permeability supports using a microscope the 
least invasive technique to monitor cell monolayer development is a technique known 
as trans-epithelial electronic resistance (TEER) measurement. This is widely 
implemented to indicate confluence and ensure integrity of the monolayer prior to 
permeability assessment. The TEER of the seeded membranes was measured following 
each media change to provide a profile for the cell development (Figure 92) and provide 
indication as to when the cells would be suitable for use when grown under the specified 
conditions 
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Figure 92 – TEER profile as Caco-2 monolayers develop over time when grown on 
transwell inserts. Results are generated from triplicate repeats (n=3) and error bars 
indicate standard deviation (RSD). 
 
 In keeping with literature (Tokumura et al 2014) the TEER value for the 
monolayers peaked at approximately 425Ω at 11 days following the seeding of the 
membranes. At this point the cells are confluent and TEER readings level off. The TEER 
values remained constant confirming that the monolayers were suitable for use. 
Permeability experiments were performed after 21 days of culture to ensure stable TEER 
values over 400Ω and also to ensure the enzymes and transporters which have a roll in 
drug absorption have adequate time to be fully expressed. 
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5.4.2 HPLC Methods Accounting for HBSS Inclusion 
 Prior to undertaking the permeability experiments, calibration curves for each of 
the Lisinopril (Figure 93), Ramipril (Figure 94) and Spironolactone (Figure 95) HPLC 
methods were required to be produced integrating HBSS into the production of 
calibration standards. This is necessary as samples collected from the basolateral 
compartment of the permeability assay transwell set up would be in HBSS and even a 
small concentration of salt solution can potentially have significant effects on the 
behaviour of HPLC separation and detection. Retention time, peak size and peak shape 
can all be affected. HBSS is a salt solution designed to maintain optimum physiological 
pH for the cultured cells during permeability experiments and the salt concentrations are 
relatively low.    
 
 
Figure 93 – Lisinopril HPLC calibration using standards produced in HBSS. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 94 – Ramipril HPLC calibration using standards produced in HBSS. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD) 
N.B. some error bars are obscured by the data point. 
 
 
Figure 95 – Spironolactone HPLC calibration using standards produced in HBSS. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard 
deviation (RSD) N.B. some error bars are obscured by the data point. 
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 All of the calibrations produced following the incorporation of HBSS into standard 
production were found to produce curves with comparable equations and R2 values to 
the validated HPLC methods produced in house. This is most likely due to the effect of 
the standards undergoing dilution in mobile phase for all of the methods prior to running 
reducing the salt solution to a point where it would have a negligible effect on the method 
performance. The dilution in mobile phase also has the effect of reducing the presence 
of a solvent front as the refractive index of the injected sample more closely matches 
that of the mobile phase already passing through the detector. 
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5.4.3 In Vitro Drug Transport and Calculation of Papp 
 TEER values were measured before and after the permeability experiments for 
each transwell used to ensure that the TEER did not drop. If this had been observed 
then it would have indicated that the integrity of the monolayer had been compromised. 
In all cases the TEER remained above an acceptable level of 300Ω (Figure 96). 
 
Figure 96 - TEER values before and after permeability investigations for all formulations 
tested. Results are generated from triplicate repeats (n=3) and error bars indicate 
standard deviation (RSD).  
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 Following permeability experiments, samples were analysed via HPLC and the 
findings from which were plotted to reveal the percentage of drug which had been 
transported from the apical compartment of the transwell to the basolateral compartment 
of the transwell as a factor of time (Figures 97-108).  
 
Figure 97 - Percentage of drug which had been transported from the apical compartment 
of the transwell to the basolateral compartment of the transwell as a factor of time for 
the sweetened Lisinopril solution. Results are generated from triplicate repeats (n=3) 
and error bars indicate standard deviation (RSD). 
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Figure 98 - Percentage of drug which had been transported from the apical compartment 
of the transwell to the basolateral compartment of the transwell as a factor of time for 
the flavoured Lisinopril solution. Results are generated from triplicate repeats (n=3) and 
error bars indicate standard deviation (RSD). 
 
Figure 99 - Percentage of drug which had been transported from the apical compartment 
of the transwell to the basolateral compartment of the transwell as a factor of time for 
the sweetened Ramipril solution produced using HP-β-CD. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 100 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the flavoured Ramipril solution produced using HP-β-CD. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 101 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the sweetened Ramipril solution produced using acetic acid as a co-solvent. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard 
deviation (RSD). 
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Figure 102 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the flavoured Ramipril solution produced using acetic acid as a co-solvent. 
Results are generated from triplicate repeats (n=3) and error bars indicate standard 
deviation (RSD). 
 
Figure 103 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the sweetened Ramipril suspension. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 104 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the flavoured Ramipril suspension. Results are generated from triplicate 
repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 105 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the sweetened Spironolactone suspension (10mg/ml). Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
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Figure 106 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the flavoured Spironolactone suspension (10mg/ml). Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
Figure 107 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the sweetened Spironolactone suspension (5mg/ml). Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD).  
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Figure 108 - Percentage of drug which had been transported from the apical 
compartment of the transwell to the basolateral compartment of the transwell as a factor 
of time for the flavoured Spironolactone suspension (5mg/ml). Results are generated 
from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
  
 The data generated from the production of the transport vs time charts allowed 
for the calculation of Papp. Applying the Papp equation to the data collected from the 
permeability assay carried out on the Ramipril and Lisinopril Solutions produced the Papp 
values detailed in figures 98 to 108.   
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Figure 109 – Apparent permeability values for Lisinopril, Ramipril and Spironolactone 
formulations. It is generally accepted that completely absorbed drugs have Papp >1x10-
6cm/s. (LogPapp > -6) and incompletely or poorly absorbed drugs have Papp <1x10
-6cm/s. 
(LogPapp < -6). This threshold is indicated by the red line. Results are generated from 
triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 In previous investigations into Papp the permeability coefficients ranged from 
approximately 5x10-8 to 5x10-5. The permeability coefficients for the Ramipril, Lisinopril 
and Spironolactone formulations are in keeping with these findings. The permeability 
coefficient or apparent permeability of a molecule (Papp) is considered to be a reliable 
indicator for the expected in vivo drug absorption (Fraction Absorbed (fa)). It is generally 
accepted that completely absorbed drugs have Papp >1x10-6cm/s. (LogPapp > -6) and 
incompletely or poorly absorbed drugs have Papp <1x10-6cm/s. (LogPapp < -6). This 
threshold is indicated by the red line in figure 98. It is known that Spironolactone is fully 
absorbed in vivo, this is confirmed with a Log (Papp) greater than -6.00 for all of the 
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formulations. In addition, it is known that Ramipril and Lisinopril have 50-60% and 20-
30% in vivo absorption respectively. By comparing Log (Papp) to expected absorption 
in humans (%) (Figure 110) it is seen that the results observed in vitro is a good indication 
of the anticipated in vivo absorption. In addition the comparison of our data with that from 
existing literature indicates that drugs used in our assay fit the expected profile. 
 
Figure 110 – Comparison of Papp data to predicted human absorption and also data from 
existing literature.  
 
5.4.4 In Vivo Drug Absorption  
 The plasma concentration-time profile for the formulations developed and 
examined for in vivo absorption is shown below (Figure 111). Spironolactone showed 
the highest plasma concentrations for the duration of the analysis with the Lisinopril 
solution showing the next highest and the Ramipril formulations showing the lowest 
plasma concentrations. 
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Figure 111 - Plasma Concentrations Following Oral Administration. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 From the plasma concentration-time profile, values for AUC, CMAX and TMAX were 
determined and are shown below in table 42.  
Table 42 – In vivo results for AUC, CMAX and TMAX. 
 Formulation AUC (ug*h/mL) CMAX (ug/ml) TMAX (h) 
Lisinopril Solution 200.6525467 82.08 1 
Ramipril Cyclodextrin Solution 15.07348068 29.58 0.75 
Ramipril Co-solvent Solution 7.945549365 10.48 2.5 
Ramipril Suspension 18.54717314 13.04 2.5 
Spironolactone Suspension 1052.801405 375.37 2.5 
 
 Lisinopril and Ramipril AUC values are within the anticipated range although is 
not surprising as bioavailability is highly variable between individuals for both drugs with 
reports showing variation as great as 6-60% for both drugs. It is surprising to see 
Lisinopril absorption higher than Ramipril as Based on the majority of existing literature. 
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Lisinopril bioavailability is reported to be on average between 20-30% and Ramipril 
bioavailability is reported to be on average between 50-60%.  The initial concentration 
of formulations will have an effect due to different concentration gradients and Lisinopril 
was dosed at 10mg/kg, Ramipril was dosed at 5mg/kg and Spironolactone was dosed 
at 40mg/kg. From this it would be reasonable to expect to see higher Lisinopril peak 
plasma concentrations than Ramipril. The findings reported in table 42 reflect this with 
Lisinopril CMAX being 82.08µg/ml and Ramipril showing a CMAX range of 10.48 µg/ml for 
the Ramipril solution produced using a co-solvent, 3.84µg/ml for the Ramipril 
Suspension and 29.58µg/ml for the Ramipril solution produced using cyclodextrin as a 
solubiliser.  
 The findings for CMAX and TMAX reveal some interesting points, for the Ramipril 
solution produced using a co-solvent, the Ramipril suspension and the Spironolactone 
suspension the occurrence of TMAX 2.5h after administration is in keeping with reported 
literature. The Ramipril solution produced using cyclodextrin however shows a much 
earlier TMAX occurring only 0.75h following administration. As the only formulation 
component which is unique to the Ramipril solution produced using cyclodextrins as a 
solubiliser is the HP-β-CD it is possible that this excipient is responsible for the earlier 
TMAX and higher CMAX. There is evidence that HP-β-CD decreases GI transit time in rats 
(Pestel et al 2006). As Ramipril is absorbed mainly in the Ileum, this would result in the 
formulation reaching the site of absorption more rapidly. Ordinarily, a decrease in 
intestinal residence time would see a decrease in absorption due to a shorter absorption 
window however cyclodextrins have the ability to improve drug absorption and this has 
been reported extensively. It is generally recognized that cyclodextrins act as true 
carriers by keeping the hydrophobic drug molecules in solution and deliver them to the 
surface of the biological membrane. The relatively lipophilic membrane has low affinity 
for the hydrophilic cyclodextrin molecules and therefore they remain in the aqueous 
membrane exterior, e.g. the aqueous vehicle system or GI fluid. Conventional 
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penetration enhancers, such as alcohols and fatty acids, disrupt the lipid layers of the 
biological barrier however, cyclodextrins, on the other hand, act as penetration 
enhancers by increasing drug availability at the surface of the biological barrier.  
 Another interesting factor which has presented is that of secondary maxima in 
plasma concentrations. The appearance of secondary maxima in plasma concentration-
time curves following oral administration has been studied extensively and this is 
observed for the Lisinopril solution plasma concentration-time profile and less so in the 
Spironolactone suspension plasma concentration-time profile.  As reported by 
Takamatsu et al 2002, double peaks have also been observed with other drugs, 
including ﬂurbiprofen, penicillamine, aspirin, furosemide and acetaminophen. The 
reason for this occurrence cannot be confirmed however there are several reported 
hypotheses including region-dependent variation in absorption, enterohepatic 
recirculation, variable gastric emptying and intestinal transit rates and intestinal bacterial 
reconversion of biliary metabolite which have been proposed to account for these 
observations (Takamatsu et al 2002). 
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5.4.5 In Vitro – In Vivo Comparison 
 The findings from the in vitro and in vivo drug absorption studies were compared 
to identify a correlation between the results. For this the Log conversion of the AUC from 
the in vivo experiments was plotted against the Log Papp values calculated following the 
in vitro drug transport studies (Figure 112).  
 
Figure 112 – For each of the formulations, the Log conversion of the AUC from the in 
vivo experiments was plotted against the Log Papp values calculated following the in vitro 
drug transport studies. This returned an R2 value of 0.6946 indicating a poor correlation 
between the in vitro and in vivo findings. Results are generated from triplicate repeats 
(n=3) and error bars indicate standard deviation (RSD). 
 
 The correlation for the comparison of the in vitro and in vivo data sets was found 
to be R2 = 0.6946. The R2 value is comparable to those seen elsewhere in reported 
literature for in vitro in vivo correlations. The R2 value would perhaps be expected to be 
some distance from the perfect linearity of R2 = 1.0 as the comparison uses limited data 
points (n=5). There is also a known high degree of variation in the in vivo absorption of 
R² = 0.6946
0
0.5
1
1.5
2
2.5
3
-6.4 -6.3 -6.2 -6.1 -6 -5.9 -5.8 -5.7
Lo
g 
A
U
C
Log Papp
Correlation between Log AUC and Log Papp
 
 
236 
 
the ACE inhibitor drugs Lisinopril and Ramipril. The next stage in the investigation 
examines the gene expression levels of intestinal transporters to see if there is a greater 
correlation between in vitro gene expression and in vivo drug absorption.    
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6 INVESTIGATION INTO THE POTENTIAL APPLICATION OF MICROARRAYS 
TO DEVELOP AN IN VITRO – IN VIVO CORRELATION SCREENING 
TOOLBOX IN THE ASSESSMENT OF LIQUID RAMIPRIL, LISINOPRIL AND 
SPIRONOLACTONE FORMULATIONS 
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6.1 CHAPTER AIMS AND OBJECTIVES 
- As in chapter 5, Caco-2 cells grown on transwell inserts are used to perform in 
vitro drug transport studies for the formulations developed in chapters 2, 3 and 
4. 
- Extract RNA from cell samples 
- Analyse RNA samples using microarray technology to identify genes which 
exhibit expression changes of 2 fold or more.  
- Compare genomic data to the in vitro and in vivo findings to investigate the 
application of microarrays in the production of an in vitro – in vivo correlation 
screening toolbox.          
6.2 INTRODUCTION 
 Microarrays are a powerful tool utilised in genomics allowing high throughput 
analysis of mRNA abundance. They have found application in many areas of drug 
discovery and development including the comparative assessment of normal and 
diseased state tissues, transcription and/or expression profiling, side effect profiling, 
pharmacogenomics and the identification of biomarkers (Russell et al 2013). They 
consist of a solid support onto which hybridisation probes are immobilised in a grid array 
and they are capable of producing huge amounts of data in the magnitude of tens of 
thousands of data points for every sample analysed. Although this can generate a wealth 
of information the data analysis process is crucial if anything meaningful is to be 
deciphered about the system being examined. To do this computational statistics are 
employed to generate gene lists which highlight genes of interest. The use of online 
databases such as KEGG is then used for pathway analysis amongst other things. In 
order to produce a manageable data set from the highly complex data generated from 
microarray scans, statistical approaches such as hierarchical cluster analysis (HCA), 
 
 
239 
 
principal component analysis (PCA) and statistical analysis of microarray (SAM) 
algorithms are used.  
 This chapter investigates the application of microarrays examining expressional 
changes following drug transport to potentially provide a tool for the prediction of 
intestinal drug absorption in humans. Work published recently has investigated changes 
in gene expression of the intestinal transporters following exposure of Caco-2 cells to 
pharmaceutical formulations (Khan et al 2010 and Khan et al 2011). For this the model 
drugs paracetamol and indomethacin were used as they are absorbed by non-carrier 
mediated and carrier mediated pathways respectively. Previous studies investigating 
transporter expression levels targeted individual transporters, many of which focusing 
on multidrug resistance protein 1 (MRP1), also known as permeability glycoprotein (P-
gp). Khan et al reported for the first time that there was a wide range of genes for which 
expression was altered following indomethacin transport across Caco-2 monolayers. 
These included 25 genes in addition to MRP1 (Khan et al 2010). Findings for 
paracetamol also indicated modification in gene expression levels following transport 
studies (Khan et al 2011 and Ketterer et al 1983).  
  Lisinopril, Ramipril and Spironolactone formulations developed in house and for 
which in vitro and in vivo permeability data has been gathered are used as model 
formulations with a focus on the genes which code for the transporters ABCB1 and 
SLC15A1 for Lisinopril, SLC15A1 and SLC15A2 for Ramipril and ABCB1 (Ilka et al. 
2008), ABCC2 and SLCO1A2 for Spironolactone (Cui et al. 2009; Kanai  R. Bao, Y. 
Wolkoff, A. W. Schuster, V. L. 1996). Lisinopril is known to be an inhibitor of ABCB1 and 
a substrate for SLC15A1, Ramipril is known to be a substrate for SLC15A1 and 
SLC15A2. Spironolactone is and inhibitor of ABCB1 and SLCO1A2 and also an inducer 
of ABCC2. 
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6.3 MATERIALS AND METHODS 
6.3.1 Cell Culture 
 Caco-2 cells (passage 45) (A kind gift from Dr A. Collett and Dr Daniel Patten at 
the University of Huddersfield) were seeded at a density of 1.3x105 cells/cm2 onto 
permeability supports (Appelton Woods Ltd). Cells were cultured in an incubator (Sanyo) 
37°C in a humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days 
over a three week period. During this time TEER measurements were taken following 
each media change using an EVOM – Epithelial Voltohmmeter (World Precision 
Instruments Ltd) to develop a profile for tight junction formation and development and to 
ensure monolayer integrity. Additionally, TEER was monitored to ensure that monolayer 
integrity had been maintained for the duration of the investigation. 
6.3.2 Drug Transport Assay 
 For the flux of Ramipril, Lisinopril and Spironolactone across Caco-2 monolayers, 
culture media was removed and the monolayers washed with HBSS before the 
monolayers were incubated at 37°C for 30 minutes with 2.5ml of HBSS in the basolateral 
compartment and 1.5ml of HBSS in the apical compartment. After 30 minutes the HBSS 
was removed from the apical compartment and replaced with 1.5ml of the formulation to 
be tested. Experiments were halted and cell samples prepared for RNA extraction at 0, 
20 and 60 minutes. At each time point, ethanol/phenol (95:5) replaced HBSS and 
transwells were refrigerated for 24 hours. At which point cells were removed from the 
surface of the transwells carefully using a cell scraper. These cells were then transferred 
into centrifuge tubes and centrifuged at 2000rpm at 4°C for 10 minutes. Cell pellets were 
then stored at -80°C prior to RNA extraction. 
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6.3.3 RNA Extraction 
 RNA extraction for Caco-2 was performed using an RNeasy kit (Qiagen) following 
manufacturers guidelines. The extracted RNA was then quantified using a Nanodrop 
ND-1000 UV-VIS spectrophotometer (Thermoscientific, Wilmington, DE) (Table 43). 
Table 43 – RNA Quantification  
Formulation and Time Point RNA Abundance (ng/ul) 260/280 260/230 
Spironolactone Suspension (20min) 155.0 1.99 0.84 
Spironolactone Suspension (60min) 271.2 2.06 1.73 
Ramipril Suspension (20min) 250.0 2.04 0.61 
Ramipril Suspension (60min) 403.3 2.01 1.50 
Ramipril Solution (Cyclodextrin) (20min) 169.2 2.05 1.22 
Ramipril Solution (Cyclodextrin) (60min) 161.2 2.06 0.75 
Ramipril Solution (Cosolvent) (20min) 124.2 2.05 0.56 
Ramipril Solution (Cosolvent) (60min) 228.4 2.04 1.50 
Lisinopril Solution (20min) 382.5 2.03 1.48 
Lisinopril Solution (60min) 331.5 2.01 1.34 
Control (A) 210.2 2.06 1.11 
Control (B) 222.6 2.04 1.11 
 
6.3.4 Microarray Assay 
 The microarray assay was performed following the directions for Agilent 
Technologies’ one-colour microarray-based gene expression analysis low input quick 
amp labelling kit. In short, 1.5µl of 50ng total RNA was mixed with 2µl of spike mix 
(dilution 4), cDNA master mix (Agilent Technologies, Santa Clara, CA) was used to 
prepare cDNA for all samples ahead of labelling with cyanine 3-CTP (Cy3) in the labelling 
reaction. The labelled and amplified cRNA was then purified using RNeasy mini spin 
columns (Qiagen) and quantified using Nanodrop ND-1000 UV-VIS spectrophotometer 
(Thermoscientific, Wilmington, DE). cRNA yield and specific activity were calculated 
(Table 44). 
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Table 44 – cRNA yield and specific activity. 
Sample 
Abs@260n
m 
pmol/ul ng/ul 260/280 
Yield 
(ug) 
Specific 
Activity 
Spiro Suspension 
(20min) 
0.031 2.10 296.10 2.47 8.88 7.09 
Spiro Suspension 
(60min) 
0.043 2.80 427.30 2.37 12.82 6.55 
Ramipril Susp 
(20min) 
0.008 0.60 50.00 2.27 1.50 12.00 
Ramipril Susp 
(60min) 
0.021 1.40 63.60 1.69 1.91 22.01 
Ramipril Solution 
(CD) (20min) 
0.015 1.00 270.00 1.94 8.10 3.70 
Ramipril Solution 
(CD) (60min) 
0.030 2.00 111.80 2.23 3.35 17.89 
Ramipril Solution 
(Co) (20min) 
0.009 0.60 86.60 2.21 2.60 6.93 
Ramipril Solution 
(Co) (60min) 
0.004 0.30 62.70 2.13 1.88 4.78 
Lisinopril Solution 
(20min) 
0.005 0.30 40.00 2.36 1.20 7.50 
Lisinopril Solution 
(60min) 
0.004 0.20 36.40 2.36 1.09 5.49 
Control  
(A) 
0.006 0.40 46.50 2.36 1.40 8.60 
Control  
(B) 
0.007 0.40 41.70 2.22 1.25 9.59 
      
 All samples were then hybridised to Agilent 4x44K whole genome arrays for 17 
hours at 65°C in a hybridisation oven (Sheldon manufacturer, Corneilus, OR). Following 
the hybridisation stage slides were washed using the gene expression wash buffer kit 
(Agilent Technologies, Santa Clara, CA) and acetonitrile.  
 Scanning was carried out at the University of Birmingham with the help of staff in 
the functional genomics, proteomics and metabolomics facility where an Agilent Scanner 
(Agilent Technologies, Santa Clara, CA) ran 20 bit scans at a resolution of 50n.  
6.3.5 Data Processing 
 Feature Extraction software (V10.7, Santa Clara, CA) was implemented to 
examine the quality of the 16-bit TIFF images obtained by microarray scanning. They 
were assessed on grid alignment, signal quantification and overall slide quality at the 
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University of Birmingham with the help of staff in the functional genomics, proteomics 
and metabolomics facility. Data normalisation was carried out at the University of 
Wolverhampton with the help of Dr. David Huen and Dr. Ayesha Rahman.      
6.3.6 Data Clustering and Filtering 
 Data clustering was performed using TMEV software (version TM4, WA, USA). 
The samples were clustered according to the similarities seen in the gene expression 
patterns using hierarchical clustering algorithm (HCA). The mean values for the level of 
gene expression was used to perform comparisons between data sets. For data 
reduction, TMEV was also used to perform principal component analysis (PCA) which 
was implemented to illustrate the main degree of variability in the multidimensional data 
set. Statistical analysis was carried out using significance analysis of microarrays (SAM) 
to identify statistically significant genes which demonstrated either a 2 fold up regulation 
in expression or a 2 fold down regulation in gene expression. Delta values were selected 
so as that the median false discovery rate (FDR) was lower than 5%. These gene lists 
were then exported to EXCEL where the gene tables of SLC and ABC genes were 
prepared for data entry into KEGG http://www.genome.jp/kegg/. Here pathways in which 
the genes of interest were involved were identified and the component affected by the 
gene of interest in each pathway was highlighted in red.        
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6.4 RESULTS AND DISCUSSION 
 Investigation into gene expression changes of Caco-2 cells following drug 
transport studies were intended to identify any link between the predicted drug 
permeability and the expression of the genes which code for the intestinal transporters 
for which Lisinopril, Ramipril and Spironolactone are known to interact. Namely ABCB1 
and SLC15A1 for Lisinopril, SLC15A1 and SLC15A2 for Ramipril and ABCB1, ABCC2 
and SLCO1A2 for Spironolactone. Rather than look at genetic expression levels of only 
the genes for the specific transporters with which the drugs interact it was decided to 
investigate the transporter super families to which these transporters belong, these being 
the ABC and SLC super families. In order to do this drug transport studies were carried 
out using transwell arrangements and the genetic profiles of the subsequently harvested 
cells were examined. The expression patterns for Caco-2 cells in their basal state were 
used as a control and compared to cells which had been exposed to Lisinopril, Ramipril 
and Spironolactone. Following RNA extraction, over 40,000 cRNA were hybridised to 
their corresponding microarray probe implementing the one colour microarray based 
gene expression analysis protocol from Agilent Technologies. Scanning the microarray 
slides produced TIFF files, and example of which is shown in figure 113 which were then 
analysed for their grid alignment, signal quantification and overall slide quality.  
 
Figure 113 – TIFF image produced following microarray slide scanning. 
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6.4.1 TIFF Image analysis 
 Spot centroids are located in the corner of each array and are used to confirm 
that the image is correctly centred and that the image is of suitable quality. An example 
of which is shown in figure 114. For all of the arrays carried out the centroids were 
located correctly. 
 
Figure 114 - Spot centroids are located in the corner of each array and are used to 
confirm that the image is correctly centred and that the image is of suitable quality. 
 
 The feature extraction software also assesses the signal quality of the array 
through the production of a histogram of signals. Again an example is shown in figure 
115. This histogram plots the number of points in intensity bins against the logarithm of 
the processed signal.  
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Figure 115 - The feature extraction software assesses the signal quality of the array 
through the production of a histogram of signals. 
 
 Once again the signal quality of all of the arrays was acceptable and this is 
determined by the normal distribution of the data in the histogram and the production of 
a symmetrical chart. The Log values of the processed signal were also confirmed to 
show good linearity with the Log values of the corresponding concentrations of the 
SpikeIns (Figure 116) for all of the arrays used as seen in the example.  
 
Figure 116 - Log values of the processed signal show good linearity with the Log values 
of the corresponding concentrations of the SpikeIns. 
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 The median value for the processed signal and the median value for the 
background subtracted signal (mean signal – BG) for the whole array produced in all 
cases a horizontal line with sufficiently minimal variation about this line. There are 
multiple reference probes across the array to allow for reproducibility to be confirmed 
across the length and breadth of the array. A low median coefficient of variation in the 
signal level from these probes confirms this. An example of which is shown below (Figure 
117).   
 
Figure 117 - Multiple reference probes across the array to allow for reproducibility to be 
confirmed across the length and breadth of the array. A low median coefficient of 
variation in the signal level from these probes confirms this 
 
 Following verification that the TIFF images produced from the microarray 
scanning were suitable, data normalisation was performed prior to data analysis. 
6.4.2 Microarray Data Analysis  
 Due to the magnitude and complexity of the data generated by microarray 
experiments, the use of programs designed specifically to apply statistical techniques to 
microarray data are used to identify trends in the data. One such program is TMEV 
(TMEV software version TM4, WA, USA) which was used to perform HCA, PCA and 
SAM analysis on the microarray data. Statistically significant genes from the super 
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families SLC and ABC with a fold change in expression levels greater than 2 were then 
fed into the KEGG database to carry out pathway analysis.   
6.4.3  Hierarchical Clustering Algorithm (HCA) 
 There are multiple computational, statistical approaches broadly classified into 
supervised and unsupervised learning techniques. HCA is an example of unsupervised 
learning and in this instance clustered samples are grouped based on the similarity in 
the gene expression profiles. The algorithm measures distance between rows in the data 
for the various samples and then combines the samples for which the distance between 
the genes is the shortest. Control samples were compared to formulation samples at 
each time point using HCA analysis (Figure 118). 
 
Figure 118 - Control samples were compared to formulation samples at each time point 
using HCA analysis. 
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 The HCA clusters showed in all cases that gene expression levels in samples 
which had undergone treatment with the drug formulations had been altered from that of 
the control samples. Further HCA clustering comparing the formulations to each other 
indicated that the Spironolactone suspension elicited the greatest change in gene 
expression followed by the Ramipril suspension. The Ramipril solutions showed a 
smaller effect than the Ramipril suspension but a larger effect than the Lisinopril solution 
(Figure 119).    
 
Figure 119 - HCA clustering comparing the formulations to each other indicated that the 
Spironolactone suspension elicited the greatest change in gene expression followed by 
the Ramipril suspension. The Ramipril solutions showed a smaller effect than the 
Ramipril. 
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6.4.4 Principal Component Analysis (PCA). 
 Using TMEV, PCA was carried out on the microarray data for all of the samples, 
EVD generated 12 principal components (Table 45) and from these it was observed that 
89.105% of the variance in the data set and therefore genetic expression was accounted 
for in components 1, 2 and 3. Components 4 – 12 were discounted to aid data 
visualisation.   
Table 45 - PCA was carried out on the microarray data for all of the samples, EVD 
generated 12 principal components. 
Eigen Values 
Principal Component 1 5.666 62.80% 
Principal Component 2 1.59 17.63% 
Principal Component 3 0.782 8.67% 
Principal Component 4 0.268 2.98% 
Principal Component 5 0.192 2.12% 
Principal Component 6 0.184 2.04% 
Principal Component 7 0.12 1.33% 
Principal Component 8 0.087 0.96% 
Principal Component 9 0.059 0.65% 
Principal Component 10 0.038 0.42% 
Principal Component 11 0.025 0.28% 
Principal Component 12 0.009 0.10% 
   
First 2 components: 80.432 %   
First 3 components: 89.105 %   
 
 First and Second PCA (Figure 120) illustrated that the Spironolactone 
suspension had by far the greatest effect on the gene expression levels. A greater 
degree of change was seen at 60 minutes than was observed at the 20 minute time point 
with variance seen along both components 1 and 2. The ACE inhibitor formulations were 
tightly grouped and showed only a small degree of variance along components 1 and 2 
in comparison to the Spironolactone.   
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Figure 120 - First and Second PCA - Spironolactone suspension had by far the greatest 
effect on the gene expression levels in the samples with a greater degree of change 
seen at the 60 minutes than was observed at the 20 minute time point with variance 
seen along both components 1 and 2. The ACE inhibitor formulations were tightly 
grouped (circled area) and showed only a small degree of variance along components 
1 and 2 in comparison to the Spironolactone  
 
 First and Third PCA (Figure 121) again illustrates the large degree of variance 
seen in the gene expression for the Spironolactone formulation however in this instance 
the degree of variance along the third component illustrates the variation in effect on 
gene expression between the Ramipril suspension and the other ACE inhibitor 
formulations. Once again the magnitude in the variation at the 60 minute time point is 
greater than that for the 20 minute time point showing that the overall changes in gene 
expression have increased with time.  
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Figure 121 - First and Third PCA – A large degree of variance is seen in the gene 
expression for the Spironolactone formulation however in this instance the degree of 
variance along the third component illustrates the variation in effect on gene expression 
between the Ramipril suspension and the other ACE inhibitor formulations (circled area). 
Once again the magnitude in the variation at the 60 minute time point is greater than that 
for the 20 minute time point showing that the overall changes in gene expression have 
increased with time 
  
 Further PCA was carried out comparing individual formulations to the control 
samples in order to more clearly identify differences in gene expression levels at the 
time points tested.  
6.4.5 Lisinopril Solution PCA 
 EDV generated 4 principal components for PCA of samples relating to the 
Lisinopril solution of which 87.839% of the variance was described in components 1 
and 2 (Table 46). Components 3 and 4 were therefore discounted to further simplify 
data analysis. 
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Table 46 - EDV generated 4 principal components for PCA of samples relating to the 
Lisinopril solution  
Eigen Values 
Principal Component 1 0.274 72.54% 
Principal Component 2 0.058 15.30% 
Principal Component 3 0.033 8.82% 
Principal Component 4 0.013 3.35% 
   
First 2 components: 87.839 %   
First 3 components: 96.654 %   
  
 First and Second PCA (Figure 122) illustrates that there is variance in the gene 
expression between the samples exposed to the Lisinopril solution at both time points 
and the control samples along principal component 1 however there is only a very small 
degree of variation in the gene expression levels at the 20 minute and 60 minute time 
points in both principal components 1 and 2.  
 
Figure 122 - First and Second PCA - There is variance in the gene expression between 
the samples exposed to the Lisinopril solution at both time points and the control 
samples along principal component 1 however there is only a very small degree of 
variation in the gene expression levels at the 20 minute and 60 minute time points in 
both principal components 1 and 2. 
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6.4.6 Ramipril Co-solvent Solution PCA 
 EDV generated 4 principal components for PCA of samples relating to the 
Ramipril solution produced using a co-solvent to achieve solubilisation of which 81.033% 
of the variance was described in components 1 and 2 (Table 47). Components 3 and 4 
were therefore discounted to further simplify data analysis. 
Table 47 - EDV generated 4 principal components for PCA of samples relating to the 
Ramipril solution produced using a co-solvent. 
Eigen Values 
Principal Component 1 0.35 62.62% 
Principal Component 2 0.103 18.42% 
Principal Component 3 0.087 15.58% 
Principal Component 4 0.019 3.39% 
   
First 2 components: 81.033 %   
First 3 components: 96.614 %   
  
 As with the Lisinopril solution there is a clear difference in the gene expression 
between the control samples and the samples collected relating to the Ramipril co-
solvent solution permeability experiments in the First and Second PCA plot (Figure 123). 
There is a large degree in change across component 1 for the samples exposed to the 
formulation compared with the control samples, there is however only a limited difference 
along component 1 for the 20 minute and 60 minute time points. Unlike the Lisinopril 
formulation however there is a clear difference between the time points when principal 
component 2 is considered.  
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Figure 123 - First and Second PCA - There is a large degree in change across 
component 1 for the samples exposed to the formulation compared with the control 
samples, there is however only a limited difference along component 1 for the 20 minute 
and 60 minute time points. There is also a clear difference between the time points when 
principal component 2 is considered 
 
6.4.7 Ramipril Cyclodextrin Solution PCA 
 EDV generated 4 principal components for PCA of samples relating to the 
Ramipril solution produced using cyclodextrin to achieve solubilisation of which 78.885% 
of the variance was described in components 1 and 2 (Table 48). Components 3 and 4 
were therefore discounted to further simplify data analysis. 
Table 48 - EDV generated 4 principal components for PCA of samples relating to the 
Ramipril solution produced using cyclodextrin. 
Eigen Values 
Principal Component 1 0.202 62.77% 
Principal Component 2 0.052 16.11% 
Principal Component 3 0.048 14.96% 
Principal Component 4 0.02 6.15% 
   
First 2 components: 78.885 %   
First 3 components: 93.846 %   
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 As with the Lisinopril solution and the Ramipril solution produced using a co-
solvent there is a clear difference in the gene expression between the control samples 
and the samples collected during Ramipril Cyclodextrin Solution permeability 
experiments in the First and Second PCA plot (Figure 124). There is a large degree in 
change across component 1 for the samples exposed to the formulation compared with 
the control samples, there is in this instance limited difference along component 1 for the 
20 minute and 60 minute time points. Unlike previous observations however the 20 
minute time point exhibits a greater variation from the control samples. There is also 
once again, as with the Ramipril solution produced using a co-solvent, clear difference 
between the time points when principal component 2 is considered. 
 
Figure 124 - First and Second PCA - There is a large degree in change across 
component 1 for the samples exposed to the formulation compared with the control 
samples, there is in this instance limited difference along component 1 for the 20 minute 
and 60 minute time points. The 20 minute time point exhibits a greater variation from the 
control samples. There is clear difference between time points when principal 
component 2 is considered. 
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6.4.8 Ramipril Suspension PCA 
 EDV generated 4 principal components for PCA of samples relating to the 
Ramipril suspension of which 82.902% of the variance was described in components 1 
and 2 (Table 49). Components 3 and 4 were therefore discounted to further simplify data 
analysis. 
Table 49 - EDV generated 4 principal components for PCA of samples relating to the 
Ramipril suspension. 
Eigen Values 
Principal Component 1 0.766 63.46% 
Principal Component 2 0.235 19.44% 
Principal Component 3 0.179 14.85% 
Principal Component 4 0.027 2.25% 
   
First 2 components: 82.902 % 
First 3 components: 97.747 % 
  
 As shown in the First and Third PCA plot displaying all of the analysed 
formuations (Figure 121) there is a clear difference in the gene expression levels 
between the control samples and the formuation time points. This is seen along 
component one of the First and Second PCA for the Ramipril suspension (Figure 125). 
The difference seen bewteen the time points again shows a greater change in the gene 
expression after 60 minutes when compared to the change after 20 minutes. 
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Figure 125 - First and Second PCA - There is a clear difference in the gene expression 
levels between the control samples and the formuation time points. This is seen along 
component one. The difference seen bewteen the time points again shows a greater 
change in the gene expression after 60 minutes when compared to the change after 20 
minutes. 
 
6.4.9 Spironolactone Suspension PCA 
 EDV generated 4 principal components for PCA of samples relating to the 
Spironolactone suspension of which 88.989% of the variance was described in 
components 1 and 2 (Table 50). Components 3 and 4 were therefore discounted to 
further simplify data analysis. 
Table 50 - EDV generated 4 principal components for PCA of samples relating to the 
Spironolactone suspension. 
Eigen Values 
Principal Component 1 3.468 63.16% 
Principal Component 2 1.419 25.83% 
Principal Component 3 0.579 10.55% 
Principal Component 4 0.026 0.47% 
   
First 2 components: 88.989 % 
First 3 components: 99.534 % 
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 As shown in the First and Second PCA plot displaying all of the analysed 
formuations (Figure 121) there is a clear difference in the gene expression levels 
between the control samples and the formuation time points. This is seen along 
component one and two of the First and Second PCA for the  suspension (Figure 126), 
The difference seen bewteen the time points again shows a greater change in the gene 
expression after 60 minutes when compared to the change after 20 minutes. 
 
 
Figure 126 - First and Second PCA - there is a clear difference in the gene expression 
levels between the control samples and the formuation time points. This is seen along 
component one and two. The difference seen bewteen the time points shows a greater 
change in the gene expression after 60 minutes when compared to the change after 20 
minutes. 
 
 From the observation of the PCA in conjunction with the supporting data from the 
HCA it is interesting that the degree of gene expression change is greatest for 
Spironolactone, less great for Ramipril and lowest for Lisinopril. This mirrors the in vivo 
bioavailability trend and may indicate a potential correlation between the overall change 
in gene expression levels and drug absorption.  
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6.4.10 Significance Analysis of Microarrays (SAM) 
 SAM was carried out on the microarray data to identify genes which show a 
significant change in their level of expression following transport experiments using 
Lisinopril, Ramipril and Spironolactone formulations. Genes with a fold difference >2 in 
the SLC and ABC superfamilies were tabulated and positive or negative change in 
expression indicated.    
 For the Lisinopril Solution the significant gene expression information generated 
from the SAM analysis (Figure 127) and the SAM chart (Figure 128) are displayed below. 
For this data set the delta value used was 0.39550424 and produced a median FDR of 
4.83397%. A total of 213 positively significant genes and 240 negatively significant 
genes were identified, 40640 genes were not significant.  
 
Figure 127 - SAM Cluster Information - Gene Expression - 213 positively significant 
genes and 240 negatively significant genes were identified, 40640 genes were not 
significant. 
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Figure 128 – SAM Chart - delta value used was 0.39550424 and produced a median 
FDR of 4.83397%. 
 
 The genes from the SLC and ABC superfamilies for which a significant change 
in gene expression was seen were listed (Table 51) to form the data set which was 
subsequently used in KEGG pathway identification. For the Lisinopril solution there was 
no significant effect on any of the genes in the ABC family however there was 10 genes 
in the SLC family for which a fold change >2 was observed. For all of these genes they 
were up regulated.   
  
 
 
262 
 
Table 51 - Genes from the SLC and ABC superfamilies for which a significant change in 
gene expression was seen. 
Lisinopril Solution 
SLC 
Transporter Fold Change +ve or -ve 
SLC14A1 2.0704432 +ve 
SLC16A3 3.1122882 +ve 
SLC22A7 3.7140026 +ve 
SLC43A2 2.2528124 +ve 
SLC44A2 2.258665 +ve 
SLC4A1 2.077871 +ve 
SLC4A10 2.0645945 +ve 
SLC8A1 2.1728525 +ve 
SLC8A2 2.917442 +ve 
SLC9B2 2.417506 +ve 
ABC None 
 
 For the Ramipril solution produced using a co-solvent as a solubiliser, the 
significant gene expression information generated from the SAM analysis (Figure 129) 
and the SAM chart (Figure 130) are displayed below. For this data set the delta value 
used was 0.21017464 and produced a median FDR of 4.94209%. A total of 502 
positively significant genes and 362 negatively significant genes were identified, 40229 
genes were not significant. 
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Figure 129 - SAM Cluster Information - Gene Expression - A total of 502 positively 
significant genes and 362 negatively significant genes were identified, 40229 genes 
were not significant. 
 
 
Figure 130 - SAM Chart - delta value used was 0.21017464 and produced a median 
FDR of 4.94209%. 
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 The genes from the SLC and ABC superfamilies for which a significant change 
in gene expression was seen were listed (Table 52) to form the data set which was 
subsequently used in KEGG pathway identification. For the Ramipril solution produced 
using a co-solvent as a solubiliser there was significant effect on one gene in the ABC 
family and there was 26 genes in the SLC family for which a fold change >2 was 
observed. For all of these genes they were up regulated.   
Table 52 - Genes from the SLC and ABC superfamilies for which a significant change in 
gene expression was seen. 
Ramipril Co-solvent Solution 
SLC 
Transporter Fold Change +ve or -ve 
SLC11A1 2.0692508 +ve 
SLC16A10 2.5774577 +ve 
SLC17A7 2.4984982 +ve 
SLC22A17 2.2027316 +ve 
SLC22A23 2.3579023 +ve 
SLC23A3 3.3429158 +ve 
SLC24A2 2.1618395 +ve 
SLC24A4 2.2888455 +ve 
SLC27A1 2.43765 +ve 
SLC30A3 4.4293623 +ve 
SLC35B4 2.6245763 +ve 
SLC39A7 2.1983893 +ve 
SLC4A1 2.2079337 +ve 
SLC5A2 2.004006 +ve 
SLC6A13 2.2618265 +ve 
SLC8A1 2.7300835 +ve 
SLC8A2 2.9829826 +ve 
SLC9A9 2.679537 +ve 
SLC2A4RG 2.1210656 +ve 
SLC34A2 2.93993 +ve 
SLC35A4 2.2494004 +ve 
SLC43A1 2.461622 +ve 
SLC45A2 2.1256492 +ve 
SLC4A3 2.3697224 +ve 
SLC50A1 2.2596252 +ve 
SLC9B2 2.430448 +ve 
ABC ABCF2 2.2513223 +ve 
 
 For the Ramipril solution produced using a cyclodextrin, the significant gene 
expression information generated from the SAM analysis (Figure 131) and the SAM 
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chart (Figure 132) are displayed below. For this data set the delta value used was 
0.92349243 and produced a median FDR of 0.36899 %. A total of 771 positively 
significant genes and 149 negatively significant genes were identified, 40173 genes 
were not significant. 
 
Figure 131 - SAM Cluster Information - Gene Expression - A total of 771 positively 
significant genes and 149 negatively significant genes were identified, 40173 genes 
were not significant. 
 
Figure 132 - SAM Chart - delta value used was 0.92349243 and produced a median 
FDR of 0.36899 %. 
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 The genes from the SLC and ABC superfamilies for which a significant change 
in gene expression was seen were listed (Table 53) to form the data set which was 
subsequently used in KEGG pathway identification. For the Ramipril solution produced 
using a cyclodextrin as a solubiliser there was significant effect on one gene in the ABC 
family and there were 10 genes in the SLC family for which a fold change >2 was 
observed. All of these genes were up regulated.   
Table 53 - Genes from the SLC and ABC superfamilies for which a significant change in 
gene expression was seen 
Ramipril Cyclodextrin Solution 
SLC 
Transporter Fold Change +ve or -ve 
SLC11A1 2.7121615 +ve 
SLC16A10 2.2996733 +ve 
SLC17A7 2.564548 +ve 
SLC29A4 2.3865407 +ve 
SLC2A4RG 2.415126 +ve 
SLC30A3 3.506687 +ve 
SLC35B4 2.9588718 +ve 
SLC9A9 3.2706385 +ve 
SLC22A17 2.29381 +ve 
SLC27A1 3.686685 +ve 
ABC ABCA2 2.5894725 +ve 
 
 For the Ramipril suspension, the significant gene expression information 
generated from the SAM analysis (Figure 133) and the SAM chart (Figure 134) are 
displayed below. For this data set the delta value used was 0.6749133 and produced a 
median FDR of 0.00000%. A total of 2143 positively significant genes and 293 negatively 
significant genes were identified, 38675 genes were not significant. 
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Figure 133 - SAM Cluster Information - Gene Expression - A total of 2143 positively 
significant genes and 293 negatively significant genes were identified, 38675 genes 
were not significant. 
  
 
Figure 134 - SAM Chart - delta value used was 0.6749133 and produced a median FDR 
of 0.00000%. 
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 The genes from the SLC and ABC superfamilies for which a significant change 
in gene expression was seen were listed (Table 54) to form the data set which was 
subsequently used in KEGG pathway identification. For the Ramipril suspension there 
was significant effect on 2 genes in the ABC family and there were 29 genes in the SLC 
family for which a fold change >2 was observed. All of these genes were up regulated. 
Table 54 - Genes from the SLC and ABC superfamilies for which a significant change in 
gene expression was seen. 
Ramipril Suspension 
SLC 
Transporter Fold Change +ve or -ve 
SLC16A10 5.6771617 +ve 
SLC16A11 2.9428 +ve 
SLC17A7 5.3337197 +ve 
SLC18A2 9.033469 +ve 
SLC22A10 2.8761852 +ve 
SLC22A12 4.0482225 +ve 
SLC22A17 3.8142965 +ve 
SLC22A23 4.1997943 +ve 
SLC24A4 5.2337623 +ve 
SLC26A1 6.197696 +ve 
SLC27A1 4.6477814 +ve 
SLC2A10 3.12832 +ve 
SLC2A5 4.3415933 +ve 
SLC30A7 3.027596 +ve 
SLC35B4 3.4955595 +ve 
SLC6A6 4.3639517 +ve 
SLC6A7 2.9340563 +ve 
SLC9A9 9.54847 +ve 
SLC22A31 34.691284 +ve 
SLC23A3 6.286539 +ve 
SLC25A28 23.11727 +ve 
SLC25A39 69.7663 +ve 
SLC2A3 12.64015 +ve 
SLC30A3 6.3733015 +ve 
SLC35C1 8.036819 +ve 
SLC35C2 12.777995 +ve 
SLC38A1 13.190632 +ve 
SLC41A3 82.516136 +ve 
ABC 
SLC7A6OS 13.556567 +ve 
ABCA5 11.006652 +ve 
ABCC6 10.992928 +ve 
 
 
269 
 
 For the Spironolactone suspension, the significant gene expression information 
generated from the SAM analysis (Figure 135) and the SAM chart (Figure 136) are 
displayed below. For this data set the delta value used was 0.34634054 and produced 
a median FDR of 1.48148%. A total of 2576 positively significant genes and 1235 
negatively significant genes were identified, 37282 genes were not significant. 
 
Figure 135 - SAM Cluster Information - Gene Expression - A total of 2576 positively 
significant genes and 1235 negatively significant genes were identified, 37282 genes 
were not significant. 
 
Figure 136 – SAM Chart - delta value used was 0.34634054 and produced a median 
FDR of 1.48148%. 
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 The genes from the SLC and ABC superfamilies for which a significant change 
in gene expression was seen were listed (Table 55) to form the data set which was 
subsequently used in KEGG pathway identification.  
Table 55 - Genes from the SLC and ABC superfamilies for which a significant change in 
gene expression was seen. 
Spironolactone Suspension 
SLC 
Transporter Fold Change +ve or -ve 
SLC17A9 6.4354215 +ve 
SLC1A5 13.079359 +ve 
SLC25A1 10.693407 +ve 
SLC25A29 9.254947 +ve 
SLC25A6 10.979601 +ve 
SLC29A2 15.156823 +ve 
SLC29A4 10.382369 +ve 
SLC2A8 24.344704 +ve 
SLC31A1 16.562778 +ve 
SLC35B2 8.844945 +ve 
SLC35C2 17.574041 +ve 
SLC35D2 19.421774 +ve 
SLC35E2 16.530993 +ve 
SLC35F6 9.12032 +ve 
SLC38A5 7.1403027 +ve 
SLC39A1 17.563322 +ve 
SLC39A5 7.296592 +ve 
SLC39A7 18.911186 +ve 
SLC3A2 14.07006 +ve 
SLC6A10P 7.336151 +ve 
SLC6A8 16.636656 +ve 
SLC7A5 13.480293 +ve 
SLC7A8 8.355325 +ve 
SLC9A8 9.476612 +ve 
SLC11A2 31.62154 +ve 
SLC16A4 7.989935 +ve 
SLC1A1 19.64092 +ve 
SLC22A5 8.93393 +ve 
SLC23A3 10.974421 +ve 
SLC25A10 17.145796 +ve 
SLC25A13 9.850117 +ve 
SLC25A23 26.403795 +ve 
SLC25A24 7.24933 +ve 
SLC25A36 10.516455 +ve 
SLC25A37 13.912533 +ve 
SLC25A46 10.360896 +ve 
SLC25A5 53.59311 +ve 
 
 
271 
 
SLC25A6 46.862362 +ve 
SLC26A11 16.092371 +ve 
SLC26A3 9.05577 +ve 
SLC27A1 13.418841 +ve 
SLC29A3 13.328121 +ve 
SLC2A2 7.823031 +ve 
SLC2A3 13.813991 +ve 
SLC2A4RG 14.815919 +ve 
SLC30A3 20.643759 +ve 
SLC31A2 7.2412624 +ve 
SLC35A2 8.219815 +ve 
SLC35B1 17.630474 +ve 
SLC35C1 20.138887 +ve 
SLC35D2 20.541061 +ve 
SLC35E1 15.807547 +ve 
SLC38A1 18.407154 +ve 
SLC38A6 10.197243 +ve 
SLC39A11 6.759471 +ve 
SLC39A13 9.199426 +ve 
SLC39A14 24.078133 +ve 
SLC3A1 18.950901 +ve 
SLC41A3 11.449558 +ve 
SLC43A2 39.156944 +ve 
SLC44A1 10.62931 +ve 
SLC44A2 13.139595 +ve 
SLC45A3 6.9271073 +ve 
SLC50A1 11.52964 +ve 
SLC5A11 5.9074626 +ve 
SLC5A6 20.858412 +ve 
SLC6A19 6.3885436 +ve 
SLC6A4 6.203496 +ve 
SLC7A4 8.900564 +ve 
SLC7A7 11.712494 +ve 
SLC9A3R1 6.900848 +ve 
SLCO2B1 10.498462 +ve 
ABC 
ABCC10 7.0169935 +ve 
ABCC8 7.0988774 +ve 
ABCF2 8.409261 +ve 
ABCB6 11.907367 +ve 
ABCB7 7.421333 +ve 
ABCC3 6.1075015 +ve 
ABCC5 9.429524 +ve 
ABCD4 16.697014 +ve 
ABCF3 13.205725 +ve 
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 For the Spironolactone suspension there was significant effect on 9 genes in the 
ABC family and there were 72 genes in the SLC family for which a fold change >2 was 
observed. All of these genes were up regulated. Following the production of the SLC 
and ABC gene tables the gene names were entered into KEGG to identify the pathways 
affected by the changes in gene expression.  
6.4.11 KEGG Pathway Analysis 
 KEGG pathway analysis of the significantly up regulated ABC transporter genes 
indicated that the genes listed (Table 56) only provided specific pathway information for 
the genes ABCA2, ABCC3, ABCC8 and ABCD4. ABCA2 was identified as coding for a 
Lysosome membrane protein, ABCC3 plays a role in bile secretion pathways, while 
ABCC8 was identified in pathways linked to Type II diabetes mellitus and insulin 
secretion pathways. Finally ABCD4 was found in Peroxisome pathways. None of the 
pathways were linked to intestinal absorption pathways, and as such not investigated 
further. 
Table 56 – KEGG Pathways in which significantly up-regulated genes are active.  
KEGG Pathways 
Gene KEGG Pathway Identification 
ABCA2 Eukaryotic Type ABC Transporter 
Lysosome Membrane Protein 
ABCA5 Eukaryotic Type ABC Transporter 
ABCB6 Eukaryotic Type ABC Transporter 
ABCB7 Eukaryotic Type ABC Transporter 
ABCC10 Eukaryotic Type ABC Transporter 
ABCC3 Eukaryotic Type ABC Transporter 
Bile Secretion Pathways 
ABCC5 Eukaryotic Type ABC Transporter 
ABCC6 Eukaryotic Type ABC Transporter 
ABCC8 Eukaryotic Type ABC Transporter 
Insulin Secretion Pathways 
Type II Diabetes Mellitus 
ABCD4 Eukaryotic Type ABC Transporter 
Peroxisome Pathways 
SLC16A10 Protein Digestion and Absorption 
Thyroid Hormone Signalling 
SLC1A1 Protein Digestion and Absorption 
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SLC1A5 Glutamatergic Synapse 
Protein Digestion and Absorption 
SLC22A7 Bile Secretion Pathways 
SLC25A10 Proximal Tubule Bicarbonate Reclamation 
SLC26A3 Mineral Absorption 
Pancreatic Secretion 
SLC2A2 Maturity Onset Diabetes in the Young 
Type II Diabetes Mellitus 
Carbohydrate Digestion and Absorption 
Prolactin Signalling Pathway 
Insulin Secretion Pathways 
SLC2A5 Carbohydrate Digestion and Absorption 
SLC31A1 Mineral Absorption 
SLC36A5 GABAergic Synapse 
SLC38A1 GABAergic Synapse 
Glutamatergic Synapse 
SLC3A1 Protein Digestion and Absorption 
SLC3A2 Protein Digestion and Absorption 
SLC45A3 MicroRNAs in Cancer 
Transcriptional Misregulation in Cancer 
SLC4A1 Collecting Duct and Secretion 
SLC5A6 Vitamin Digestion and Absorption 
SLC6A19 Mineral Absorption 
Protein Digestion and Absorption 
SLC6A4 Serotonergic Synapse 
SLC7A7 Protein Digestion and Absorption 
SLC7A8 Protein Digestion and Absorption 
 
 KEGG pathway analysis of the significantly up regulated SLC transporter genes 
returned pathway information for all of the genes listed (Table 56) however as seen with 
the ABC transporters many of the pathways were unrelated to intestinal absorption 
pathways. However, SLC16A10, SLC1A1, SLC1A5, SLC3A1, SLC3A2, SLC6A19, 
SLC7A7 and SLC7A8 were identified as having involvement in the intestinal absorption 
of proteins (Figure 137), coding for the TAT1, EAAT3, ASCT2, rBAT, 4F2hc, B0AT1, 
y+LAT1, and LAT2 transporters respectively. SLC16A10 was seen to be significantly up 
regulated for all of the Ramipril formulations however not for Lisinopril or Spironolactone 
formulations. SLC1A1, SLC1A5, SLC3A1, SLC3A2, SLC6A19, SLC7A7 and SLC7A8 
were all significantly up regulated by the Spironolactone suspension only. EAAT3, 
ASCT2, B0AT1 and rBAT are located in the apical membrane of intestinal epithelial cells 
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here EAAT3 facilitates the uptake of anionic amino acids from the intestinal lumen, 
ASCT2 and B0AT1 facilitate the transport of neutral amino acids and rBAT works with 
B0,+AT1 (not significantly up regulated)  to facilitate the uptake of cationic amino acids. 
TAT1, y+LAT1, LAT2 and 4F2hc are present in the basolateral membrane of intestinal 
epithelial cells and transport neutral amino acids into and out of the blood (Ramadan et 
al 2001, del Amo et al 2008).  
 There are significant expressional changes for numerous SLC transporters in the 
protein absorption pathway across the intestinal epithelial but not SLC15A1, the 
transporter for which Ramipril and Lisinopril are substrates. SLC15A1 codes for the 
PEPT1 transporter which is present in the apical membrane of intestinal epithelial cells 
and responsible for the absorption of small peptides (Daniel 2004, Buyse et al 2001).    
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Figure 137 – KEGG pathway for protein digestion and absorption. Transporters 
highlighted in red are significantly up-regulated.  
 
  
 
 
 
276 
 
 In addition to the protein absorption pathway, the Spironolactone formulation 
caused up regulation in genes which code for transporters is mineral absorption 
pathways (Figure 1387). SLC26A3, SLC6A19 and SLC31A1 code for the transporters 
DRA, B0AT1 and CTR1 found in the apical membrane of intestinal epithelial cells (Lee 
et al 2012, Ganapathy et al 2009, Tennant et al 2002).  
 
Figure 138 – KEGG pathway for mineral absorption. Transporters highlighted in red are 
significantly up-regulated. 
 
 The Spironolactone formulation also caused up regulation in SLC5A6, this gene 
codes for the protein SMVT which is again found in the apical membrane of intestinal 
epithelial cells (Weisz and Rodriguez-Boulan 2009) as part of the vitamin absorption 
pathway (Figure 139).  
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Figure 139 – KEGG pathway for Vitamin digestion and absorption. Transporters 
highlighted in red are significantly up-regulated. 
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 Finally, the Spironolactone suspension caused up regulation in SLC2A2 and the 
Ramipril suspension caused up regulation in SLC2A5, these genes both code for 
transporter proteins in the carbohydrate absorption pathway (Figure 140). SLC2A2 
codes for GLUT2 and SLC2A5 codes for GLUT5, these transporters are responsible for 
the uptake of Glucose and Fructose from the intestinal lumen and the transport of 
Glucose, Galactose and Fructose across the basolateral membrane of the cell into the 
blood (Sakar et al 2009, Concha et al 1997, Mahraoui et al 1994). 
 
Figure 140 - KEGG pathway for Carbohydrate digestion and absorption. Transporters 
highlighted in red are significantly up-regulated. 
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 The pathways and proteins, for which the SLC and ABC genes displayed 
significant modification in gene expression are not clearly linked to the formulations used 
in the investigations. The changes in expression levels could have resulted following 
interaction with the API in the formulations, however the excipients present could have 
also had an effect. This would account for up regulation in genes coding for transporter 
proteins which would not have necessarily been anticipated as a result of interaction with 
the API alone. For example, the sweetening agent Xylitol and the suspending agent 
Xanatural 180 present in the Ramipril and Spironolactone suspensions could potentially 
contribute to the changes in gene expression linked to the carbohydrate absorption 
pathway (Levin 1994). Likewise the Spironolactone suspension contains sodium 
benzoate and sodium metabisulphate which could attribute to the up regulation of genes 
coding for proteins present in the mineral absorption pathway (Wood and Han 1998). 
This lends strength to the recently developing ideology that excipients potentially 
possess a degree of biological activity and are not in actual fact truly inactive ingredients 
(Osman et al 2013, Kalinkova 1999). 
6.4.12 Application of microarray to develop an in vitro and in vivo correlation screening 
toolbox. 
 Following the analysis of the microarray data it was identified that the shortlisted 
genes of interest, namely ABCB1 (Inhibitor) and SLC15A1 (Substrate) for Lisinopril, 
SLC15A1 (Substrate) and SLC15A2 (Substrate) for Ramipril and ABCB1 (Inhibitor), 
ABCC2 (Inducer) and SLCO1A2 (Inhibitor) for Spironolactone were all found to show 
non-significant changes in their expression levels following transport studies using the 
Lisinopril, Ramipril and Spironolactone formulations. There were however numerous 
SLC and ABC genes for which the expression had changed significantly.  
 Due to the variety of genes expressed and the lack of common genes affected 
by all formulations in the data presented, a means by which human drug absorption can 
be predicted by measuring gene expression levels of a single gene or a family of genes 
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is impossible to derive. There is however indication that examination of genome wide 
expression changes in the total number of genes showing significant change (Figure 
141) correlates to the predicted absorption in humans. Plotting the number of genes with 
significantly altered expression levels for each drug against the percentage absorption 
in humans (Figure 142) provides a linear correlation with an R2 value of 0.9934.  
 
 
Figure 141 - Total number of genes expressed at a significantly altered level in 
comparison to controls for all lisinopril, ramipril and spironolactone formulations. Results 
are generated from triplicate repeats (n=3) and error bars indicate standard deviation 
(RSD).  
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Figure 142 - Correlation between gene expression and human absorption. Results are 
generated from triplicate repeats (n=3) and error bars indicate standard deviation (RSD). 
 
 It must be stressed however that this correlation is based on minimal amounts of 
data and for any trend between human drug absorption and the level of genome wide 
gene expression changes to be considered as a model for the prediction of human drug 
absorption many more formulations would need to be analysed investigating a range of 
dosage forms, dosage concentrations and degree of human absorption.  
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7 DEVELOPMENT OF AN IN VITRO TASTE ASSESSMENT MODEL - 
ESTABLISHMENT OF LONG-TERM FUNCTIONAL CULTURES OF BOVINE 
TASTE RECEPTOR CELLS (BTRCS): ISOLATION, CULTURE AND 
CHARACTERISATION. 
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7.1 CHAPTER AIMS AND OBJECTIVES 
- Isolate and culture bovine taste receptor cells (BTRCs) to provide a platform for 
the production of an in vitro taste assessment model. 
- Optimise culture method.  
- Characterise cultured BTRCs cells to confirm that the cultured cells are taste 
receptor cells. 
- Investigate in vitro functionality of BTRCs in response to model tastants.    
7.2 INTRODUCTION 
 Investigations into taste receptor cell (TRC’s) function has been done using 
explant cultures from rodents (Mbiene 1997), semi-intact taste buds in tissue slices 
(Caicedo 2000) and primary cultures established from freshly isolated TRC’s (Ruiz et al 
2001, Ookura 2002, Qin 2008). The lack of progress in this area is quite likely due to the 
limitations of primary culture, most notably limited passage number typically below P5, 
which have been encountered by many of the groups who have attempted primary 
culture of TRC’s. One group in particular has reported more promising results and have 
successfully established long term cultures of both Rat (Ozdener 2006) and Human 
(Ozdener 2011, Ozdener 2013) TRC’s. Both of these cell lines are useful in their own 
right however there are refinements which can be made to significantly reduce both the 
cost and complexity of establishing and maintaining the cultures while at the same time 
maintaining and adding to the reported advantages which each of these cultures provide. 
 TRC’s are found in the taste buds which are clustered within structures known as 
taste papillae. These taste bud containing papillae exist in three distinct forms which are 
located in specific areas on the tongue depending upon the type of papillae. The three 
types of papillae which contain taste buds are; fungiform, circumvallate and foliate. 
Fungiform papillae are located on the anterior portion of the tongue while circumvallate 
and foliate papillae are located in posterior areas of the tongue (Figure 143). The taste 
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buds which are contained within the papillae are constructed of four different cell types 
(Figure 144). 
 
Figure 143 - Location of the three types of papillae which contain taste buds (fungiform, 
circumvallate and foliate). Fungiform papillae are located on the anterior portion of the 
tongue while circumvallate and foliate fungiform are located on the posterior portion of 
the tongue 
 
Figure 144 - Taste bud structure illustrating cell arrangement and distribution. Taste buds 
are contained within the papillae are constructed of four different cell types. The support 
cells (Type 1 cells, or dark cells), account for 50% of the cells present in a taste bud. The 
sensory cells (Types 2 &3 or light cells), account for around 25% of the cells present in 
a taste bud. Basal cells (Type 4 cells) account for the remaining 25% of the cells. 
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 The support cells (Type 1 cells, or dark cells), account for 50% of the cells present 
in a taste bud. The sensory cells (Types 2 &3 or light cells), account for around 25% of 
the cells present in a taste bud. Basal cells (Type 4 cells) account for the remaining 25% 
of the cells. Of the sensory cells, type 2 cells are thought to be responsible for the 
detection of bitter, sweet and umami tastants through transduction pathways involving 
proteins such as Gustducin and Phospholipase C (PLC) -β2, which are used as reliable 
indicators of Type 2 TRC presence in TRC cultures. Likewise, neural cell adhesion 
molecule (NCAM) is a reliable indicator of Type 3 sensory cells. These are thought to be 
the cells responsible for the detection of acid taste while the cell type responsible for the 
detection of salty taste is yet to be identified. 
 Following initial attempts which failed to deliver a suitable a bovine taste receptor 
cell culture (BTRC-CR1,2,3 and 4’s), this report details the establishment and 
characterization of a long-term primary culture of bovine taste receptor cells (BTRC-
CR5s), taking the first step towards the development of a high-throughput, low cost, easy 
to use means of assaying the taste of oral pharmaceutical preparations throughout the 
pharmaceutical formulation process.  
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7.3 MATERIALS AND METHODS 
7.3.1 Preparation of Culture Media 
 The media for the culture of BTRC-CR5s consists of two parts mixed 1:5 as 
described by Ozdener et al 2011.    
7.3.2 Preparation of Pronase and Elastase Solution 
 The enzyme solution used in the enzymatic digestion of the bovine fungiform 
papillae consists of 26mM Sodium Bicarbonate, 2.5mM Sodium Dihydrogen Phosphate, 
20mM Glucose, 65mM Sodium Chloride, 20mM Potassium Chloride and 1mM 
Ethylenediaminetetraacetic acid made up in sterile ultrapure water supplemented with 
1.5mg/ml Pronase E (Sigma) and 1mg/ml elastase (Sigma). 
7.3.3 Preparation of Calcium free Ringer’s Solution 
  Calcium free ringers solution was prepared by dissolving NaCl (14.5%w/v),  KCl 
(0.0373%w/v), MgCl2 (0.0203%w/v), EDTA (2mM), Na-pyruvate (0.0110%w/v), and (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid-Na (0.476%w/v) in sterile ultrapure 
water.  
7.3.4 Isolation of BTRCs and Establishment of BTRC-CR5 culture 
 Bovine tongues were collected fresh from the slaughter house (C.H. Rowley LTD) 
and transported to the lab on ice in a cool box. Cells were isolated following standard 
techniques used in primary culture. 48 hours after seeding the culture medium was 
changed and the plates returned to the incubator. The media was then changed once 
every 7 days until the cells reached confluence. 
7.3.5 First Passage (P1) of BTRC-CR5s 
 Following three weeks in culture the cells reached confluence and were removed 
from the surface of the wells in the 24 well plates AND split into T25 flasks. Media was 
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then changed 48 hours after seeding and then every 7 days until confluent. Upon 
reaching confluence the cells from T25 flasks were passaged split into T75 flasks (P2).  
7.3.6 Routine Maintenance of BTRC-CR5s   
  Once flasks reach confluence, tissue culture media is removed and cells are 
washed twice with HBSS. A 1:5 dilution of trypsin with HBSS is then added and the cells 
incubated at 37°C for 5-8 minutes. Following gentle tapping to dislodge any remaining 
cells, culture media is added to prevent any further action from the trypsin. The resulting 
cell suspension is adjusted to contain 6x104 cells/ml before 2ml is added to each T75 
continuation flask. If the flask is not required to reach confluence quickly then this 
concentration can be reduced and flasks cells can be cultured for 4 weeks before 
reaching confluence. This is then made up to a volume of 25ml with culture media. The 
remaining cell suspension is then used to seed any additional plastic-ware or glass-ware 
as required for experimental procedures.  
7.3.7 Culture of Cells on Coverslips 
 A cell suspension with a cell concentration of 6x104 cells/ml was produced 
following the passage of a confluent T75 flask and cover slips were seeded. Media was 
changed after 48 hours and then every 7 days, or the day before intended use, until the 
coverslips were deemed suitable for use.    
7.3.8 Senescence test for BTRC-CR5s     
 To test for senescence a senescence cells histochemical staining kit (Sigma) was 
used. BTRC-CR5s from each passage were grown to confluence in six well plate plates. 
Once confluent the test was performed as per the manufacturer’s instructions. Imaging 
was performed using a light microscope at x10 magnification.   
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7.3.9 Cryogenic Preservation of BTRC-CR5s  
 Cells were removed from a confluent T75 (P2) flask and Biofreeze was added to 
produce a cell suspension, this was then added to cryo vials (Gibco Invitrogen)) before 
they were transferred to a -18°C freezer in an insulated container for 60 minutes. After 
this time the insulated container was transferred to a -80°C freezer overnight. The 
following day the vials were removed from the -80°C freezer and transferred into liquid 
nitrogen. 
7.3.10 Revival of Cryogenically Preserved BTRC-CR5s 
 Three vials of banked stock BTRC-CR5s were removed from liquid nitrogen 
storage conditions following 1 month in storage. The cell suspensions were defrosted in 
a 37°C incubator following which the contents of each vial was transferred to separate 
T25 flasks. 5ml of tissue culture media was added and the flasks returned to the 
incubator at 37°C in a humidified 5% CO2 atmosphere. The media in the flask was 
changed after 48 hours and then at 7 day intervals. Once confluent the cells were 
transferred to T75 flasks and from here the cells were treated as described for the routine 
maintenance of BTRC-CR5s.   
7.3.11 Intracellular Ca2+ and cAMP Response to Taste Stimuli 
 Taste stimuli, 2mM Denatonium, 1mM Sucralose, 250ppm Acesulfame-K and 
3mM Monopotassium Glutamate, were dissolved in calcium free ringers solution.  
 For calcium assays, BTRC-CR5s were grown on coverslips for 4 days following 
seeding to produce a relatively sparse covering of cells. Tissue culture media was 
removed from the wells of the six well plate and replaced with modified culture media 
which contained Pluronic F127 (1%w/v) and Fluo-4 (14mM). The cells were then 
incubated for 2 hours at 37°C to allow for the uptake of Fluo-4 into the BTRC-CR5s. 
During experiments solutions for test were perfused over coverslips mounted onto the 
 
 
289 
 
stage and images were taken every 5 seconds using a fluorescence microscope. 
Calcium assays were carried out with the help of Dr Rhein Parri. 
 cAMP assays were carried out with the help of Professor David Poyner at Aston 
University. BTRC-CR5s were cultured in 24 well plates and each well treated with 
various concentrations of the model tastants for 30 minutes. Experiments were then 
immediately terminated by removing tastant solutions and adding 100% ethanol. cAMP 
concentration analysis then followed.      
7.3.12 Confocal Identification of TRC markers Gustducin and PLC-β2 
 BTRC-CR5s were grown on coverslips for 4 days following seeding to produce a 
relatively sparse covering of cells. Tissue culture media was removed from the wells of 
the six well plate and replaced with 4% Paraformaldehyde (PFA) in PBS. The plate was 
then incubated for 10 minutes at room temperature. Following this incubation the PFA in 
PBS was removed and a blocking buffer added followed by a further incubation of 60 
minutes at room temperature. The blocking buffer consisted of normal goat serum (3% 
v/v), bovine serum albumin (3% w/v) and Triton X-100 (0.3% v/v) made up in PBS. The 
primary antibody solutions, Rabbit polyclonal Gαgust (I-20) and Rabbit polyclonal PLC-β2 
(Q-15) were both diluted 1:400 in blocking buffer.  After the 60 minutes, the blocking 
buffer was removed, the primary antibody solutions were added to their respective wells 
and the plate was incubated at 4°C overnight. The following day the secondary 
antibodies Goat anti-rabbit IgG Alexa 633 and Goat anti-rabbit IgG Alexa 488 were both 
diluted 1:400 in fresh blocking buffer. Primary antibodies were removed, the cells were 
washed with PBS and then the secondary antibody solutions were added. The plate was 
incubated for 30 minutes at room temperature before the secondary antibody solutions 
were removed and the coverslips were washed thoroughly with PBS and then ultrapure 
water. The coverslips were allowed to dry before being mounted to the microscope slides 
using Vectashield hardset mounting medium. The slides were left undisturbed for 15 
minutes to allow the mounding media to harden and then either imaged immediately or 
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stored at 4°C until they were imaged. All slides were imaged within 24 hours of mounting 
using a Leica TCS SP5 II confocal imaging system. An Argon laser at 488nm and a 
HeNe laser at 633nm were used in conjunction with a HCX PL APO CS 40X oil 
immersion lens and the numerical aperture set to 1.25.  
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7.4 RESULTS AND DISCUSSION 
7.4.1 Establishment of BTRC-CR5 culture. 
 The aim of this investigation was to isolate and culture TRC’s from a bovine 
tongue. The first stage in the isolation procedure was to harvest the fungiform papillae 
from the apical region of the tongues. Fungiform papillae were selected in favour of 
foliate and circumvallate as their structure has clear boundaries and allows for the easy 
removal of only the papillae (Figure 145).  
 
Figure 145 - Illustration demonstrating how the raised structure of fungiform papillae has 
clear boundaries and allows for the easy removal of only the papillae without the risk of 
taking excess tissue.  
 
 It was important to harvest as cleanly as possible just the fungiform papillae and 
not surrounding tissue in order to maximise the percentage of desired cells entering the 
culture process. It was observed that the fungiform papillae on the bovine tongues were 
significant and obvious structures with a diameter of between 1-3mm (Figure 146). The 
number of fungiform papillae found on the bovine tongues used (n=7) ranged from 37 to 
58 with an mean number of 46. Thanks to this we found that only one tongue is required 
to yield enough taste cells to initiate up to 24 primary culture lines.  
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Figure 146 - Close up image of an area of the anterior region of a bovine tongue. The 
raised structures which can be clearly seen are the fungiform papillae which are the 
target for extraction during the dissection procedure. 
 
 Following the removal of the fungiform papillae, half were treated with a 
Pronase/Elastase solution for 30 minutes following existing protocol (Ozdener et al 2011). 
The other half were not subjected to the enzymatic digestion stage. Both methods 
produced suspensions of fungiform which were then cultured. It was observed that 
initially and up to 24 hours following the seeding of the plates there was a very 
heterogeneous mix of cells with a very low degree of adhesion (Figure 147a, 148a). 
Following the first media change which occurred two days after the initial seeding, 
(Figure 147b, 148b) the cells appeared much more homogeneous with a significant 
number of adhered cells displaying the expected morphology of TRC’s. There were still 
some cells present which did not display the morphology expected of TRC’s. Following 
the next media change (Figure 147c, 148c), 7 days following the initial seeding the TRC’s 
had proliferated and the number of non-TRC’s had decreased indicating that the culture 
conditions were not suited to non-taste cells and as such over time the culture will contain 
only the desired TRC’s. This was seen after the change of media 14 days following 
seeding (Figure 147d, 148d) which contained a greatly increased number of TRC’s and 
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no cells which were not of the expected morphology. The cells were grown to confluence 
which was observed by day 21 (Figure 147e, 148e). It was also interesting to see that 
both sets of cells, one which had undergone enzymatic treatment and the other which 
had not, when cultured in parallel behaved in an identical manner with similar cell 
numbers at each time point, identical morphology throughout and reaching confluence 
at the same time (Figure 147a-e, 148a-e). This indicates that the enzymatic digestion 
step is superfluous and removing it from the protocol would shorten the process, reduce 
cost and also eradicate any potentially significant damage, however unlikely, that the 
enzymes may be inflict upon the cells.  
 
 
Figure 147- Culture of BTRC-CR5s achieved using enzymatic digestion during the 
isolation stage. Time points following seeding at 24h (A), 2 days (B), 7 days (C), 14 days 
(D) and 21 days (E). 
 
 
Figure 148 – Culture of BTRC-CR5s achieved using mechanical disruption during the 
isolation stage. Time points following seeding at 24h (A), 2 days (B), 7 days (C), 14 days 
(D) and 21 days (E). 
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7.4.2 Maintenance of BTRC-CR5 culture. 
 Following three weeks in culture the primary BTRC-CR5s reached confluence 
and were removed from the surface of the wells in the 24 well plates and seeded into 
T25 flasks, cells were seeded into both untreated and collagen coated flasks to 
investigate the need for collagen. It was found that the cells proliferated at a similar rate 
to that seen in the cells harvested fresh from the bovine tongue (Figure 149a-e, 150a-e) 
with confluence being reached after around 21 days. It was also evident that collagen 
coating was not necessary for the adhesion of the BTRC-CR5s to the plastic ware.  
 
Figure 149 - Culture of BTRC-CR5s in collagen coated T25 flask. Time points following 
seeding at 24h (A), 2 days (B), 7 days (C), 14 days (D) and 21 days (E). 
 
 
Figure 150 - Culture of BTRC-CR5s in an uncoated T25 flask. Time points following 
seeding at 24h (A), 2 days (B), 7 days (C), 14 days (D) and 21 days (E). 
 
 Once the cells were confluent in the T25 flasks they were then split to produce a 
cell suspension containing 6x104 cells, from which 2ml was used to seed each T75 flasks 
to upscale and generate sufficient numbers of cells for experimentation. At this 
concentration, T75 flasks reached confluence within 7 days (Figure 151). It is possible 
to reduce the seeding concentration and in this way extend the time it takes for cells to 
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reach confluence. In this way the cells have been maintained in culture for 8 months 
from the initial isolation. The cells were maintained for up to 8 passages before 
unacceptable levels of senescence and loss of cell morphology was observed (Figure 
152). 
 
Figure 151 - Culture of BTRC-CR5s in a T75 flask. Time points following seeding at 2 
days (A), 4 days (B), 7 days (C). 
 
 
Figure 152 - Confluent cell cultures following senescence testing, blue staining indicates 
senescence. Early passages represented by 10a show no signs of senescence. Later 
passages P8 (10b) and P9 (10c) show the onset of senescence and extensive 
senescence respectively. At this point cells would be considered unsuitable for use in 
assay. 
 
 As reaching senescence is an inevitable limitation of primary cell cultures the 
potential to establish a stock of frozen cells is of great benefit, reducing how regularly 
isolation of cells from fresh tongues must be carried out. Cells were frozen down at 
passages 2 and 3 in bulk to provide a large stock of early passage cells. To ensure 
successful cryogenic preservation sample vials have been revived (n=3 from each 
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batch) (Figure 153). The revived cells have been tested in the same manner as the initial 
primary cultures and have performed in the same way for every assay showing that the 
cells have been successfully preserved. 
 
Figure 153 – Revived culture of BTRC-CR5s in an uncoated T25 flask. Time points 
following seeding at 24h (A), 2 days (B), 7 days (C), 14 days (D) and 21 days (E). 
    
7.4.3 Intracellular Ca2+ and cAMP Responses to Taste Stimuli 
 An increase in intracellular calcium is the one of the final stages in the signalling 
cascade that leads to the release of neurotransmitter following the stimulation of TRC’s 
with a relevant tastant. We tested cells at early (P2), middle (P4) and late (P7) passages 
to provide firstly evidence that the cells which were being cultured were TRC’s and in 
addition that the cellular response was not altered by passage number. Cells were grown 
on coverslips and then exposed to the model tastants, Denatonium, Sucralose, 
Acesulfame-K and Monopotassium glutamate. These are tastants which have been used 
previously in the assay of intracellular calcium response of TRC’s to tastants (Ozdener 
et al 2006, Ozdener et al 2011) and as such will allow us to draw comparisons between 
our findings and the results reported previously in the literature. The cultured cells 
displayed intracellular calcium increases to all of the tastants (Figure 154). Our results 
indicated that increases in passage number had no effect on the intracellular calcium 
response of BTRC-CR5s to the model tastants. The highest frequency of response was 
to 2mM Denatonium with on average 17% of cells eliciting a response. Sucralose and 
Acesulfame-K showed on average 5% and 8% of cells eliciting a response respectively 
and Monopotassium glutamate elicited a response in on average 3% of cells. All of the 
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responses were seen within 150 seconds of the tastants being added and there was no 
problems stemming from autofluorescence of photo bleaching.       
 
Figure 154 – Example images of fluorescence before stimulation (A) and after 
stimulation (B), Example traces showing intracellular calcium levels (C) and average 
number of BTRCs responding per field of view when exposed  to the model tastants 
Denatonium, Sucralose, Acesulfame-K and Monopotassium Glutamate (D). 
 
 As with intracellular Ca2+, intracellular cAMP is another important marker in taste 
transduction cascades with decreases in cAMP being observed following stimulation of 
BTRCs with model tastants (Table 57). The analytical process involved in the 
measurement of cAMP provides the benefit that repeatable quantitative results can be 
collected. In addition, as with intracellular calcium concentrations, intracellular cAMP flux 
is dependent upon stimuli concentration. As it stands, cAMP measurement allows for the 
concentration of known tastant to be calculated following the production of a calibration 
chart using standards of know concentrations. 
Table 57 - Intracellular cAMP concentration changes in BTRCs which have been 
stimulated with the model tastants Denatonium (D), Monopotassium Glutamate (MPG), 
Acesulfame-K (A) and Sucralose (S). 
 
Tastant Max response Log EC50 
Denatonium 68.50 ±11.37 -4.944±0.4428 
Monopotassium Glutamate 99.37±10.07 -4.449±0.2619 
Acesulfame-K 97.49±8.29 -4.403±0.2706 
Sucralose 79.53±12.86 -3.881±0.4302 
             A      B                                   C                                                    D 
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 The term half maximal effective concentration (EC50) refers to the concentration 
of tastant which induces a response halfway between the baseline and maximum after 
a specified exposure time. It is indicative as a measure of tastants potency. 
7.4.4 Confocal Identification of TRC markers Gustducin and PLC-β2 
 Confocal microscopy was used to examine the cultured BTRC-CR5s for proteins 
which are considered to be reliable markers for the presence of TRC’s. The proteins 
Gustducin and PLC-β2 which are proteins involved in the transduction of bitter, sweet 
and umami taste and are markers for Type 2 sensory cells. We tested cells at early (P2), 
middle (P4) and late (P7) passages. From the observations it was clear that the cells 
expressed both of the proteins of interest and determined that 56% of the examined cells 
exhibited Gustducin (Figure 155) and around 38% of the examined cells were found to 
exhibit PLC-β2 (Figure 156). Testing for non-specific binding was performed and found 
not to be present, validating the results collected. It was found that the effect of 
increasing passage number had no effect on the level of proteins detected and the 
detection of the proteins added more evidence to confirm that the cells cultured were 
definitely TRC’s.    
 
Figure 155 - Phase contrast (A) and Confocal (B) imaging of BTRC-CR5s expressing 
the taste marker Gustducin 
 
A                                            B 
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Figure 156 - Phase contrast (A) and Confocal (B) imaging of BTRC-CR5s expressing 
the taste marker PLC- β2 
 Work carried out by Ruiz-Avila et al 2000 utilised taste papillae harvested from a 
bovine source to develop a method to screen for high-potency bitterness inhibitors, in 
their paper they identified the presence of the taste specific G-protein Gustducin. This 
protein is known to be present in the TRC’s of many species including fish, amphibians, 
rodents, cattle and humans (Ruiz et al 2001). As such, before commencing this work 
there was evidence that cells derived from the bovine tongue would contain relevant 
taste apparatus and a culture of these cells would be beneficial. The cell line could also 
serve as a useful model in endocrinological and neurobiological investigations 
(Dasgupta et al 1990) in addition to the broad application of a taste assay which is of 
primary concern. Relatively little attention has been devoted to the bovine tongue and 
no reported attempt to culture TRC’s from a bovine source has been found in searches 
of existing literature. One of the immediately apparent observations is the size of a 
bovine tongue, this means that bovine tongue provides a plentiful source of taste papillae, 
this contrasts to work which has been previously carried on rodents (Ozdener et al 2006) 
and humans (Ozdener et al 2011). This carries the advantage that relatively few organs 
are required to generate significant numbers of TRC’s and culture lines. Ozdener et al 
2011 reported that from each human subject, a maximum of 8 fungiform papillae were 
harvested and also mention that an oral surgeon was required for the collection of the 
A                                             B 
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papillae. The bovine tongue, on average yielded 46 papillae (37 minimum) and the 
isolation of the papillae structures was a simple procedure which even a novice at 
dissection procedures could easily achieve. The method for isolation and culture uses 
the taste papillae from one tongue to seed each well in a 24 well plate and from each 
well there are enough cells to initiate a T25 flask meaning that each tongue has the 
potential to initiate a total of 24 cultures. In addition to this the use of a bovine source 
means that ethical issues which may be associated with maintaining lab animals or using 
human subjects are avoided. Finally costs are kept low with each tongue costing less 
than £5. 
 BTRC-CR5s have been successfully cultured up to passage 7 and flasks seeded 
at lower densities have permitted the cell line to be active for a total of 8 months. At 
passage 8 changes in cell morphology were seen and by passage 9 the cell morphology 
was changed significantly indicating senescent cells. Senescence is an inevitable 
eventuality with all primary cell cultures and it was identified through the use of a 
histochemical staining kit that senescence did not present until passage 8 and was not 
widely prevalent in the cultures until passage 9. In both cases the cells were deemed 
unfit for use in assays. The cells in passages 2-7 maintained their morphology and 
performed consistently in intracellular calcium level investigations and also confocal 
microscopy examinations.  
 The method of culture described in this paper is based upon methods presented 
elsewhere in literature for the culture of rat and human TRC’s (Ozdener et al 2006, 
Ozdener et al 2011) with modifications implemented to simplify the procedure, 
minimising time required and financial expenditure without jeopardising quality of the 
cultures produced. 
 The method of culture described removes the need to collagen coat all plastic 
and glass ware, as cells have been shown to grow equally well without the need for 
coating. This has the benefit of reducing the cost if pre-coated plastic or glassware was 
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intended for use. Where plastic and glassware would be self-coated time required to 
coat plastic and glassware would be saved and in addition the eradication of this 
requirement in the method would avoid any inconsistencies which may result from 
potential variables in the coating such as thickness, dryness and collagen concentration.   
   During the isolation procedure in all of the previously reported TRC culture 
methods there is an enzymatic digestion stage. In the culture of BTRC-CR5s this has 
been shown to be superfluous with comparable cultures of BTRC-CR5s having been 
developed both when implementing and bypassing this stage. This is of benefit as the 
implementation of an enzymatic digestion procedure can cause damage to cells. For 
example trypsin and Pronase provide excellent disaggregation properties however can 
damage cells. Trypsin is known to be too aggressive for mild enzyme digestions as it 
removes cell-cell and cell-extracellular matrix connections too aggressively (Kaeffer 
2002). Enzymatic digestion requires careful optimisation to avoid problems associated 
with yield and viability. Low yield low viability (LYLV), low yield high viability (LYHV), high 
yield low viability (HYLV) and high yield high viability (HYHV) are all possible outcomes. 
If the enzymes used are too digestive and used at too great a concentration or if 
incubation time is incorrect then this can lead to LYLV and HYLV returns. Similarly too 
low of an enzyme concentration can lead to LYHV, only through trial and error is it 
possible to ensure HYHV.   
 One further stage implemented in our culture has been the cryopreservation of 
the BTRC-CR5s in a liquid nitrogen cell bank. Freezing TRC’s for storage has been 
reported before however only at -80°C (Ozdener et al 2011) and not below -130°C, the 
temperature at which liquid water will no longer exist and where the only physical states 
which exist are crystalline or glassy. -196°C is the temperature of liquid nitrogen and at 
this point there is insufficient energy for thermal reactions to occur hence such a high 
efficiency for cell preservation. Contrary to popular belief it is not the extremely low 
temperatures which are a threat to cell preservation but the transition periods during 
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freezing and thawing procedures when the cells are in the region of -15°C to -60°C. 
Although some cells will remain viable over reasonably long periods of time at -80°C 
there is evidence in the literature stating that some cells will remain viable as briefly as 
3-4 months (Mishra et al 2010). This is due to the fact that the biological events in cells 
stored at -80°C have only been slowed and so cellular damage, and/or changes can still 
occur. In addition the cells may be unstable due to traces of unfrozen solution still 
existing (Mazur 1984). In contrast cells stored in liquid nitrogen have been shown to 
remain viable for decades. Storing at -196°C prevents all thermally driven chemical 
reactions meaning that so long as they are preserved correctly the cells will remain viable 
indefinitely (Mazur 1984). From the cultures which have been established, BTRC-CR5s 
have been successfully cryogenically preserved at -196°C and revived at various time 
intervals to ensure continued cell viability. The revived cells have been shown to behave 
in an identical way to cells which had not been subjected to the cryogenic storage 
procedures when tested for responses to taste stimuli and during examination through 
confocal microscopy. Currently it is estimated that there are enough viable BTRC-CR5s 
frozen to maintain the current rate of work for the next 15 years.  
 In the culture of primary cells has the initial hurdle of starting with a 
heterogeneous cell mix from which the target cells need to be selected for. It is the 
culture media which provides this selection and it was observed than non-taste cells did 
not proliferate during culture. In order to confirm the cells cultured as TRC’s, 
Immunofluorescence confocal microscopy was implemented. Immunofluorescence 
confocal microscopy is a widely used technique in identifying the presence of a protein 
of interest in a sample of cells or tissue (Hegde et al 2002, Schwab et al 2013, Wang et 
al 2013, Woods et al 2013, Yang et al 2013). In the instance of this investigation, the 
proteins of interest were gustducin and PLC-β2, both proteins mentioned are considered 
to be reliable markers for the presence of Type 2 TRC’s and are involved in taste 
transduction signalling cascades. The extent of cells expressing gustducin and PLC-β2 
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in BTRC-CR5 cultures was found to be 56% and 38% respectively and these are 
numbers reflected in the data presented in existing literature for the TRC’s of rats and 
humans (Ozdener et al 2006, Ozdener et al 2011). 
 Isolating and culturing cells is only one part in the challenge of developing a 
representative cell model, the cultured cells need to maintain their in vivo functionality if 
they are to produce an accurate model. Cells in culture often behave differently in culture 
to how they would in their real world environment, this is at times due to the loss of the 
synergistic effect of surrounding cells. In order to illustrate that the BTRC-CR5s cultured 
still respond in a manner which is suitably representative of their in vivo activity, in vitro 
measures of TRC response to taste stimuli was performed. To do this intracellular 
calcium levels were examined following the exposure of BTRC-CR5 cultures to model 
taste stimuli. Increases in intracellular calcium levels are common to all of the taste 
transduction cascades and is the precursor to neurotransmitter release (Gilbertson et al 
2000).  
 It has been illustrated that TRC’s cells will elicit a spike in intracellular 
concentration in response to exposure of the TRC’s to model taste stimuli for the bitter, 
sweet and umami taste groups (Ozdener et al 2006, Ozdener et al 2011). BTRC-CR5s 
which have been exposed to the same model tastants returned responses which were 
in keeping with the data reported previously in the literature for rat and human cells. This 
is important in not only confirming that the cultured cells have retained the relevant 
mechanistic characteristics but also that there is similarity in the performance of cells 
gained from a bovine source when compared to cells which have been gained from a 
human source. Observing responses through increases in intracellular calcium at this 
stage is incapable of differentiating between tastant type, i.e. bitter or sweet, this is not 
to say that measurements of intracellular calcium may not play a part in the final model 
for taste assessment. It has been observed (data not shown) and previously reported 
(Ozdener et al 2006) that the degree of calcium increase is affected by the concentration 
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of tastant and therefore indicative of the tastant strength. As such there is a chance that 
measurement of intracellular calcium may play a role in the final in vitro taste assay.       
 In conclusion a method for the long term culture of BTRC-CR5 taste receptor 
cells harvested from a bovine tongue has been developed. The method of culture has 
been simplified to reduce time and cost of the process when compared to existing 
methods for the culture of taste receptor cells, eradicating the need for collagen coating 
of plastic and glassware and the removal of an enzymatic digestion stage in the isolation 
procedure. The cells have been maintained in culture up to passage 7 before signs of 
senescence were first observed and conformation of cell type and activity has been 
achieved through confocal microscopy and the measurement of intracellular calcium 
level responses to model tastants. This has been the successful first step into the 
development of an in vitro taste assay which would have far reaching application.   
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8 CLOSING COMMENTARY 
 The objectives of the work carried out in project can be categorized into three 
main areas of research; 
1. Reformulation of the angiotensin converting enzyme (ACE) inhibitors lisinopril 
and ramipril and potassium-sparing diuretic spironolactone to produce oral liquid 
formulations better targeting the paediatric patient segment.  
2. Using the model formulations produced in the first stage of the project, an in vitro 
– in vivo correlation between changes in gene expression following in vitro 
transport studies and in vivo absorption will be investigated using microarray 
technology.        
3. During the production of any oral formulation targeting any patient segment the 
palatability of the formulation is an important consideration. It became apparent 
during the formulation development stages of the project that the available 
analytical techniques for taste assessment are inadequate. As such initial stages 
into the development of an in vitro cell based taste assessment method merited 
investigation.  
 It is recognized globally that the drug products currently available for treating the 
paediatric population, which suitably meet the needs of the patient segment are lacking 
in their coverage. In order to improve on this situation bodies such as the FDA and the 
EMA have devised legislation to guide the research and development of paediatric 
medicines through priority listings. By selecting and reformulating off patent medications 
as oral liquids in cases where oral liquids are not already available the paediatric 
population have been more appropriately targeted.    
 Angiotensin converting enzyme (ACE) inhibitors lisinopril and ramipril were 
selected from EMA/480197/2010 and the potassium-sparing diuretic spironolactone was 
selected from the NHS specials list for November 2011 drug tariff with the view of 
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producing oral liquid formulations providing dosage forms targeting paediatrics. Lisinopril, 
ramipril and spironolactone were chosen for their interaction with transporter proteins in 
the small intestine. Previous research illustrated that gene expression of intestinal 
membrane transporters changes in response to drug transport. It was therefore 
considered worthwhile investigating the relationship between the expressional changes 
seen and the extent of drug absorption as the development of an in vitro – in vivo 
correlation would be of benefit to a number of fields, potentially aiding in the areas of 
drug discovery and development as well as potentially reducing the need for animal 
based drug absorption studies.  
 Formulation limitations such as poor solubility or pH sensitivity needed 
consideration. Lisinopril was formulated without extensive development as drug and 
excipients were water soluble. Ramipril and spironolactone are both insoluble in water 
and strategies combating this were employed. Characterisation, stability profiling and 
permeability assessment were then performed following formulation development.  
 As detailed, for the Lisinopril solution, the API and all excipients are soluble in 
water the production of the formulation is simple. Following excipient selection the 
constituent parts for Lisinopril solutions are as follows;  
 Lisinopril (2mg/ml) 
 Citric Acid (3mg/ml) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (30% w/v in sweetened formulation) (10% w/v in flavoured formulation) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
 Where Ramipril is concerned, the poor aqueous solubility of the drug is a 
limitation in the production of an oral liquid dosage form and to combat this, three 
formulation strategies were employed. Two of these involved the production of Ramipril 
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solutions, one using a co-solvency approach of acetic acid and water to dissolve the API 
and the other utilising complexation of the drug with HP-β-CD. The final formulation of 
the Ramipril solution produced using acetic acid as a co-solvent is as follows; 
 Ramipril (1mg/ml) 
 Acetic Acid (0.02% v/v) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (20%) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
 For production of the formulation, a 0.02% v/v acetic acid solution was produced. 
Into this Ramipril was added and under stirring allowed to fully dissolve before any further 
excipients were added. With Ramipril dissolved in the acetic acid solution the other 
excipients were added with flavouring being added as the final excipient. The 
development of a Ramipril solution using complexation with HP-β-CD, arrived at a final 
formulation as follows; 
 Ramipril (1mg/ml) 
 HP-β-CD (3.51mg/ml) 
 Ascorbic Acid (0.1mg/ml) 
 Propyl Paraben (0.1mg/ml) 
 Butyl Paraben (0.06mg/ml) 
 Xylitol (20%w/v) 
 Orange Flavour (0.1% v/v) (Flavoured formulation only) 
 For production of the formulation a cyclodextrin solution was first produced by 
dissolving 3.51mg/ml in distilled water. With this produced the next stage was to add the 
Ramipril until it was completely dissolved. Following this the other excipients are added 
until fully dissolved with flavour being added last. 
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 The remaining Ramipril formulation approach was that of a suspension. Due to 
the inherent stability concerns that are associated with suspensions additional excipients 
are necessary. Hydrophilic polymers are includeed as suspending agents and have the 
effect of increasing the viscosity of the liquid vehicle. This prolongs suspension of 
particles but can in the same way make it difficult to re-suspend particles which sediment. 
To get the best results from the addition of hydrophilic polymers, a suspensions resulting 
flow profile was required to be pseudoplastic or shear thinning and thixotropic. This is 
useful as the relatively high viscosity under low shear conditions e.g. during storage 
slows the sedimentation process and the relatively low viscosity under high shear 
conditions e.g. shaking or pouring, allows for the easy re-dispersion of any sediment and 
easy dispensation of the medication. Xanatural 180 is a hydrophilic polymer which 
provides such rheology and is utilised in the suspensions produced in this project. The 
suspension was further optimised through investigations into the rate and volume of 
sedimentation, Ostwald ripening, zeta potential and wettability. The result was an 
elegant formulation with the desired physical stability. The final composition of the 
Ramipril suspensions are as follows; 
Flavoured Suspension: 
 Ramipril (1mg/ml) 
 Xanatural 180 (0.1% w/v)  
 Sodium Metabisulphate (1.0% w/v) 
 Sodium Benzoate (0.5% w/v) 
 Xylitol (40% w/v) 
 Strawberry Concentrate (0.2%v/v) (Flavoured formulation only) 
 The suspensions were produced by first producing a 0.1% Xanatural 180 solution. 
Into this Ramipril was then added slowly during vigorous stirring and evenly distributed 
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throughout the vehicle. The remaining excipients are then added to the formulation with 
the strawberry concentrate being added as the last ingredient. 
 Spironolactone dosages were too high for solubilisation techniques to be 
effective so suspensions were developed following the same methodology as used in 
the Ramipril formulations. There were slight differences in that a buffer system was 
needed to control formulation pH for the maximum stability of the sensitive drug. 
Additionally, a precisely balanced surfactant and suspending agent mix was needed to 
produce a pseudoplastic liquid vehicle in which the drug did not clump together during 
formulation production. The resulting vehicle provided excellent physical stability. From 
the investigations carried out Xanatural 180 and Pluronic F127 are essential components 
in the liquid vehicle. Based on knowledge gained in the Ramipril and Lisinopril 
formulations, the other excipients selected for the formulation were Sodium 
Metabisulphate and Sodium benzoate to act as an antioxidant and preservative 
respectively. Flavouring would be present in the form of Xylitol as a sweetener and 
strawberry flavour included in a flavoured variety. 
The final ingredients for the formulation are as follows; 
 Spironolactone (10mg/ml or 5mg/ml) 
 Xanatural 180 (0.4%w/v) 
 Pluronic F127 (1.0%w/v) 
 Sodium Metabisulphate (1.0%w/v) 
 Sodium Benzoate (0.5%w/v) 
 Xylitol (40%w/v) 
 Strawberry Flavour (0.2%) (Flavoured Formulation Only) 
 Following production of the formulations they were entered into stability testing 
conditions as laid out in ICH guidelines. According to the parameters outlined by the ICH 
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harmonised tripartite guideline stability testing of new drug substances and products 
Q1A(R2), “significant change” for a drug product is defined as:  
1. A 5% change in assay from its initial value; or failure to meet the acceptance 
criteria for potency when using biological or immunological procedures;  
2. Any degradation product’s exceeding its acceptance criterion;  
3. Failure to meet the acceptance criteria for appearance, physical attributes, and 
functionality test (e.g., colour, phase separation, resuspendibility, caking, 
hardness, dose delivery per actuation); however, some changes in physical 
attributes (e.g., softening of suppositories, melting of creams) may be expected 
under accelerated conditions;  
and, as appropriate for the dosage form:  
4. Failure to meet the acceptance criterion for pH; or  
5. Failure to meet the acceptance criteria for dissolution for 12 dosage units. 
 The Lisinopril formulations tested under accelerated conditions showed 
significant decrease in the drug assayed in comparison to the day zero analysis. The 
formulations in long term storage conditions did not show any significant decrease in the 
drug assayed even after 12 months in storage. This suggests that the degradation seen 
under accelerated conditions is a result of the elevated temperature.  It is known that 
Lisinopril diketopiperazine (DKP) degradate is the primary degradation compound for 
Lisinopril. Degradation occurs through intramolecular condensation and sees the 
formation of a second amide bond. This reaction is known to occur when Lisinopril 
experiences conditions of elevated temperature, as such the advice for storage of the 
medication would have to emphasise storage in a cool location (<25°C). The humidity of 
the storage conditions is not a large issue as the medication will be contained within 
bottles impervious to moisture. With regards to excursions outside of the storage 
conditions such as transport during distribution, degradation due to temperature should 
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not be a concern so long as excursions are short in duration and infrequent. This is as 
degradation was only seen to be significant after >1 month and the temperature at which 
degradation was seen is higher than most environmental temperatures the medication 
would experience. 
 The Ramipril formulations tested under accelerated conditions showed 
significant decrease in the drug assayed in comparison to the day zero analysis. This 
was seen in all formulations regardless of the method of formulation. The formulations 
in long term storage conditions did not show any significant decrease in the drug assayed 
even after 12 months in storage. This suggests that the degradation seen under 
accelerated conditions is a result of the elevated temperature. It is known that Ramipril 
diketopiperazine (DKP) degradate is the primary degradation compound for Ramipril. 
Degradation occurs through intramolecular condensation and sees the formation of a 
second amide bond.  
  This reaction is known to occur with Ramipril as was seen with Lisinopril when 
the drug experiences conditions of elevated temperature. The pH of the formulation in 
both accelerated and long term conditions did not change beyond the acceptance levels 
for the formulation. In addition, the appearance and odour of the formulations remained 
acceptable for the duration of the stability testing and in both long term and accelerated 
conditions. The advice for storage of the medication would have to emphasise storage 
in a cool location (<25°C), the humidity of the storage conditions is not a large issue as 
the medication will be contained within glass bottles impervious to moisture. With 
regards to excursions outside of the storage conditions such as transport during 
distribution, degradation due to temperature should not be a concern so long as 
excursions are short in duration and infrequent. This is as degradation was only 
considered significant after >1 month and the temperature at which degradation was 
seen is higher than most environmental temperatures the medication would experience. 
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 The Spironolactone formulations tested under all conditions showed no 
significant decrease in the drug assayed in comparison to the day zero analysis. This 
was seen in all formulation types and at all dosages. In addition, the appearance and 
odour of the formulations remained acceptable for the duration of the stability testing and 
in both long term and accelerated conditions. Sedimentation did not occur in formulations 
stored in long term storage conditions and some degree of sedimentation was observed 
in formulations stored in accelerated storage conditions. The reason behind the 
sedimentation seen is most likely the increased temperature decreasing the viscosity of 
the vehicle and thus allowing particles to gravitate more easily. Caking did not occur 
however and the suspension was returned to a homogenous state easily and with 
minimal agitation meaning that the physical stability of the formulations in all conditions 
was maintained for the duration of testing. The advice for storage of the medication 
would have to advise against storage in hot conditions and directions for the procedure 
of re-suspension would have to be provided to ensure formulation homogeneity 
immediately prior to administration. With regards to excursions outside of the storage 
conditions such as transport during distribution, degradation and lack of physical stability 
should not be a concern.  
 Although formulations were successfully produced for Ramipril, Lisinopril and 
Spironolactone, the formulation process highlighted serious shortcomings in currently 
available techniques for taste assessment of pharmaceutical preparations resulting in 
early stage research into a novel in vitro cell based assay. A method for the long term 
culture of BTRC-CR5 taste receptor cells harvested from a bovine tongue has been 
developed. The method of culture has been simplified to reduce time and cost of the 
process when compared to existing methods for the culture of taste receptor cells, 
eradicating the need for collagen coating of plastic and glassware and the removal of an 
enzymatic digestion stage in the isolation procedure. The cells have been maintained in 
culture up to passage 7 before signs of senescence were first observed and 
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conformation of cell type and activity has been achieved through confocal microscopy 
and the measurement of intracellular calcium level responses to model tastants. This 
has been the successful first step into the development of an in vitro taste assay which 
would have far reaching application.   
 The formulations developed in the initial phase of the research were used as 
model formulations investigating potential microarray application in an in vitro-in vivo 
correlation for carrier mediated drug absorption. The in vitro and in vivo rate of drug 
absorption was first examined for correlation. The findings from the in vitro and in vivo 
drug absorption studies were compared to identify a correlation between the results. For 
this the Log conversion of the AUC from the in vivo experiments was plotted against the 
Log Papp values calculated following the in vitro drug transport studies. The correlation 
for the comparison of the in vitro and in vivo data sets was found to be R2 = 0.6946. The 
R2 value is comparable to those seen elsewhere in reported literature for in vitro in vivo 
correlations. The R2 value would perhaps be expected to be some distance from the 
perfect linearity of R2 = 1.0 as the comparison uses limited data points (n=5). There is 
also a known high degree of variation in the in vivo absorption of the ACE inhibitor drugs 
Lisinopril and Ramipril. The next stage in the investigation examines the gene 
expression levels of intestinal transporters to see if there is a greater correlation between 
in vitro gene expression and in vivo drug absorption. 
 Caco-2 cells were subsequently assessed following transport studies for 
changes in genetic expression of the ATP-binding cassette and solute carrier transporter 
superfamilies using microarray technology. Following the analysis of the microarray data 
it was identified that the shortlisted genes of interest, namely ABCB1 and SLC15A1 for 
Lisinopril, SLC15A1 and SLC15A2 for Ramipril and ABCB1, ABCC2 and SLCO1A2 for 
Spironolactone were all found to show non-significant changes in their expression levels 
following transport studies using the Lisinopril, Ramipril and Spironolactone formulations. 
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There were however numerous SLC and ABC genes for which the expression had 
changed significantly.  
 Due to the variety of genes expressed and the lack of common genes affected 
by all formulations in the data presented, a means by which human drug absorption can 
be predicted by measuring gene expression levels of a single gene or a family of genes 
was impossible to derive. There is however indication that examination of genome wide 
expression changes in the total number of genes showing significant change correlates 
to the predicted absorption in humans. Plotting the number of genes with significantly 
altered expression levels for each drug against the percentage absorption in humans 
provides a linear correlation with an R2 value of 0.9934. It must be stressed however that 
this correlation is based on minimal amounts of data and for any trend between human 
drug absorption and the level of genome wide gene expression changes to be 
considered as a model for the prediction of human drug absorption many more 
formulations would need to be analysed investigating a range of dosage forms, dosage 
concentrations and degree of human absorption.  
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